*Zheng L et al.*, Endovascular therapy in acute ischaemic stroke with large infarction with matched or mismatched clinical-radiological severities: a post-hoc analysis of the ANGEL-ASPECT trial

## Caption for supplementary material

Supplemental Materials	PDF
Protocol	PDF
Author Statement Form	PDF
ICMJE COI Form	PDF

- 1 Zheng L et al., Endovascular therapy in acute ischaemic stroke with large infarction with matched or
- 2 mismatched clinical-radiological severities: a post-hoc analysis of the ANGEL-ASPECT trial

#### 3 SUPPLEMENTAL MATERIALS

#### 4 Table of Content

5	List of committees and coordinating centres in ANGEL-ASPECT2
6	List of participating sites and investigators in ANGEL-ASPECT7
7	Supplemental Figure S1. Forest plots on the associations of EVT versus medical management with the
8	efficacy (panel a) and safety outcomes (panel b) in the 4 subgroups9
9	Supplemental Table S1. Infarct locations by ASPECTS regions in the four subgroups stratified by NIHSS
10	and infarct-core volume10
11	Supplemental Table S2. Efficacy and safety outcomes in the 4 subgroups, adjusting for variables
12	unbalanced between the two treatment arms in each subgroup11
13	Supplemental Table S3. Efficacy and safety outcomes in the 4 subgroups classified by a combination
14	of NIHSS < or $\geq$ 16 and infarct core volume < or $\geq$ 50mL12
15	

Study organization	Member	Department	Hospital	
	Yongjun Wang	Department of Neurology	Beijing Tiantan Hospital, Capital Medical University	
	Yilong Wang	Department of Neurology	Beijing Tiantan Hospital, Capital Medical University	
	Liping Liu	Department of Neurology	Beijing Tiantan Hospital, Capital Medical University	
Steering Committee	David S. Liebeskind	Department of Neurology	University of California at Los Angeles	
	Zhongrong Miao	Department of Interventional Neuroradiology	Beijing Tiantan Hospital, Capital Medical University	
	Zeguang Ren	Department of Neurosurgery	The Affiliated Hospital of Guizhou Medical University	
	Vitor Mendes Pereira	Department of Neurosurgery, Division of Surgery	St Michael's Hospital, University of Toronto	
	Xunming Ji	Department of Neurosurgery	Xuanwu Hospital, Capital Medical Universit	
	Qiang Dong	Department of Neurology	Huashan Hospital, Fudan University	
Advisory Board	Anding Xu	Department of Neurology and Stroke Centre	The First Affiliated Hospital, Jinan Universit	
Autiony Dould	Xinfeng Liu	Department of Neurology	Affiliated Jinling Hospital, Medical School of Nanjing University	
	Qingwu Yang	Department of Neurology	Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University	
	Jing Jing (Chair)	Tiantan Neuroimaging Centre of Excellence (T- NICE)	China National Clinical Research Centre for Neurological Diseases	
	Zhe Zhang	Tiantan Neuroimaging Centre of Excellence (T- NICE)	China National Clinical Research Centre for Neurological Diseases	
Independent Imaging Core	Yingkui Zhang	Tiantan Neuroimaging Centre of Excellence (T- NICE)	China National Clinical Research Centre for Neurological Diseases	
Lab	Wei Wu	Department of Neurology	Qilu Hospital, Shandong University	
	Dapeng Sun	Department of Interventional Neuroradiology	Beijing Tiantan Hospital, Capital Medical University	
	Zhongqi Qi	Department of Interventional Neuroradiology	Beijing Tiantan Hospital, Capital Medical University	

List of committees and coordinating centres in ANGEL-ASPECT

t of Interventional Beijing Tiantan Hospital, Capital Medical
logy University
t of Interventional Beijing Tiantan Hospital, Capital Medical logy University
t of Interventional Beijing Tiantan Hospital, Capital Medical logy University
t of Interventional Beijing Tiantan Hospital, Capital Medical logy University
t of Interventional Beijing Tiantan Hospital, Capital Medical logy University
t of Interventional Beijing Tiantan Hospital, Capital Medical logy University
t of Interventional Beijing Tiantan Hospital, Capital Medical logy University
Changhai Hospital, Naval Medical Jar Centre University
t of Medical Peking University First Hospital
t of Neurology University University
t of Neurology Huashan Hospital, Fudan University
The First Affiliated Hospital of Zhengzhou University
t of Neurology Huashan Hospital, Fudan University
t of Interventional Beijing Tiantan Hospital, Capital Medical logy University
t of Interventional Beijing Tiantan Hospital, Capital Medical logy University
t of Interventional Beijing Tiantan Hospital, Capital Medical logy University
t of Emergency Xiangtan Central Hospital
t of Neurology Linyi People's Hospital
Zhangzhou Affiliated Hospital of Fujian Medical University
t of Neurosurgery Tianjin huanhu hospital
t of Neurology Anyang People's Hospital


Zhiming Zhou	Department of Neurology	Yijishan Hospital of Wannan Medical College	
Xiaoxi Yao	Department of Neurology	The first people's hospital of Chenzhou	
Guoqing Wang	Department of Neurology	Bin zhou People's Hospital	
Weigen Song	Department of Neurology	Yancheng Third People's Hospital	
Xueli Cai	Department of Neurology	Lishui Municipal Central Hospital	
Guangxian Nan	Department of Neurology	China-Japan Union Hospital of Jilin University	
Di Li	Department of Neurointervention	Dalian Municipal Central Hospital affiliated with Dalian Medical University	
Yizhou Wang	Department of Neurosurgery	Guangdong Provincial Hospital of Chinese Medicine	
Wentong Ling	Department of Neurology	ZhongShan City People's Hospital	
Chuwei Cai	Department of Neurology	Shantou Central Hospital	
Changming Wen	Department of Neurology	Nanyang Central Hospital	
En Wang	Department of Neurology	Taizhou hospital of Zhejiang Province	
Liyong Zhang	Department of Neurosurgery	Liaocheng People's Hospital	
Changchun Jiang	Department of Neurology	Baotou Centre Hospital	
Yajie Liu	Department of Neurology	Shenzhen Hospital, Southern Medical University	
Geng Liao	Department of Neurology	Maoming People's Hospital	
Xiaohui Chen	Department of Neurology	The Second Affiliated Hospital of GuangZhou Medical University	
Tianxiao Li	Department of Cerebrovascular Disease	Henan Provincial People's Hospital, Zhengzhou University	
Shudong Liu	Department of Neurology	Yongchuan Hospital of Chongqing Medical University	
Jinglun Li	Department of Neurology	The affiliated hospital of South West medical university	
Yaxuan Sun	Department of Neurology	Shanxi Provincial People's Hospital	
Na Xu	Department of Neurology	The Second Affiliated Hospital to Xiamen Medical College	
Zong'en Gao	Department of Neurology	Shengli Oilfield Central Hospital	
Dongsheng Ju	Department of Neurology	Songyuan Jilin oil Field Hospital	
Cunfeng Song	Department of Interventional Neuroradiology	Liao Cheng the third people's hospital	

	Jinggang Xuan	Department of Neurology	The First People's Hospital of Changzhou
	Feng Zhou	Department of Neurology	Taiyuan Central Hospital
	Qing Shi	Department of Neurology	Affiliated Jiangmen Traditional Chinese Medicine Hospital of Ji'nan University
	Jun Luo	Department of Neurology	Sichuan Mianyang 404 Hospital
	Yan Liu	Department of Neurology	JingJiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University
	Zaiyu Guo	Department of Neurosurgery	Tianjin TEDA Hospital
	Tong Li	Department of Neurosurgery	The second Nanning People's Hospital
	Hongbo Zheng	Department of Neurology	West China Hospital, Sichuan University
	Linzhi Dai	Department of Neurosurgery	First Affiliated Hospital School of Medicine Shihezi University
	Junfeng Zhao	Department of Neurology	Siping Central People's Hospital
	Liqiang Gui	Emergency and Critical Stroke Ambulance Centre	Langfang Changzheng Hospital
	Xiaokun Geng	Department of Neurology	Beijing Luhe Hospital, Capital Medical University
	Yufeng Tang	Department of Neurology	Mianyang Central Hospital
	Congguo Yin	Department of Neurology	Hangzhou First People's Hospital
	Hua Yang	Department of Neurosurgery	The affiliated Hospital of Guizhou Medical University
<b>T</b> .:	Xiaochuan Huo	Department of Interventional Neuroradiology	Beijing Tiantan Hospital, Capital Medical University
Trial manager	Gaoting Ma	Department of Interventional Neuroradiology	Beijing Tiantan Hospital, Capital Medical University
	Ruiyang An	Quality Assurance	Ericure Medical Technology. Co., Ltd.
Independent	Yuying Sun	Quality Assurance	Ericure Medical Technology. Co., Ltd.
Monitoring	Yanan Wu	Quality Assurance	Ericure Medical Technology. Co., Ltd.
Committee	Chunlai Yu	Quality Assurance	Ericure Medical Technology. Co., Ltd.
	Shuangcheng Zheng	Quality Assurance	Ericure Medical Technology. Co., Ltd.
Statistical and	Yuesong Pan	China National Clinical Res earch Centre for Neurologic al Diseases	Relling Liantan Hospital Canital Medic
Data Management Centre	Aoming Jin	China National Clinical Res earch Centre for Neurologic al Diseases	Relling Liantan Hospital Capital Medic

	Xianglong	China National Clinical Res	Beijing Tiantan Hospital, Capital Medica University	
	Xiang	earch Centre for Neurologic al Diseases		
	Mengxing	China National Clinical Res	Beijing Tiantan Hospital, Capital Medica University	
	Wang	earch Centre for Neurologic al Diseases		
	Hongyi Yan	China National Clinical Res earch Centre for Neurologic al Diseases	Beijing Tiantan Hospital, Capital Medica University	
ndependent	Yuanling He	Senior Statistician	Blueballoon Medical Research Co. LTD	
DSMB Statistics	Chunyang Li	Project department	Blueballoon Medical Research Co. LTD	
team	Weixia Kong	Medicine department	Blueballoon Medical Research Co. LTD	
	Yuhuan Chen	Project Operation	Wisemed Medical Technology. Co., Ltd.	
	Chenhao Guo	Project Operation	Wisemed Medical Technology. Co., Ltd.	
	Fengjie Ji	Project Operation	Wisemed Medical Technology. Co., Ltd.	
	Pengshan Ji	Project Operation	Wisemed Medical Technology. Co., Ltd.	
	Lei Liu	Project Operation	Wisemed Medical Technology. Co., Ltd.	
	Xinghua Lu	Project Operation	Wisemed Medical Technology. Co., Ltd.	
	Guangkuo Luo	Project Operation	Wisemed Medical Technology. Co., Ltd.	
	Nanjing Wang	Project Operation	Wisemed Medical Technology. Co., Ltd.	
	Yu Zhang	Project Operation	Wisemed Medical Technology. Co., Ltd.	
Contract	Bo Liu	Data Management	Wisemed Medical Technology. Co., Ltd.	
Research Organization	Jian Yang	Data Management	Wisemed Medical Technology. Co., Ltd.	
	Jingjing Deng	Medical Sciences	Wisemed Medical Technology. Co., Ltd.	
	Juan Wang	Medical Sciences	Wisemed Medical Technology. Co., Ltd.	
	Wanru Wang	Medical Sciences	Wisemed Medical Technology. Co., Ltd.	
	Hang Yu	Medical Sciences	Wisemed Medical Technology. Co., Ltd.	
	Le Cui	IT Support	Wisemed Medical Technology. Co., Ltd.	
	Wenwen Liu	IT Support	Wisemed Medical Technology. Co., Ltd.	
	Ziyong Wang	IT Support	Wisemed Medical Technology. Co., Ltd.	
	Xia Zhao	IT Support	Wisemed Medical Technology. Co., Ltd.	
	Zhou Zhou	IT Support	Wisemed Medical Technology. Co., Ltd.	

Site Pls	Department	Hospital Beijing Tiantan Hospital, Capital Medical University	
Zhongrong Miao	Department of Interventional Neuroradiology		
Guangxiong Yuan	Department of Emergency	Xiangtan Central Hospital	
Hongxing Han	Department of Neurology	Linyi People's Hospital	
Wenhuo Chen	Department of Neurology	Zhangzhou Affiliated Hospital of Fujian Medical University	
Ming Wei	Department of Neurosurgery	Tianjin huanhu hospital	
Jiangang Zhang	Department of Neurology	Anyang People's Hospital	
Zhiming Zhou	Department of Neurology	Yijishan Hospital of Wannan Medical College	
Хіаохі Үао	Department of Neurology	The first people's hospital of Chenzhou	
Guoqing Wang	Department of Neurology	Bin zhou People's Hospital	
Weigen Song	Department of Neurology	Yancheng Third People's Hospital	
Xueli Cai	Department of Neurology	Lishui Municipal Central Hospital	
Guangxian Nan	Department of Neurology	China-Japan Union Hospital of Jilin University	
Di Li	Department of Neurointervention	Dalian Municipal Central Hospital affiliated with Dalian Medical University	
Alvin Yi-Chou Wang	Department of Neurosurgery	Guangdong Provincial Hospital of Chinese Medicine	
Wentong Ling	Department of Neurology	ZhongShan City People's Hospital	
Chuwei Cai	Department of Neurology	Shantou Central Hospital	
Changming Wen	Department of Neurology	Nanyang Central Hospital	
En Wang	Department of Neurology	Taizhou hospital of Zhejiang Province	
Liyong Zhang	Department of Neurosurgery	Liaocheng People's Hospital	
Changchun Jiang	Department of Neurology	Baotou Centre Hospital	
Yajie Liu	Department of Neurology	Shenzhen Hospital, Southern Medical University	
Geng Liao	Department of Neurology	Maoming People's Hospital	
Xiaohui Chen	Department of Neurology	The Second Affiliated Hospital of GuangZhou Medical University	
Tianxiao Li	Department of Cerebrovascular Disease	Henan Provincial People's Hospital, Zhengzhou University	
Shudong Liu	Department of Neurology	Yongchuan Hospital of Chongqing Medical University	
Jinglun Li	Department of Neurology	The affiliated hospital of South West medical university	

Yaxuan Sun	Department of Neurology	Shanxi Provincial People's Hospital	
Na Xu	Department of Neurology	The Second Affiliated Hospital to Xiamen Medical College	
Zong'en Gao	Department of Neurology	Shengli Oilfield Central Hospital	
Dongsheng Ju	Department of Neurology	Songyuan Jilin oil Field Hospital	
Cunfeng Song	Department of Interventional Neuroradiology	Liao Cheng the third people's hospital	
Jinggang Xuan	Department of Neurology	The First People's Hospital of Changzhou	
Feng Zhou	Department of Neurology	Taiyuan Central Hospital	
Qing Shi	Department of Neurology	Affiliated Jiangmen Traditional Chinese Medicine Hospital of Ji'nan University	
Jun Luo	Department of Neurology	Sichuan Mianyang 404 Hospital	
Yan Liu	Department of Neurology	JingJiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University	
Zaiyu Guo	Department of Neurosurgery	Tianjin TEDA Hospital	
Tong Li	Department of Neurosurgery	The second Nanning People's Hospital	
Hongbo Zheng	Department of Neurology	West China Hospital, Sichuan University	
Linzhi Dai	Department of Neurosurgery	First Affiliated Hospital School of Medicine Shihezi University	
Junfeng Zhao	Department of Neurology	Siping Central People's Hospital	
Liqiang Gui	Emergency and Critical Stroke Ambulance Centre	Langfang Changzheng Hospital	
Xiaokun Geng	Department of Neurology	Beijing Luhe Hospital, Capital Medical University	
Yufeng Tang	Department of Neurology	Mianyang Central Hospital	
Congguo Yin	Department of Neurology	Hangzhou First People's Hospital	
Hua Yang	Department of Neurosurgery	The affiliated Hospital of Guizhou Medical University	



1 2

Supplemental Figure S1. Forest plots on the associations of EVT versus medical management with the efficacy (panel a) and safety outcomes (panel b) in the 4

#### 3 subgroups

4 P for interaction of treatment arms x 4 subgroups by the clinical and radiological severities are provided in the figure.

5 Abbreviations: NIHSS indicates National Institutes of Health Stroke Scale; MM, medical management; EVT, endovascular therapy; mRS, modified Rankin Scale; sICH,

6 symptomatic intracranial haemorrhage; ICH, intracranial haemorrhage.

ASPECTS regions	Lower NIHSS & Smaller Core (n=139)	Higher NIHSS & Larger Core (n=106)	Higher NIHSS & Smaller Core (n=130)	Lower NIHSS & Larger Core (n=80)	p value
Overall					
Internal capsule	99 (71.2)	73 (68.9)	95 (73.1)	44 (55.0)	0.04
Caudate nucleus	90 (64.8)	69 (65.1)	80 (61.5)	45 (56.3)	0.58
Lenticular nucleus	122 (87.8)	84 (79.3)	107 (82.3)	62 (77.5)	0.19
Insular ribbon	133 (95.7)	105 (99.1)	130 (100.0)	79 (98.8)	0.04
M1	79 (56.8)	80 (75.5)	75 (57.7)	58 (72.5)	0.01
M2	100 (71.9)	99 (93.4)	104 (80.0)	74 (92.5)	<0.001
M3	59 (42.5)	71 (67.0)	53 (40.8)	44 (55.0)	<0.001
M4	61 (43.9)	71 (67.0)	67 (51.5)	57 (71.3)	<0.001
M5	105 (75.5)	98 (92.5)	100 (76.9)	71 (88.8)	0.001
M6	61 (43.9)	72 (67.9)	55 (42.3)	44 (55.0)	0.001
Left hemisphere					
Internal capsule	27 (19.4)	50 (47.2)	66 (50.8)	9 (11.3)	< 0.001
Caudate nucleus	26 (18.7)	49 (46.2)	56 (43.1)	9 (11.3)	< 0.001
Lenticular nucleus	31 (22.3)	56 (52.8)	74 (56.9)	13 (16.3)	<0.001
Insular ribbon	34 (24.5)	70 (66.0)	88 (67.7)	16 (20.0)	<0.001
M1	15 (10.8)	57 (53.8)	49 (37.7)	15 (18.8)	<0.001
M2	22 (15.8)	67 (63.2)	69 (53.1)	15 (18.8)	<0.001
M3	14 (10.1)	50 (47.2)	31 (23.9)	8 (10.0)	< 0.001
M4	13 (9.4)	48 (45.3)	45 (34.6)	12 (15.0)	<0.001
M5	25 (18.0)	66 (62.3)	71 (54.6)	16 (20.0)	< 0.001
M6	15 (10.8)	48 (45.3)	35 (26.9)	10 (12.5)	< 0.001
Right hemisphere					< 0.001
Internal capsule	72 (51.8)	23 (21.7)	29 (22.3)	35 (43.8)	<0.001
Caudate nucleus	64 (46.0)	20 (18.9)	24 (18.5)	36 (45.0)	< 0.001
Lenticular nucleus	91 (65.5)	28 (26.4)	33 (25.4)	49 (61.3)	< 0.001
Insular ribbon	99 (71.2)	35 (33.0)	42 (32.3)	63 (78.8)	<0.001
M1	64 (46.0)	23 (21.7)	26 (20.0)	43 (53.8)	<0.001
M2	78 (56.1)	32 (30.2)	35 (26.9)	59 (73.8)	<0.001
M3	45 (32.4)	21 (19.8)	22 (16.9)	36 (45.0)	< 0.001
M4	48 (34.5)	23 (21.7)	22 (16.9)	45 (56.3)	< 0.001
M5	80 (57.6)	32 (30.2)	29 (22.3)	55 (68.8)	<0.001
M6	46 (33.1)	24 (22.6)	20 (15.4)	34 (42.5)	<0.001

Supplemental Table S1. Infarct locations by ASPECTS regions in the four subgroups stratified by NIHSS and infarct-core volume

2 Abbreviations: ASPECTS indicates Alberta Stroke Program Early Compute Tomography Score; NIHSS, National Institutes of Health Stroke Scale; M1, anterior middle cerebral artery cortex; M2, middle cerebral artery

3 cortex lateral to the insular ribbon; M3, posterior middle cerebral artery cortex and M4, M5, M6, anterior, lateral and posterior middle cerebral artery territory immediately superior to M1, M2 and M3.

1

Supplemental Table S2. Efficacy a	and safety outcomes in the 4 subgroups	. adjusting for variables unbalanced bet	ween the two treatment arms in each subgroup
Supplemental Table SEI Emedey a	and salety sates in the 4 subgroups	, adjusting for variables and alanced bet	ween the two treatment arms in cath subgroup

	Clinical-Radiological Matched Subgroups				Clinical-Radio	Adjusted p value for interaction <sup>e</sup>				
	(n=139)		Higher NIHSS & Larger Core (n=106)		Higher NIHSS & Smaller Core (n=	Lower NIHSS & Larger Core (n	Matched vs.	4		
			Adjusted treatment Effect p value (95% CI) <sup>b</sup>		Adjusted treatment Effect (95% CI) <sup>c</sup> p value		Adjusted treatment Effect p value (95% CI) <sup>d</sup>		Mismatched Subgroups	subgroups
Primary outcome										
90-day mRS	2.58 (1.40 to 4.77)	0.01	2.20 (1.02 to 4.75)	0.04	1.38 (0.74 to 2.58)	0.32	1.47 (0.66 to 3.29)	0.34	0.17	0.09
Secondary outcomes										
90-day mRS of 0-2	2.41 (1.46 to 3.99)	<0.001	NA	NA	4.71 (1.43 to 15.53)	0.01	1.22 (0.48 to 3.11)	0.68	0.73	0.75
Change in infarct core volume, mL	12.72 (-14.44 to 39.89)	0.36	-29.75 ( -67.79 to 8.30)	0.12	-9.16 ( -45.38 to 27.06)	0.62	-17.46 (-59.83 to 24.91)	0.41	0.37	0.21
Target-artery recanalization at 36h	1.93 (1.41 to 2.65)	<0.001	1.47 (1.13 to 1.92)	0.01	1.82 (1.34 to 2.49)	<0.001	2.88 (1.40 to 5.95)	0.01	0.97	0.15
Safety outcomes										
sICH within 48h	2.87 (0.59 to 14.03)	0.19	0.87 (0.15 to 5.13)	0.87	1.95 (0.20 to 19.09)	0.57	NA	NA	0.43	0.80
Any ICH within 48h	2.36 (1.38 to 4.03)	0.01	2.48 (1.09 to 5.67)	0.03	2.74 (1.58 to 4.77)	<0.001	3.30 (1.48 to 7.38)	0.01	0.50	0.77
Death within 90d	0.82 (0.26 to 2.64)	0.74	0.72 (0.34 to 1.50)	0.38	1.01 (0.49 to 2.05)	0.99	2.50 (0.83 to 7.52)	0.10	0.12	0.48
Decompressive hemicraniectomy during hospitalization	2.30 (0.21-24.68)	0.49	NA	NA	4.15 (0.48 to 35.95)	0.20	3.05 (0.81 to 11.50)	0.10	0.95	0.99

<sup>2</sup> <sup>a</sup>Adjusted for atrial fibrillation; <sup>b</sup>Adjusted for ASPECTS, infarct core volume and critically hypoperfused to infarct core ratio ≥1.8 and penumbra volume ≥15 mL; <sup>c</sup>Adjusted for diabetes; <sup>d</sup>Adjusted for ASPECTS and

3 wake-up stroke; <sup>e</sup>Adjusted for diabetes, atrial fibrillation, ASPECTS, infarct core volume, critically hypoperfused to infarct core ratio ≥1.8 and penumbra volume ≥15 mL and wake-up stroke.

4 Abbreviations: NIHSS indicates National Institutes of Health Stroke Scale; CI, confidence interval; mRS, modified Rankin Scale; sICH, symptomatic intracranial haemorrhage; ICH, intracranial haemorrhage; ASPECTS,

5 Alberta Stroke Program Early Compute Tomography Score.

1

Supplemental Table S3. Efficacy and safety outcomes in the 4 subgroups classified by a combination of NIHSS < 0	or ≥16 and infarct core volume < or ≥50mL
---	---

		Clinical-Radiological Matched Subgroups						Clinical-Radiological Mismatched Subgroups								p value for interaction		
	NIHSS <16 & core volume <70mL (n=98)			8)	NIHSS ≥16 & core volume ≥70mL (n=148)			NIHSS ≥16 & core volume <70mL (n=88)			NIHSS <16 & core volume ≥70mL (n=121)				Matched vs.	4		
	MM (n=47)	EVT (n=51)	Treatment Effect (95% CI)	р	MM (n=68)	EVT (n=80)	Treatment Effect (95% CI)	р	MM (n=42)	EVT (n=46)	Treatment Effect (95% CI)	р	MM (n=68)	EVT (n=53)	Treatment Effect (95% CI)	р	Mismatche	subg roup s
Primary outcome																		
90-day mRS	4 (3-5)	2 (2-4)	3.16 (1.52- 6.56)	0.01	5 (4-6)	4 (3-6)	1.73 (0.97- 3.10)	0.06	4 (3-6)	4 (3-6)	1.28 (0.61- 2.70)	0.51	4 (3-5)	3 (2-4)	1.48 (0.78- 2.80)	0.23	0.17	0.31
Secondary outcomes																		
90-day mRS of 0-2	9 (19.2)	29 (56.9)	2.97 (1.57- 5.60)	<0.001	3 (4.4)	15 (18.8)	4.25 (1.28- 14.06)	0.01	1 (2.4)	10 (21.7)	9.13 (1.22- 68.32)	0.01	13 (19.1)	15 (28.3)	1.48 (0.77- 2.84)	0.24	0.22	0.14
Change in infarct core volume, mL	58.9 (28.1- 112.9)	47.5 (10.9- 111.4)	2.74 (-28.33- 33.82)	0.86	109.6 (57.0- 170.7)	79.3 (27.9- 170.7)	-8.83 (- 42.5-24.9)	0.61	100.0 (29.9- 165.7)	51.2 (32.0- 132.6)	-24.11 (- 59.18- 10.96)	0.18	87.7 (43.3- 151.7)	86.3 (37.2- 134.0)	-0.38 (- 33.1-32.3)	0.98	0.66	0.87
Target-artery recanalization at 36h	16 (40.0)	38 (80.9)	2.02 (1.35- 3.03)	<0.001	17 (31.5)	57 (89.1)	2.83 (1.89- 4.23)	<0.001	15 (45.5)	38 (88.4)	1.94 (1.32- 2.87)	<0.001	19 (33.3)	36 (83.7)	2.51 (1.70- 3.71)	<0.0 01	0.88	0.53
Safety outcomes																		
sICH within 48h	1 (2.1)	4 (7.8)	3.69 (0.43- 31.81)	0.20	3 (4.4)	4 (5.0)	1.13 (0.26- 4.89)	0.87	0 (0.0)	2 (4.4)	4.57 (0.23- 92.62)	0.17	2 (2.9)	4 (7.6)	2.57 (0.49- 13.5)	0.25	0.53	0.81
Any ICH within 48h	9 (19.2)	25 (49.0)	2.56 (1.34- 4.91)	0.01	10 (14.7)	39 (48.8)	3.32 (1.79- 6.13)	<0.001	8 (19.1)	23 (50.0)	2.63 (1.32- 5.22)	0.01	12 (17.7)	26 (49.1)	2.78 (1.55- 4.98)	<0.0 01	0.84	0.96
Death within 90d	5 (10.6)	3 (5.9)	0.53 (0.13- 2.22)	0.39	23 (33.8)	21 (26.3)	0.73 (0.41- 1.32)	0.30	11 (26.2)	14 (30.4)	1.17 (0.53- 2.58)	0.70	6 (8.8)	12 (22.6)	2.77 (1.04- 7.37)	0.04	0.03	0.10
Decompressive hemicraniectomy during hospitalization	1 (2.1)	1 (2.0)	0.92 (0.06- 14.32)	0.95	4 (5.9)	8 (10.0)	1.70 (0.54- 5.40)	0.36	0 (0.0)	1 (2.2)	2.74 (0.11- 65.59)	0.34	3 (4.4)	7 (13.2)	2.99 (0.81- 11.03)	0.08	0.46	0.85

2 Abbreviations: NIHSS indicates National Institutes of Health Stroke Scale; MM, medical management; EVT, endovascular therapy; CI, confidence interval; mRS, modified Rankin Scale; sICH, symptomatic intracranial

3 haemorrhage; ICH, intracranial haemorrhage.

1

# Protocol and Statistical Analysis Plan

This trial protocol has been provided by the authors to give readers additional information about their work.

Protocol for: Study of Endovascular Therapy in Acute Anterior Circulation Large VeSsel Occlusive Patients with a LargE InfarCT Core: A Multicenter, Prospective, Open-Label, Blinded-Endpoint, Randomized Controlled Trial.

# Study of Endovascular Therapy in Acute Anterior Circulation Large VeSsel Occlusive Patients with a LargE InfarCT Core: A Multicenter, Prospective, Open-Label, Blinded-Endpoint, Randomized Controlled Trial (ANGEL-ASPECT)



# Protocol

Research team: Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Principal Investigator: Zhongrong Miao, MD, Professor of Neurology
Co- Principal Investigator: Zeguang Ren, Vitor Mendes Pereira
Protocol Version 6.0
Date: July 23, 2020

# **Table of Contents**

Protocol Signature Page	7
ANGEL-ASPECT Protocol Synopsis	8
Abbreviations	14
1. Background	16
1.1 The rational of EVT for large infarct core volume	16
1.2 Image modality to identify large infarct core volume	
1.3 ASPECTS and infarct core volume selection	19
1.4 EVT time window for large infarct core volume	19
1.5 ANGEL-ASPECT Trial design	20
2. Study objective	21
2.1 Primary objective	21
2.2 Secondary objective	21
3. Study design	21
3.1 Study design	21
3.2 Randomization	22
3.3 Follow-up schedule	22
3.4 Blind design	22
4. Participant selection	23
4.1 Inclusion Criteria	23
4.1.1 Center Inclusion Criteria	23
4.1.2 Clinical Inclusion Criteria	23
4.1.3 Neuroimaging Inclusion Criteria	24
4.2 Exclusion Criteria	24
4.2.1 Center Exclusion Criteria	24
4.2.2 Clinical Exclusion Criteria	24
4.2.3 Neuroimaging Exclusion Criteria	25
5. Imaging protocol	25
5.1 Baseline imaging	25
5.2 Intraoperative and follow-up imaging:	27
5.3 Imaging core lab	
3	

6.	Treatments	
	6.1 Endovascular Therapy (EVT)	28
	6.2 Best Medical Management (BMM)	29
7.	. Study endpoints	30
	7.1 Primary efficacy endpoint	
	7.2 Secondary efficacy endpoint	
	7.3 Primary safety endpoint	
	7.4 Secondary safety endpoint	31
8.	Data collection and Study procedure	31
	8.1 Screening and Inclusion	31
	8.2 Data to be collected during procedure	
	8.3 Post Treatment (Through Hospital Discharge)	
	8.4 Follow-up Visit at Day 30 ( $\pm$ 3), Day 90 ( $\pm$ 7) and 12 Months ( $\pm$ 14 days)	
	8.5 Unscheduled Follow-up Visit	
	8.6 Schedule of activities and assessments	35
9.	. Study risk pre-assessment and risk management	
	9.1 Monitoring of adverse events	
	9.2 Definitions of adverse events	
	9.2.1 Adverse event (AE)	
	9.2.2 Serious adverse event (SAE)	
	9.3 Recording of adverse events	
	9.4 Causal relationship between adverse events and study:	
	9.5 Obligation of the investigator regarding safety reporting	37
	9.5.1 Adverse events	37
	9.5.2 Serious adverse event	
	9.5.3 Follow-up and risk management	
1	0. Statistical Analysis	
	10.1 Sample size estimation	
	10.2 Data collection and entry	
	10.2.1 Paper-based CRF filled out by investigator	
	10.2.2 Data entry to the EDC system by CRC	

	10.2.3 Submission to the EDC system after the approval of investigator	40
	10.2.4 Data monitoring and query by CRA via EDC	40
	10.2.5 Data exportation from the EDC system	40
1	10.3 Statistical considerations	40
	10.3.1 Analysis sets	40
	10.3.2 Statistical considerations	41
1	10.4 Interim analysis	42
11.	. Ethical standards	43
1	11.1 Ethical standards	43
1	11.2 Law and regulations	44
1	11.3 Informed consent	44
1	11.4 Institutional review board/institutional ethics committee (IRB/IEC)	44
12.	. Confidentiality and publication of research findings	45
13.	. Study Organization	45
1	13.1 Constitution	45
1	13.2 Site training and certification	47
14.	. Study monitoring and quality assurance control	48
1	14.1 Responsibilities of the investigator(s)	48
1	14.2 Study monitoring	48
15.	. Data retention	49
16.	. Data Security Monitoring	49
17.	. Registration and Publication	50
1	17.1 Registration of study summary and results	50
1	17.2 Publication of study results	50
18.	. Ownership and use of data	51
1	18.1 Ownership of the data	51
1	18.2 Use of collected data	51
19.	. Funding and conflict of interest	51
20.	. Reference	52
21.	. Appendix	55
A	Appendix Table 1. Modified Rankin Scale	55

Appendix Table 2. Extended Treatment In Cerebral Ischemia (eTICI) Scale	56
Appendix Table 3. National Institute of Health Stroke Scale (NIHSS)	57
Appendix Table 4. EuroQoL 5D-5L	61
Appendix Table 5. Heidelberg bleeding classification	63
Appendix Table 6. Alberta Stroke Program Early CT Score (ASPECTS)	64

# **Protocol Signature Page**

I have read this protocol and agree to adhere to the requirements.

By signing this document we confirm that the clinical study will be conducted in accordance with the protocol and all applicable laws and regulations including, but not limited to, the International Conference on Harmonisation Guideline for Good Clinical Practice (GCP) and the ethical principles that have their origins in the Declaration of Helsinki.

Clinical Site

Site Principal Investigator Signature

Date

Study of Endovascular Therapy in Acute Ant Circulation Large Vessel Occlusive Patients with Large Infarct Core: A Multicenter, Prospective, O	th a				
Official Title Large Infarct Core: A Multicenter, Prospective, O	nen-				
	Large Infarct Core: A Multicenter, Prospective, Open-				
Label, Blinded-Endpoint, Randomized Contro	olled				
Trial					
Acronym ANGEL-ASPECT					
Sponsor Beijing Tiantan Hospital, Capital Medical Univers	ity				
Study Centers ~50 centers in China					
Best medical management (BMM) combined	with				
	endovascular Therapy (EVT) might be superior to				
Statement of Hypothesis BMM alone in acute anterior circulation large v	BMM alone in acute anterior circulation large vessel				
occlusive (LVO) patients with a large infarct core.	occlusive (LVO) patients with a large infarct core.				
To evaluate if acute ischemic stroke patients	To evaluate if acute ischemic stroke patients with				
	anterior circulation LVO and large infarct core at 0-24				
Primary hours after stroke onset have improved neurolo	gical				
objective         functional outcomes when treated with BMM	plus				
Study EVT compared to BMM alone.					
<b>Objectives</b> To assess if acute ischemic stroke patients with ant	erior				
Secondary circulation LVO and large infarct core at 0-24 h	ours				
after stroke onset have increased risk of symptom	natic				
objective intracranial hemorrhage (sICH) when treated	with				
BMM plus EVT compared to BMM alone.					
Multicenter, Prospective, Randomized, Open-1	abel,				
Study settings Blinded End-point (PROBE) design					
Study settings	d on				

# ANGEL-ASPECT Protocol Synopsis

		randomization system to receive BMM plus EVT or					
		BMM alone.					
		A total of 488 patients are planned to be enrolled.					
		Interim analysis will take place when 1/2 (244 cases)					
Sample Size		and 3/4 (366 cases) have completed 3-month follow-					
		up.					
	Primary Endpoint	90 days (±7 days) modified Rankin Scale (mRS)					
		(1) 90 days (±7 days) mRS 0-2					
17 6 <b>6</b> *		(2) 90 days (±7 days) mRS 0-3					
		(3) 36 hours ( $\pm 12$ hours) NIHSS 0-1 or decrease $\geq 10$					
Efficacy	Secondary	from baseline					
Endpoints		(4) Infarct core volume change from baseline, at 7					
	Endpoints	days (±1 day) or at discharge assessed with NCCT					
		or at 36 hours (±12 hours) assessed with MRI					
		(5) 36 hour (±12 hours) target artery recanalization					
		rate assessed with CTA or MRA					
	Primary	Rate of sICH within 48 hours from randomization					
	Safety	(Heidelberg Bleeding Classification)					
	Endpoint						
Safaty		(1) All-cause mortality within 90 days ( $\pm$ 7 days)					
Safety	Secondary	(2) Any intracranial hemorrhage within 48 hours from					
Endpoints	· ·	randomization (Heidelberg Bleeding					
	Safety	Classification)					
	Endpoints	(3) Decompressive hemicraniectomy during					
		hospitalization					
	Inclusion	Center Inclusion Criteria					
Participants		(1) Equipped with emergency department and					
	Criteria	neurology department for stroke patients					

(2	) Equipped with stroke team operating 24/7
(3	) Capable of EVT and intravenous (IV)
	thrombolysis for acute ischemic stroke patients
С	linical Inclusion Criteria:
(1	) Age 18-80 years
(2	) Presenting with symptoms consistent with acute
	ischemic stroke
(3	) Pre-stroke mRS score 0-1
(4	) NIHSS score 6-30 at the time of randomization
(5	) Randomization can be finished within 24 hours
	from stroke onset (stroke onset time is defined as
	last known well time)
(6	) Informed consent signed
Ν	euroimaging Inclusion Criteria:
(1	) CTA or MRA proven occlusion of the Internal
	Carotid Artery (ICA) terminus or M1 segment of
	Middle Cerebral Artery
(2	) Imaging evidence of low Alberta Stroke Program
	Early CT Score (ASPECTS) (based on non-
	contrast CT) or large infarct Core (defined as rCBF
	<30% on CT perfusion or ADC<620 $\times$ $10^{-6}$ mm²/s
	on MRI) fulfilling one of the following criteria:
	1) ASPECTS 3–5
	2) ASPECTS >5 (6-24 h) with infarct core volume
	70-100 ml
	3) ASPECTS <3 with infarct core volume 70-100
	ml
(3	) Mismatch ratio on CT perfusion or MRI (Tmax>6s
	volume / Ischemic core volume) >1.2
	· ·

	Center Exclusion Criteria
	(1) Centers in which the number of acute ischemic
	stroke cases treated with endovascular procedures
	are less than 20 per year;
	(2) Centers unable to comply with the research
	protocol
	Clinical Exclusion Criteria
	(1) Females who are pregnant, or those of childbearing
	potential with positive urine or serum beta Human
	Chorionic Gonadotropin test
	(2) Known severe allergy (more severe than skin rash)
	to contrast agents uncontrolled by medications
	(3) Refractory hypertension that is difficult to control
Exclusion	by medication (defined as persistent systolic blood
Criteria	pressure >185 mmHg or diastolic blood
	pressure >110 mmHg)
	(4) Known hemorrhagic tendency (including but not
	limited to): Baseline platelet count $< 100 \times 10^{9}/L$ ;
	Heparin was administered within 48 hours with
	aPTT≥35s; on anticoagulant therapy with warfarin
	and International Normalized Ratio (INR) > 1.7
	(Patients with no history or suspected
	coagulopathy do not need to wait for laboratory
	results of INR or aPTT prior to enrollment)
	(5) Parenchymal organ surgery and biopsy were
	performed in the past one month
	(6) Any active bleeding or recent bleeding
	(gastrointestinal bleeding, urinary bleeding, etc.)

		in the past one month
		(7) Undergoing hemodialysis or peritoneal dialysis;
		Known severe renal insufficiency with glomerular
		filtration rate <30 ml/min or serum creatinine >220
		mmol/L (2.5mg/dl)
		(8) Brain tumor (with mass effect)
		(9) The expected survival time is less than 1 year (such
		as comorbidity with malignant tumor, serious heart
		and lung diseases, etc.)
		(10)Participation in other interventional randomized
		clinical trials that may confound the outcome
		assessment of the trial
		(11)Other circumstances that the investigator considers
		inappropriate for participation in the trial or that
		may pose significant risk to the patient (such as
		inability to understand and/or follow the study
		procedures and/or follow up due to mental
		disorders, cognitive or emotional disorders)
		Neuroimaging Exclusion Criteria
		(1) Midline shift or herniation, mass effect with
		effacement of the ventricles
		(2) Evidence of acute intracranial hemorrhage
		(3) Acute bilateral strokes or multiple intracranial
		vessel occlusion
		BMM plus EVT
Treatment	Study Arm	prop
Allocation	Control	
	Arm	BMM alone
	•	

Follow-up schedule	Study visits will take place on the day of randomization, at 36 hours ( $\pm$ 12 hours), 7 days ( $\pm$ 1 day)/at discharge whichever is earlier, 30 days ( $\pm$ 3
	days), 90 days ( $\pm$ 7 days) and 12 months ( $\pm$ 14 days).
Subgroup analysis	Subgroup analysis will be performed based on the
	following variables:
	(1) Age (< 70 years vs. ≥70 years)
	(2) Last known well to randomization time (< 6 h vs. $\geq$
	6 h)
	(3) Stroke severity before randomization (NIHSS<16
	vs. NIHSS≥16)
	(4) IV thrombolysis
	(5) Occlusion site (intracranial ICA vs. M1 segment)
	(6) ASPECTS score (< 3 vs. $\geq$ 3 points)
	(7) Infarct core volume (< 70ml vs. ≥70ml)
	(8) Etiological subtype of stroke (cardiac embolism vs.
	large artery atherosclerosis)
Study duration	August 2020 to October 2022 (enrolment completed
	October 2021)

# Abbreviations

ADC	Apparent Diffusion Coefficient
AE	Adverse Event
aPTT	Activated Partial Thromboplastin Time
ASPECTS	Alberta Stroke Program Early CT Score
BMM	Best Medical Management
CEC	Clinical Events Adjudication Committee
CI	Confidence Interval
CRA	Clinical Research Associate
CRC	Clinical research coordinator
CRF	Case Report Form
CSA	Chinese Stroke Association
СТ	Computer Tomography
СТА	Computed Tomography Angiography
СТР	Computed Tomography Perfusion Imaging
	DWI or CTP Assessment with Clinical Mismatch in the Triage of
DAWN	Wake-Up and Late Presenting Strokes Undergoing Neurointervention
	with Trevo
DEFUSE 3	Endovascular Therapy Following Imaging Evaluation for Ischemic
	Stroke 3
DICOM	Digital Imaging and Communications in Medicine
DSA	Digital Subtraction Angiography
DSMB	Data Safety Monitoring Board
DWI	Diffusion Weighted Imaging
ECG	Electrocardiogram
EDC	Electronic Data Capture
EQ-5D-5L	EuroQoL 5-Dimensions 5-Level questionnaire
eTICI	Expanded Thrombolysis in Cerebral Infarction
EVT	Endovascular Therapy
FAS	Full Analysis Set
FLAIR	FLuid Attenuated Inversion Recovery
GCP	Good Clinical Practice
GRE	Gradient Echo
GSR-ET	German Stroke Registry – Endovascular Treatment
ICA	Internal Carotid Artery
ICH	The International Council for Harmonisation of Technical
	Requirements for Pharmaceutical for Human Use
ICMJE	International Committee of Medical Journal Editors
IEC	Institutional Ethics Committee
INR	International Normalized Ratio

IRB	Institutional Review Board
ITT	Intention-To-Treat
IV	Intravenous
LICV	Large Infarct Core Volume
LLC	Limited Liability Company
LVO	Large Vessel Occlusive
MCA	Middle Cerebral Artery
MM	Medical Management
MRA	Magnetic Resonance Angiography
MRI	Magnetic Resonance Imaging
mRS	Modified Rankin Scale
NCCT	Non-contrast computed tomography
NCSS	Number Cruncher Statistical System
NIHSS	National Institute of Health stroke scale
NMPA	National Medical Products Administration
OR	Odd Ratio
PASS	Power Analysis and Sample Size
PPS	Per Protocol Set
PROBE	Prospective, Randomized, Open-label, Blinded End-point
PWI	perfusion weighted imaging
SAE	Serious Adverse Event
SAP	Statistical Analysis Plan
SAS	Safety Analysis Set
SELECT	Optimizing Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke
sICH	Symptomatic intracranial hemorrhage
THRACE	Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke
TICI	Thrombolysis In Cerebral Infarction
T-NICE	Tiantan Neuroimaging Center of Excellence
TOAST	Trial of ORG 10172 in Acute Stroke Treatment

## 1. Background

Large clinical trials on early and late window stroke patients have helped to establish the indications for endovascular treatment (EVT) of acute ischemic stroke (AIS) patients with large vessel occlusion (LVO).<sup>1,2</sup> The neuroimaging criteria upon which the trials have shown benefit includes patients presenting with Alberta Stroke Program Early CT Scores (ASPECTS) score  $\geq 6$  within 6 hours,<sup>3-7</sup> and patients meeting DWI or CTP Assessment with Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention with Trevo (DAWN) and Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke (DEFUSE 3) trial imaging criteria at 6-24 and 6-16 hours from time last seen well, respectively.<sup>8,9</sup> Since then, many clinical trials have undergone an expansion of the indications of EVT for AIS patients with LVO. Whether patients with large infarct core volume (LICV) are suitable for EVT is one of the unanswered questions.

#### 1.1 The rational of EVT for large infarct core volume

Several retrospective studies, prospective studies, and meta-analyses suggest that patients with LICV may benefit from EVT. The Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE) trial was one of the early randomized trials to enroll patients with ASPECTS<6.<sup>10</sup> A subgroup analysis of the THRACE trial showed that among 53 subjects with a diffusion-weighted imaging (DWI) volume of >70 ml, 12 (22.6%) patients of the EVT group had good clinical outcomes (mRS  $\leq$  2 at 90 days).<sup>11</sup> The prospective German Stroke Registry – Endovascular Treatment (GSR-ET) also showed that 22% of 152 thrombectomy patients with ASPECTS <6 achieved independence with mRS 0-2 at 90 days.<sup>12</sup> The Highly Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials (HERMES) collaboration pooled their data from six early window trials. It showed a benefit of EVT over control was observed in patients with ASPECTS 0–4 or DWI-determined infarct core volume  $\geq$  70 ml. Functional improvement (mRS 0-2 at 90 days)

rates in the EVT group compared with the control group were 25% vs. 14% and 30% vs.20%, respectively.<sup>13,14</sup>

In the Optimizing Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT) trial, the prespecified secondary analysis of 105 patients (of whom 62 received EVT) with ASPECTS  $\leq 5$  or CTP-determined ischemic core volume  $\geq 50$  ml showed that functional independence was achieved in 31% in the EVT group vs. 14% in the control group.<sup>15</sup> Incidence rates of death, neurologic decline, and symptomatic intracerebral hemorrhage (sICH) were similar in both groups. In addition, EVT was associated with less infarct growth (44 vs. 98 mL; p=0.006) and smaller final infarct volume (97 vs. 190 mL; p=0.001) compared to medical management (MM).

One meta-analysis including 17 studies and 1378 patients with ASPECTS 0–6 (1194 EVT, 184 MT) found that mRS 0–2 was achieved in 30.1% of cases after EVT and in 3.2% after MM (OR 4.76, p=0.01).<sup>16</sup> The marked lower rate in the MM group compared to previous RCTs (HERMES: 14%, SELECT: 14%) is likely due to the imbalance of baseline characteristics of the patients in these retrospective studies. For example, patients in the MM group were older (75 years vs 68.7 years), had higher NIHSS scores (19 vs. 18), lower rate of intravenous (IV) thrombolysis (47.8% vs. 56.8%) and longer symptom onset to admission time (130 min vs. 115 min). Successful recanalization (Thrombolysis in Cerebral Infarction (TICI) grade 2b–3) led to higher odds of mRS 0–2 than unsuccessful reperfusion (OR 5.2, p=0.001). Another pooled random-effect meta-analysis, including 12 studies of large core patients (ASPECTS <6 or ischemic core volume  $\geq$  50 ml), demonstrated higher functional independence (mRS 0–2) rates with EVT (25% vs 7%; pooled OR: 4.39, 95% CI: 2.53 to 7.64), and decreased mortality (23% vs. 33%; pooled OR: 0.53, 95% CI: 0.40 to 0.71).<sup>17</sup>

In a matched case-control study of 56 patients (28 pairs) with ICA, M1 and M2 occlusion and CTP-determined infarct core > 50mL, EVT led to higher rates of functional independence (90-day mRS 0-2, 25% vs 0%; p=0.04), and smaller final infarct volumes (87 vs 242 mL; p <0.001).<sup>18</sup> One control (4%) and two treatment patients (7%) developed a parenchymal hematoma type 2 (p>0.99). The rates of

hemicraniectomy (7% vs 21%; p=0.10) and 90-day mortality (29% vs 48%; p=0.75) were lower in the EVT arm. Sensitivity analysis for patients with a baseline infarct core volume greater than 70 mL (12 pairs) revealed a significant reduction in final infarct volumes (110 vs. 319 mL; p<0.001) but only a nonsignificant improvement in the overall distribution of mRS scores favoring the treatment group (p=0.18).

Interestingly, one observational cohort study included a consecutive sample of 170 patients with anterior circulation stroke and initial ASPECTS  $\leq 5$  (99 patients in the EVT group, 71 patients in the MM group). The study showed that clinical outcome after failed or incomplete EVT (TICI 0–2b) was significantly better compared to patients with MM only (median mRS 5, interquartile range 4–6 vs. 5–6, p=0.03). Failed EVT (TICI 0–2a) was not associated with a worse outcome than MM.<sup>19</sup>

#### 1.2 Image modality to identify large infarct core volume

Generally speaking, there are two imaging evaluation methods for large infarct core, one is a semi-quantitative evaluation based on CT/MRI-ASPECTS, and the other is a quantitative evaluation based on CTP/MRI with the aid of automated artificial intelligence software. ASPECTS is a widely accepted tool used to assess infarct volume. In general, ASPECTS < 6 is regarded as a "large core infarct." However, multiple studies have shown low interrater agreement with ASPECTS.<sup>20,21</sup> An inaccurate ASPECTS can misclassify patients between the EVT and control groups, weakening any trial conclusions. Quantitative determination of infarct core volume using CTP/MRI could compensate for poor inter-rater reliability in the interpretation of ASPECTS.

Notably, the correlation between the CTP/MRI-determined infarct core volume and ASPECTS is not well established. Therefore, the optimal imaging modality for evaluating patients with LICV in clinical trials remains to be explored. The subgroup analysis in a meta-analysis comparing outcomes between these two imaging modalities did not find significant heterogeneity in the results when LICV was defined based on ASPECTS or ischemic core volume of CTP.<sup>17</sup> While one study<sup>22</sup> found a good

correlation between ASPECTS and CTP/MRI volume, others found them to be discordant.<sup>15,17,23</sup> To expedite enrollment, this study allowed the use of non-contrast CT (NCCT)-ASPECTS and/or CTP/MRI imaging modalities to screen patients with LICV.

## 1.3 ASPECTS and infarct core volume selection

A recent meta-analysis of 17 studies and 1378 patients reported functional independence, or a mRS 0-2, was achieved by 37.7%, 33.3%, 22.1%, and 17.1% of patients with ASPECTS 6, 5, 4 and 0-4 respectively.<sup>16</sup> The studies by Mourand et al.<sup>24</sup> and Inoue et al.<sup>25</sup> showed favorable outcomes in between 16% and 20% of patients with ASPECTS 0–3 after EVT. Another meta-analysis showed that patients presenting with an ASPECTS 0-2 had better outcomes with MM instead of EVT.<sup>13</sup> The benefit of EVT declined with decreasing in ASPECTS, especially with ASPECTS < 3, because the infarct core volume was very large and there was less salvageable brain tissue, which might make EVT ineffective.<sup>13,26,27</sup> Therefore, this study limited the ASPECTS of enrolled patients to 3-5.

There is some debate about whether "large core" should be defined as 50ml vs. 70ml on CTP. In ANGEL-ASPECT, the infarct core volume > 70 ml was defined as LICV. Similar to patients with ASPECTS 0-2, patients with excessive infarct core volume may also be less likely to benefit from EVT. Previous studies showed a lack of benefit if CTP-determined core volume exceeded 100 ml and 150 ml.<sup>14,15</sup> Therefore, when patients were enrolled only based on the infarct core volume as assessed by CTP/MRI, this study limited the infarct core volume to 70 ml-100 ml.

#### 1.4 EVT time window for large infarct core volume

Patients in the hyperacute phase of stroke may exhibit an increased ASPECTS lesion growth from imaging to recanalization, suggesting a benefit of faster recanalization in these patients.<sup>28</sup> A meta-analysis by Cagnazzo et al. demonstrated that a shorter time from onset to reperfusion was associated with a higher probability of

functional independence after EVT in patients with ASPECTS 0–6.<sup>16</sup> The SELECT trial found that patients with LICV had a gradual decline in functional outcomes with prolonged treatment time, with a lower likelihood of benefit from EVT after 12 hours from symptom onset or time last seen well.<sup>15</sup> This suggested that for LICV patients, earlier EVT may be more beneficial. However, a recent meta-analysis found that patients with LICV did not show a significant difference in outcomes among studies reporting <6 hours, <12 hours, and <24 hours for stroke to EVT time windows.<sup>17</sup> This may be because most LICV patients presented in the early time window, reducing the power to detect a difference between early and late windows. The reason may also be that the efficacy of MM declines over time, thus preserving the efficacy of EVT. In this context, it is important to study whether EVT also benefits patients with LICV in the late time window, therefore the time window of ANGEL-ASPECT is 0-24 hours.

#### **1.5 ANGEL-ASPECT Trial design**

The ANGEL-ASPECT trial is a PROBE study initiated by researchers to explore the effectiveness and safety of EVT in patients with anterior circulation large vessel occlusion stroke with ASPECTS 3-5 or infarction core volume 70-100ml within 24 hours of symptom onset. The ANGEL-ASPECT trial allows multiple imaging modalities to screen for LICV patients, but at the same time imposes limitations on the range of ASEPCTS or infarct core volume. The purpose was to reduce the risk of EVT while enrolling as many LICV patients as possible. The primary image inclusion criteria of ANGEL-ASPECT was NCCT-ASPECTS 3-5, and the infarct core volume of 70 ml-100 ml was used as auxiliary inclusion criteria. Briefly, the inclusion criteria for LICV are: (1) If NCCT-ASPECTS is 3-5 and presentation is within 24 hours of onset, patients are enrolled without limitation of infarct core volume. (2) For NCCT-ASPECTS 0-2 and core infarction volume 70 ml-100 ml, patients are enrolled. (3) If NCCT-ASPECTS is >5 and between 6 to 24 hours from symptom onset, only patients with infarct core volume 70 ml-100 ml are enrolled.

Subgroup analysis will focus on age, LKW to randomization time, NIHSS score,

IV thrombolysis, occlusion site, ASPECTS, infarct core volume, and stroke etiology.

ANGEL-ASPECT is the only randomized controlled trial conducted in China for LICV patients thus far. The results of this trial will clarify whether EVT is effective and safe in Chinese patients with LICV.

## 2. Study objective

#### 2.1 Primary objective

To evaluate if acute ischemic stroke patients with anterior circulation LVO and large infarct core at 0-24 hours after stroke onset have improved neurological functional outcomes when treated with BMM plus EVT compared to BMM alone.

#### 2.2 Secondary objective

To assess if acute ischemic stroke patients with anterior circulation LVO and large infarct core at 0-24 hours after stroke onset have an increased risk of sICH when treated with BMM plus EVT compared to BMM alone.

## 3. Study design

#### 3.1 Study design

Multicenter, Prospective, Randomized, Open-label, Blinded End-point (PROBE) trial design (Figure 1).




Figure 1. Study design: Randomization Algorithm

#### **3.2 Randomization**

The random code will be generated by a central network randomization system with 24h real-time randomization online based on the simple randomization method. The researcher in each center will obtain the random code from the central network randomization system according to the enrollment order. Patients who meet the inclusion criteria and in whom written informed consent can be obtained, will be randomly assigned to the following treatment groups in a 1:1 ratio:

- BMM plus EVT group: patients will receive EVT with stent retriever or contact aspiration as first-line devices for thrombectomy plus BMM;
- BMM group: Patients will receive BMM alone.

#### **3.3 Follow-up schedule**

- Face-to-face visit: day of randomization, 36 hours (±12 hours), 7 days (±1 day) /at discharge whichever is earlier
- (2) Telephone visit: 30 days ( $\pm$ 3 days), 90 days ( $\pm$ 7 days), and 12 months  $\pm$ 14 days

#### 3.4 Blind design

(1) Only the patient and the treating physician are aware of the randomization

information, and the evaluation of information at baseline and in-hospital visits that relate to the study endpoints should be evaluated by an investigator who is not aware of the patient groups and actual treatment.

- (2) The primary endpoint visits are standardized visits conducted by trained third party personnel who are not aware of the patient's randomization assignment and their treatment. All follow-up calls will be recorded, and a follow-up report will be formed.
- (3) All imaging data related to the study will be collected for centralized interpretation. The images at each visit site will be interpreted independently by a core lab, and the readers will be unaware about the baseline, treatment received (except EVT angiography images), and prognosis.

### 4. Participant selection

#### 4.1 Inclusion Criteria

#### 4.1.1 Center Inclusion Criteria

- (1) Equipped with an emergency department and neurology department for stroke patients
- (2) Equipped with a stroke team operating on 24/7
- (3) Capable of endovascular therapy and IV thrombolysis for acute ischemic stroke patients

#### 4.1.2 Clinical Inclusion Criteria

- (1) 18 to 80 years of age
- (2) Presenting with symptoms consistent with an acute ischemic stroke
- (3) Pre-stroke mRS score 0-1
- (4) NIHSS score 6-30 at the time of randomization
- (5) Randomization can be finished within 24 hours of stroke onset (stroke onset time is defined as last known well time)
- (6) Informed consent signed by the patient or legally authorized representative

## 4.1.3 Neuroimaging Inclusion Criteria

- CTA or MRA proven occlusion of the Internal Carotid Artery (ICA) terminus or M1 segment of the Middle Cerebral Artery (MCA)
- (2) Imaging evidence of low ASPECTS (based on NCCT) or large infarct Core (defined as rCBF <30% on CT perfusion or ADC<620 ×10<sup>-6</sup> mm<sup>2</sup>/s on MRI) fulfill one of the following criteria:
  - 1) ASPECTS 3-5
  - 2) ASPECTS >5 (6h-24 h) with infarct core volume 70-100 ml
  - 3) ASPECTS <3 with infarct core volume 70-100 ml
- (3) Mismatch ratio on CT perfusion or MRI (Tmax>6s volume / Ischemic core volume) >1.2

#### 4.2 Exclusion Criteria

#### 4.2.1 Center Exclusion Criteria

- Centers in which the number of acute ischemic stroke cases treated with endovascular procedures are less than 20
- (2) Incapable of complying with the protocol to proceed with the research

## 4.2.2 Clinical Exclusion Criteria

- Females who are pregnant, or those of childbearing potential with positive urine or serum beta Human Chorionic Gonadotropin test
- (2) Known severe allergy (more than a rash) to contrast media uncontrolled by medication
- (3) Refractory hypertension that is difficult to be controlled by medication (defined as persistent systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg)
- (4) Known hemorrhagic tendency (including but not limited to): Baseline platelet count < 100×10<sup>9</sup>/L; Heparin was administered within 48 hours with aPTT≥35s; on anticoagulant therapy with warfarin and International Normalized Ratio (INR) > 1.7 (Patients with no history or suspected coagulopathy do not need to wait for laboratory results of INR or

aPTT prior to enrollment)

- (5) Parenchymal organ surgery and biopsy were performed in the past one month
- (6) Any active bleeding or recent bleeding (gastrointestinal bleeding, urinary bleeding, etc.) in the past one month
- (7) Undergoing hemodialysis or peritoneal dialysis; Known severe renal insufficiency with glomerular filtration rate <30ml/min or serum creatinine >220mmol/L (2.5mg/dl)
- (8) Brain tumor (with mass effect)
- (9) The expected survival time is less than 1 year (such as comorbidity with malignant tumor, advanced heart or lung disease, etc.)
- (10) Participation in another interventional randomized clinical trial that may confound outcome assessment of the study
- (11) Other circumstances that the investigator considers inappropriate for participation in the study or that may pose significant risks to patients (such as inability to understand and/or follow the study procedures and/or follow up due to mental disorders, cognitive or emotional disorders)

#### 4.2.3 Neuroimaging Exclusion Criteria

- (1) Midline shift or herniation, mass effect with effacement of the ventricles
- (2) Evidence of acute intracranial hemorrhage
- (3) Acute bilateral strokes or multiple intracranial vessels occlusions


# 5. Imaging protocol

#### 5.1 Baseline imaging

All researchers will be trained in the course of the imaging protocol, the use of RAPID software, participate in the network training, simulation test and examination of NCCT-ASPECTS before enrollment. The ASPECTS training and test are conducted through the online training system of the trial website (http://angel-aspect.org). Those

who pass the exam (accuracy rate more than 80%) will obtain the ASPECTS assessment qualification certificate and be qualified for imaging assessment. During imaging screening, researchers in the sub-center with imaging evaluation qualifications and two trained neuroradiologists from the trial team will conduct real-time online image evaluation of ASPECTS, occlusion site, infarct core volume to ensure the accuracy of the imaging assessment (Figure 2).

- (1) ASPECTS: All patients presenting within 24h of symptom onset will undergo a plain CT scan. After the preliminary screening of ASPECTS by trained clinicians in research centers, two dedicated clinicians from the trial team will conduct real-time online evaluation. When the ASPECT score reaches a consensus that is between 3 to 5, the patient is suitable for enrollment. NCCT-ASPECTS will be manually determined independently before RAPID ASPECTS<sup>®</sup> (version 5.0.4, iSchemaView, CA, USA) assessment.
- (2) Infarct core volume: The infarct core volume will be automatically evaluated by iSchemaView automated RAPID<sup>®</sup> software (version 5.0.4, iSchemaView, CA, USA), and the infarction core volume is defined as rCBF<30% based on CTP or ADC<620  $\times 10^{-6}$  mm<sup>2</sup>/s based on MRI. For patients who present with NCCT-ASPECTS 0-2 within 6 hours from symptom onset, if the infarct core volume is between 70ml and 100ml, then the patient is eligible for enrollment. If the infarct core volume is between 70ml and 100ml in an extended time window (6-24 hours) of stroke onset, the patient is also suitable for inclusion regardless of ASPECTS.
- (3) Target arterial occlusion: The site of arterial occlusion will be determined by CTA or MRA. Occlusion of the ICA or M1 segment of the MCA is suitable for enrollment. Patients with ipsilateral extracranial internal carotid artery occlusion or stenosis with the above artery occlusion will also be included in this trial. As a tandem lesion can be difficult to distinguish on CTA or MRA, patients with tandem lesion in the EVT group will be confirmed during angiography.



## Figure 2. Imaging evaluation workflow

## 5.2 Intraoperative and follow-up imaging:

- (1) Intraoperative imaging: In the EVT group, preoperative DSA will be required to determine the site of vascular occlusion and eTICI score,<sup>29</sup> and postoperative angiography will be required to evaluate the eTICI score. It is recommended to conduct NCCT or cone-beam CT immediately after EVT to exclude bleeding.
- (2) Imaging evaluation of hemorrhage: The NCCT scan 36 hours ( $\pm 12$  hours) after

randomization will be utilized as the main criterion to adjudicate hemorrhage, and the Heidelberg Bleeding Classification will be used for hemorrhage classification.<sup>30</sup>

- (3) Vascular imaging follow-up: Vascular imaging (CTA/MRA) will be conducted within 36 hours (±12 hours) h after randomization to determine vascular patency.<sup>31</sup>
- (4) Evaluation of postoperative infarct volume: The infarct core volume will be determined at 7 days (±1 day) or at discharge as assessed with NCCT or at 36 hours (±12 hours) assessed with MRI, and the infarct core volume will be determined manually by the imaging core lab using validated automated software.<sup>32</sup>

#### 5.3 Imaging core lab

The Tiantan Neuroimaging Center of Excellence (T-NICE) is the imaging core lab of this trial. During the period from patient presentation to discharge, all imaging data (CT, CTA, CTP, MRI, MRA, PWI, DSA) will be collected by CRO in DICOM format. All images will be quality controlled, rendered anonymous and sent to T-NICE for central adjudication. The final results will be reviewed and confirmed by the imaging assessment committee, and then input into the database.

# 6. Treatments

Patients meeting the eligibility criteria and signing the informed consent will be randomized. Patients randomized to the interventional arm will receive BMM plus EVT. Artery puncture should be performed within 1 hour of randomization. Patients randomized to the medical arm will receive BMM.

#### 6.1 Endovascular Therapy (EVT)

When the patient's condition permits, local anesthesia is the first choice for rapid initiation of puncture and endovascular therapy. Conscious sedation can be used, and intubation can be considered for patients at high risk of airway collapse. If the patient is expected to have poor intraprocedure cooperation, is at high risk of using sedation or if there are other airway conditions due to the patient's illness, general anesthesia should be used. Return to the Neuro-Intensive Care Unit (NICU) with intubation or not will be determined according to the procedural results.

Systemic heparinization is not recommended for preoperative and intraoperative treatment. Femoral artery is suggested for arterial puncture, and a long sheath, guiding catheter or balloon guide catheter can be used. Stent retriever (Solitaire, EMBOTRAP, Reco, Captor or other first-line stent retriever systems) and/or contact aspiration (Penumbra aspiration system or other first-line aspiration system) are recommended as the first-line choice for thrombectomy. If successful reperfusion (eTICI 2b50-3) is not achieved after routine thrombectomy, other techniques are allowed for rescue treatment, including replacement of thrombectomy technique, replacement of thrombectomy device, intra-arterial thrombolysis, balloon angioplasty or stent implantation, etc. The need for rescue treatment is defined (including, but not limited to, a decision made by the investigator based on intraprocedure conditions) as follows: three thrombectomy passes with the same device (stent retriever or aspiration catheter) without successful recanalization; Target vessels were successfully recanalized and reoccluded; Target vessel dissection or stenosis  $\geq$ 70%, with any degree of antegrade blood flow disturbance; New intraluminal/stent thrombolysis resulting in a decrease of eTICI score.

All the above procedures should be performed using devices approved by the National Medical Products Administration (NMPA) and should be performed in accordance with the approved intended use and operating instructions.

#### 6.2 Best Medical Management (BMM)

All enrolled patients should receive BMM in accordance with the recommendation of the "Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders" by the Chinese Stroke Association (CSA).<sup>33</sup> This includes IV thrombolysis therapy for patients meeting the guideline. Patients who meet criteria should receive IV thrombolysis therapy according to the guidelines. Patients who plan to undergo or are undergoing IV thrombolysis therapy can decide whether to terminate IV thrombolysis therapy in advance according to the investigator's judgment after enrollment. Patients who had completed IV thrombolysis prior to randomization are also eligible for inclusion in this study. All patients will be required to record the name, dosage and time of IV thrombolysis medication in detail. Antiplatelet agents are not recommended within 24 hours after IV thrombolysis unless the patient has undergone balloon dilatation or stent implantation, at which time the antithrombotic strategy is determined by the investigator. Based on the time window and infarct core volume for ANGEL-ASPECT, it is anticipated that most patients enrolled in ANGEL-ASPECT will not have received IV thrombolysis prior to randomization. Non-IV thrombolysis patients will be treated with aspirin, unless an indication for early anticoagulation is present.

# 7. Study endpoints

## 7.1 Primary efficacy endpoint

90 days (±7 days) modified Rankin Scale (mRS)

#### 7.2 Secondary efficacy endpoint

- (1) 90 days (±7 days) mRS 0-2
- (2) 90 days (±7 days) mRS 0-3
- (3) 36 hours ( $\pm 12$  hours) NIHSS 0-1 or decrease  $\geq 10$  from baseline
- (4) Infarct core volume change from baseline, at 7 days (±1 day) or at discharge assessed with NCCT or at 36 hours (±12 hours) assessed with MRI
- (5) 36 hour (±12 hours) target artery recanalization rate assessed with CTA or MRA

## 7.3 Primary safety endpoint

Rate of sICH within 48 hours from randomization (Heidelberg Bleeding Classification, Appendix 5)

## 7.4 Secondary safety endpoint

- (1) All-cause mortality within 90 days ( $\pm$ 7 days)
- (2) Any intracranial hemorrhage within 48 hours from randomization (Heidelberg Bleeding Classification)
- (3) Decompressive hemicraniectomy during hospitalization

# 8. Data collection and Study procedure

Investigator(s) should keep a record, the eligibility Case Report Form (CRF), of subjects who enter pre-study screening. The sub-center number must be indicated. The screening table will be used to analyze and determine whether the enrolled patients in different study sites are representative. Referring to the procedure manual and data collection guidelines, investigators should guarantee the input of CRF is precise, complete and timely, and answer the queries in time. Brain imaging which includes: CT, CTA, CTP, MRI (T1+T2+DWI+FLAIR+ADC+GRE-T2\*/SWI+MRA±PWI) and DSA will be collected as DICOM format. Laboratory results will be collected via photocopies of the reports.

## 8.1 Screening and Inclusion

- Basic data collection: hospital name, name of patient identification, age, sex, allergy to contrast agent.
- History of present event: time of onset (time of last known well), time of arrival at the hospital, type of onset, IV thrombolysis after onset (initial time, name and dose of the drug).
- Medical history and medication before onset

Medical history (smoking, drinking, hypertension, diabetes, dyslipidemia, cardiac arrhythmia, valvular heart disease, cardiac insufficiency, coronary atherosclerotic heart disease, peripheral arterial disease, TIA, cerebral infarction, cerebral hemorrhage, intracranial tumors), pre-stroke mRS;

Combination therapy: Antiplatelet drugs (aspirin, clopidogrel, cilostazol, prasugrel, ticagrelor, ticlopidine, etc.), anticoagulants (warfarin, dabigatran, rivaroxaban, apixaban, edoxaban, heparin, argatroban, etc.), statins (atorvastatin, pitavastatin, rosuvastatin, pravastatin, simvastatin, fluvastatin, etc.).

• Physical examination

Height and weight, blood pressure, pulse, neurological evaluation (NIHSS and Glasgow scale), 12-lead electrocardiogram (ECG).

• Emergency laboratory examinations

Emergency blood routine, emergency renal function, emergency liver function (transaminase), emergency coagulation, random blood glucose, etc.

• Imaging

A head CT is required to rule out hemorrhage and perform ASPECTS evaluation; a CTA or MRA is essential to confirm the site of artery occlusion; a CTP or MRI is required to calculate the infarct core volume

- All participants or his/her authorized representative need to sign a written informed consent form
- Included subjects will be randomized

# 8.2 Data to be collected during procedure

• General anesthesia with intubation or conscious sedation with local anesthesia at start of procedure

- Procedure times: groin puncture time, time of each pass finish, time of initial flow restoration, time of successful recanalization and the end of the procedure
- eTICI score: pre-procedure and post-procedure
- Details of procedure: Accessory and adjunctive devices used (guide catheter, guidewire, intermediate catheter, microcatheter), number and type of devices for thrombectomy, number of recanalization attempt deployments, rescue procedures with medications besides thrombectomy
- Medication during the procedure: heparin, tirofiban, alteplase, urokinase.
- Intraprocedural complications: Presence of vasospasm (time of onset, vessels involved, time resolved, treatment required), evidence of clot migration or embolization, dissection, perforation, etc.

## **8.3 Post Treatment (Through Hospital Discharge)**

A face-to-face observation will be performed at 36 hours ( $\pm 12$  hours) and 7 days ( $\pm 1$  day)/at discharge whichever is earlier after randomization.

- Brain imaging performed at 36 (±12) hours after randomization: CT/CTA or MRI/MRA.
- A physical exam, as well as clinical and neurological assessments, will be completed at 36 (±12) hours and 7 (±1) days/at discharge whichever is earlier after randomization. Data to be collected include: vital signs (blood pressure and heart rate), relevant concomitant medications (including antiplatelet, anticoagulant, and antihypertensive agents), significant findings from clinical assessment and physical exam (i.e. all new, worsening, or improved conditions), all significant neurological findings, NIHSS Score (both), mRS (7 days or discharge only), and adverse event (AE).
- Head CT evaluation is needed at 7 days  $(\pm 1 \text{ day})$  or at discharge whichever is earlier
- Laboratory examinations will be collected at 24 hours (±12 hours) and 7 days (±1 day) or at discharge whichever is earlier after randomization, including: blood routine, renal function, liver function, coagulation, fasting blood glucose, etc.

## 8.4 Follow-up Visit at Day 30 (±3), Day 90 (±7) and 12 Months (±14 days)

These follow-up evaluations can be performed via telephone if it's not convenient for an in-person visit at the investigational site. All subjects entered into the study will undergo a standard neurological assessment by experienced physicians who are blinded to treatment assignment. Data to be collected include:

- mRS
- Patient-reported functional health status and quality of life using EuroQoL 5-Dimensions 5-Level questionnaire (EQ-5D-5L)<sup>34</sup>
- Relevant concomitant medications
- Significant findings from clinical assessment and physical exam (i.e. all new, worsening, or improved conditions since discharge)

## 8.5 Unscheduled Follow-up Visit

If an unscheduled follow-up visit occurs after randomization at the investigational site during the study, the incidence of any new or unresolved AEs will be assessed. If the visit is due to a change in neurological status, NIHSS and mRS will be completed by a certified rater.

## 8.6 Schedule of activities and assessments

Measurements	Baseline	36-hour	7±1 day	30-day (±3	90-day	12-month ±14
		(±12 hours)	/at discharge	days) visit	(±7 days)	days visit
		visit	visit		visit	
Informed Consent	Х					
Inclusion/Exclusion	х					
Randomization	х					
Demographic characteristics	Х					
History of present illness	Х					
Past medical history	Х					
Relevant Concomitant Medications	х	Х	Х	Х	х	х
mRS	х		х	х	х	х
NIHSS	х	Х	Х			
Head CT	Х		x <sup>3</sup>			
CTA±CTP or	$\mathbf{x}^1$					
MRI*+MRA±PWI						
CT+CTA or MRI*+SWI+MRA		x <sup>2</sup>				
Carotid CTA/MRA/ultrasound		x <sup>4</sup>				
ASPECTS on CT	х					
Ischemic volume on CTP/DWI	Х	x <sup>5</sup>	x <sup>5</sup>			
Laboratory examinations	Х	х	Х			
Electrocardiogram	х					
TOAST			Х			
EQ-5D-5L scale				Х	Х	х
AE/SAE		Х	Х	Х	Х	х

<sup>1</sup> For all enrolled cases, CT+CTA+CTP examination will be the first choice before randomization

 $^{2}$  All the enrolled cases should be reviewed with multi-modal imaging 24-48 hours after randomization, and the imaging evaluation method should be the same as before randomization

<sup>3</sup> All enrolled cases should be examined by head CT at 7 days (±1 day) after randomization or at discharge whichever is earlier

<sup>4</sup> Only applicable to patients in the standard medical treatment group who did not undergo cervical angiography prior to randomization

<sup>5</sup> Based on head CT or MRI, determined by the core imaging laboratory

\*MRI sequence includes T1+T2+DWI+ADC+FLAIR sequence

ADC: apparent diffusion coefficient; AE: adverse event; ASPECTS: Alberta stroke program early computed tomography score; CT: computed tomography; CTA: computed tomography angiography; CTP: computed tomography perfusion; EQ-5D-5L: EuroQoL 5-Dimensions 5-Level questionnaire; FLAIR: fluid attenuated inversion recovery; MRA: magnetic resonance angiography; MRI: magnetic resonance imaging; mRS: modified Rankin scale; NIHSS: National Institutes of Health Stroke Scale; PWI: perfusion weighted imaging; SAE: serious adverse event; SWI: susceptibility weighting imaging; TOAST: Trial of ORG 10172 in Acute Stroke Treatment.

# 9. Study risk pre-assessment and risk management

## 9.1 Monitoring of adverse events

All AEs will be managed and reported in compliance with all applicable regulations and will be included in the final Clinical Study Report (CSR).

## 9.2 Definitions of adverse events

## 9.2.1 Adverse event (AE)

Adverse Events, as long as they occur from the first visit planned in the Clinical Trial Protocol/signature of the informed consent (i.e., occurring during the washout period) to the last visit planned in the protocol, are adverse medical events or deterioration of qualifying event. AEs include symptoms (ie, nausea, chest pain), signs (ie, tachycardia, liver enlargement) and abnormal laboratory results (ie, laboratory or ECG abnormalities). AEs can be classified as serious adverse events (SAEs) and non-serious AEs.

## 9.2.2 Serious adverse event (SAE)

A Serious adverse event refers to an event that :

- Results in death, or
- Is life-threatening, or

Note: The term "life-threatening" in the definition of "serious" refers to an event in which the patient is at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it was more severe.

 Requires inpatient hospitalization or prolongation of existing hospitalization, or

- Results in persistent or significant disability/incapacity, or
- Is a congenital anomaly/birth defect, or
- Is a medically important event

## 9.3 Recording of adverse events

Non-serious AE: Only some of the non-serious AEs will be collected from time of randomization throughout the treatment/follow-up periods to the Study Closure Visit. Other non-serious AEs are up to the investigator to decide whether to collect.

SAE: All SAEs will be collected and recorded.

## 9.4 Causal relationship between adverse events and study:

Attribution of: (1) Definite; (2) Probably; (3) Possibly; (4) Unlikely; (5) Not related; (6) Not applicable.

## 9.5 Obligation of the investigator regarding safety reporting

#### 9.5.1 Adverse events

All AEs will be recorded on the corresponding page(s) in the CRF. Whenever possible, symptoms should be grouped as a single syndrome or diagnosis. The Investigator should specify the date of onset, intensity, action taken with respect to the Investigational Product, corrective treatment/therapy given, outcome and his/her opinion about whether it is possible that the AE is caused by the study intervention, related to the index stroke, other cause, or intercurrent condition.

#### 9.5.2 Serious adverse event

For SAEs, the investigator must immediately take corresponding measures:

Immediately notify the representative of the Monitoring Team, send the signed and dated corresponding pages in the CRF to the representative of the Monitoring Team,

and attach a photocopy of all examinations conducted and the examination dates. For laboratory results, include the laboratory normal ranges. The contact information (name, address and fax number) of the representative is on the Clinical Trial Protocol. These measures should be completed no later than **24 hours** after SAE.

Care should be taken to ensure that the patient's identity is protected and the patient's identifiers in the Clinical Trial are properly noted on all copies of source documents provided to the Sponsor.

#### 9.5.3 Follow-up and risk management

The Investigator should take all appropriate measures to ensure the safety of the patients.

Screening of subjects should strictly follow the inclusion and exclusion criteria of the study. If an AE occurs during the study period, relevant evaluations will be performed, including blood routine examination, coagulation, creatinine, hepatic function, renal function, arterial blood gas analysis, ultrasound and computer tomography. Targeted treatment and necessary consultation should be carried out in a timely manner. When addressing SAEs, it is important to make sure the patient's airway is clear, respiration, blood pressure and heart rate are stable.

Notably, the investigator should follow up the outcome of any AEs (clinical signs, laboratory values or other, etc.) until the patient's condition returns to normal or stabilizes. The follow-up will continue even if the patient withdraws from the clinical trial, and the patient will be interviewed by telephone or face-to-face at the scheduled visit time. The monitoring team may request additional visits and investigations.

## **10.** Statistical Analysis

#### 10.1 Sample size estimation

In this study, a multicenter, open, randomized, parallel control design method will be used. The primary measure of efficacy will be the mRS score at 90 days ( $\pm 7$  days) after enrollment <sup>38</sup> Protocol Version: 6.0 July 23, 2020 (considered as ordered variable). According to the literature data and clinical expert opinions, the parameters were set as follows: (1) The proportion of mRS score 0-6 in control group will be 3%, 4%, 10%, 17%, 16%, 12% and 38%, respectively; (2) The average treatment effect of EVT improves the outcome with the common OR value for improvement of mRS reaching 1.74; (3) Two Interim analysis are considered. The adjusted level  $\alpha$  is 0.050 and power 1- $\beta$  is 0.90. (4) The randomization will be allocated to the intervention and the control group in a 1:1 ratio. Based on these parameters, the sample size will be 219 in each group. Considering a 10% attrition rate, the final total sample size will be 488 patients, with 244 patients in each group.

Interim analysis will take place when 1/2 (244) and 3/4 (366) of patients will have completed 3-month follow-up." The corresponding significance levels based on the O'Brien & Fleming boundary are 0.003 (stage 1), 0.018 (stage 2) and 0.044 (stage 3, final analysis).

The PASS software (NCSS, LLC, version 11) was used to calculate the sample size.

#### 10.2 Data collection and entry

Paper-based CRF and electronic data capture (EDC) system will be used for data collection and input. All the content required by the protocol in the system must be filled. The unfilled content should be explained, and the reason needs to be marked in the EDC system.

#### 10.2.1 Paper-based CRF filled out by the investigator

Site investigators should use black or blue-black recording pens to fill out the paper-based CRF neatly and clearly to ensure that the data is clear and readable. If the paper-based CRF information needs to be modified, it should not be altered or overwritten. The correct information should be written next to the original information, signed and dated by the person who modified it. The clinical research monitor (Clinical Research Associate, CRA) will review the completeness and accuracy of the CRF and guide the investigator to make necessary corrections and supplements.

#### 10.2.2 Data entry to the EDC system by CRC

After the paper-based CRF is completed, the Clinical research coordinator (CRC) will

input the content of the paper CRF into the EDC system.

#### 10.2.3 Submission to the EDC system after the approval of the investigator

The paper-based CRF will be submitted after the investigator has approved it. After the data is submitted, all data revisions and feedback are carried out through the EDC system. If the EDC system has submitted a form that needs to be modified, contact the CRA of this center. After the CRA opens the form, the investigator can guide the CRC to modify the data in EDC system.

#### 10.2.4 Data monitoring and query by CRA via EDC

#### 10.2.5 Data exportation from the EDC system

After the data from the EDC system is exported to the database, it will be proofread by the data administrator. Obvious errors will be corrected by the data administrator. Other errors or missing values will be filled in the data query form, and the query form will be sent to the participating center for solutions through email, express, telephone or WeChat.

The participating centers are responsible for correcting the data in the EDC system after verifying the original data and related information. Site investigators must answer these queries by verifying or modifying relevant information or data.

#### **10.3 Statistical considerations**

This section is an overview of the statistical considerations. It provides the general specifications for the analysis of the data to be collected and presented in the CSR. A final Statistical Analysis Plan (SAP) will be issued prior to database lockdown and before code breaking. The SAP will define all "pre-specified, planned analyses."

All programming will be performed using SAS Version 9.4.

#### 10.3.1 Analysis sets

#### (1) Full Analysis Set (FAS):

Protocol Version: 6.0

Based on the principles of the Intent-to-Treat (ITT) analysis, all randomized subjects, either treated with medication or with EVT will be included in the FAS. The primary efficacy endpoint analysis of this study will be performed on the FAS.

#### (2) Per Protocol Set (PPS)

The PPS is a subset that includes all subjects who were treated with the treatment assignment to which they were randomized and there are no clinically meaningful deviations from the protocol. Severe deviations from the protocol will be defined during the data auditing process, including but not limited to the following:

1) The subject is not in line with the inclusion criteria.

2) There are other treatments that potentially confound the appraisal of efficacy of the planned treatment.

3) Poor compliance.

4) Follow-up interval exceeds the required time window.

Secondary analysis will be conducted on the PPS. If its result are not consistent with that of the FAS, a detailed analysis to examine the difference(s) will be required.

#### (3) Safety Analysis Set (SAS)

The SAS consists of all subjects who received treatment with at least one evaluation of the safety outcome.

#### 10.3.2 Statistical considerations

#### (1) Baseline characteristics comparisons

T-test or Wilcoxon rank sum test will be used for comparison between continuous variables, and Chi-squared tests, Fisher's exact test or Wilcoxon sum rank test will be used for comparison between categorical variables.

#### (2) Efficacy Analysis

Primary efficacy endpoint: Based on an ITT basis, an ordinal logistic regression model is used to calculate the common odds ratio between the two treatment groups. All statistics will be two-sided with p<0.05 considered significant.

Secondary Efficacy Analyses: Endpoints including the 90-day mRS 0-2 will be analyzed using a binary logistic regression model. The infarct core volume change from baseline will be analyzed using student t-test or Wilcoxon rank sum test as appropriate.

#### (3) Safety Analysis

Safety events in the two treatment groups will be described based on the SAS dataset. Logistic regression will be used to compare the differences in safety endpoints such as intracranial bleeding events between the two groups. Chi-square test and Fisher's exact test will be used to compare the differences in the incidence of AEs and SAEs between the two groups.

#### (4) Subgroup analysis

The mRS at 90 days will be presented for each level of the covariates listed below:

- (1) Age (< 70 years vs.  $\geq$ 70 years)
- (2) Last known well to randomization time (< 6 h vs.  $\geq$  6 h)
- (3) Stroke severity before randomization (NIHSS<16 vs. NIHSS>16 points)
- (4) IV thrombolysis or not
- (5) Occlusion site (intracranial ICA vs. M1 segment)
- (6) ASPECTS (< 3 points vs.  $\geq$ 3 points)
- (7) Infarct core volume (< 70ml vs.  $\geq 70$ ml)
- (8) Etiological subtype of stroke (cardiac embolism vs. large artery atherosclerosis)

#### 10.4 Interim analysis

Interim analysis will take place when 1/2 (244 cases) and 3/4 (366 cases) have completed 3-month follow-up. The O'Brien-Fleming boundaries will be used at the interim analysis as follows:

There are no established techniques for the assessment of interim trial efficacy boundaries using an ordinal logistic regression model (proportional odds model). Instead, we will revert to a simple dichotomous analysis of the mRS score at 0-2 defined at 90 days from randomization. The Z-statistic for this analysis shall be derived from the normal approximation of the binomial distribution as an unadjusted two-sample test of proportions. For a RCT comparing two treatment groups with respect to a binary outcome and two interim analysis, corresponding significance levels based on the O'Brien & Fleming boundary are 0.003 (stage 1), 0.018 (stage 2) and 0.044 (stage 3, final analysis).

With the result of the interim analysis, the DSMB will make the decision to continue or halt the study according to the test boundaries. The study will stop prematurely for futility if the result from the interim analysis indicate that an effective conclusion with the current sample size can't be achieved. Premature stopping for early success will be achieved if the interim analysis result proves the effect of the intervention arm at significance level. Otherwise, the study will be continued until the predefined termination date. In interim analysis, the final sample size can be adjusted if the estimation of the primary outcome is drastically different from the actual data.

# 11. Ethical standards

#### 11.1 Ethical standards

This Clinical Trial will be conducted in accordance with the principles set by the 18th World Medical Assembly (Helsinki, 1964) and all applicable amendments by the World Medical Assemblies and the ICH guidelines for Good Clinical Practice. Prior to initiating the study, each site will obtain Institutional review board (IRB) or institutional ethics committee (IEC) approval for the protocol, informed consent forms and material used to recruit subjects. Before each subject is enrolled, the investigator is responsible for fully and comprehensively introducing the purpose, procedures and possible risks of the study to the patient or his/her agent, signing a written informed consent form, and informing the patient that he/she has the right to withdraw from this study at any time. The informed consent should be kept as a clinical study document for future reference. The personal privacy and data confidentiality of subjects will be protected during the study process.

#### 11.2 Law and regulations

This Clinical Trial will be conducted in compliance with all international laws and regulations, Chinese laws and regulations, as well as any applicable guidelines.

#### 11.3 Informed consent

The Investigator/sub-investigator should fully inform the patient of all pertinent aspects of the Clinical Trial, including the written information approved/preferred by the Ethics Committee (IRB/IEC). The Informed Consent Form used by the Investigator for obtaining the patient's informed consent must be reviewed and approved by the Sponsor and then submitted to the Ethics Committee (IRB/IEC) for approval.

All participants should be informed to the fullest extent possible about the study, in language and terms they are able to understand. Prior to a patient's participation in the Clinical Trial, an informed Consent Form should be signed and dated by the patient or by the patient's legal representative and by the person who conducted the informed consent discussion. A copy of the signed and dated Informed Consent Form will be provided to the patient.

#### 11.4 Institutional review board/ Institutional ethics committee (IRB/IEC)

The Investigator or the Sponsor must submit this Clinical Trial Protocol to the appropriate Ethics Committee (IRB/IEC), and the Ethics Committee is required to forward to the Sponsor a copy of the written approval/favorable opinion signed and dated by the Chairman with Ethics Committee (IRB/IEC) composition.

The Clinical Trial (study number, Clinical Trial Protocol title and version number), the documents reviewed (Clinical Trial Protocol, Informed Consent Form, Investigator's Brochure, Investigator's CV, etc.), the list of voting members along with their qualification and the date of the review should be clearly stated on the written (IRB/IEC) approval.

During the Clinical Trial, any amendment or modification to the Clinical Trial Protocol 44 should be submitted to the Ethics Committee (IRB/IEC). It should also be informed of any event likely to affect the safety of patients or the continued conduct of the Clinical Trial, in particular any change in safety. All updates to the Investigator's Brochure will be sent to the Ethics Committee (IRB/IEC). If requested, an annual progress report, as well as final summary of the Clinical Trial's outcome at the end of the Clinical Trial, will also be sent to the Ethics Committee (IRB/IEC).

# 12. Confidentiality and publication of research findings

The principal investigator has complete intellectual property rights. The entire research process and data analysis process will strictly protect the patient's information. Publication of the results of this trial will be governed by the policies and procedures developed by the Executive Committee. The trial results will be published as soon as possible after database lockdown. This trial will produce detailed data on treatment effects, medical care, and outcomes. Biostatisticians will be consulted to ensure that it is impossible to uniquely identify any participant. Diskettes with the data in comma-delimited text format, along with a data dictionary in a text file, will be sent to interested parties.

# 13. Study Organization

# **13.1** Constitution

## • The steering committee

- ✓ The steering committee will provide scientific and strategic direction for the trial and will have overall responsibility for its design, execution, and publication.
- ✓ The steering committee will also be responsible for ensuring that study execution and management are of the highest quality.

- ✓ It will approve the protocol and the operational guidelines of the trial prior to its commencement.
- The steering committee will meet regularly by teleconference or face-to-face meetings to discuss and report the progress of the study.
- ✓ The composition of the steering committee and its responsibilities are described in a charter which will be finalized before the start of the trial.

## • Executive committee

The executive committee is responsible for reviewing the status of the trial and available blinded data and will take appropriate actions regarding the conduct of the study. Executive Committee meetings will be organized to make major decisions. The composition of the Executive Committee and its responsibilities are described in a charter which will be finalized before the start of the trial.

#### • Data safety and monitoring board (DSMB)

The DSMB will meet regularly and monitor the study progress to ensure that the study meets the highest standards of ethics and patient safety. It is composed of Academic Members, including an independent statistician, who does not participate in the trial. A DSMB charter including membership, role and responsibilities will be approved by both the DSMB and the Executive Committee before the start of the trial.

Written recommendations and their rationale will be provided to the Chairs of the Steering Committee immediately after each DSMB meeting.

#### • Clinical event committee (CEC)

Clinical events and safety endpoint will be reviewed by CEC. A CEC charter including membership, role and responsibilities will be approved before the start of the trial by the CEC and the Executive Committee.

#### Imaging assessment committee

## 13.2 Site training and certification

The executive committee will provide training to their participating sites in Good Clinical Practice Guidelines and in some outcome assessments. Prior to initiation of patient enrollment, Site Investigators and Coordinators must complete all training programs.

The training programs that need to be completed are as follows:

- (1) Study procedures
- (2) ANGEL-ASPECT eligibility criteria
- (3) mRS
- (4) NIHSS
- (5) ASPECTS
- (6) iSchemaView automated RAPID® software
- (7) eTICI
- (8) TOAST etiology subtyping
- (9) Heidelberg Bleeding Classification
- (10) Collecting DICOM imaging data

Successful completion of the training program is mandatory before a site begins to enroll patients. A conference call will be held intermittently, and PI and key staff will be available to answer questions.

A detailed Manual of Procedures will serve as the primary document describing all study related procedures. It will serve as a guide to train clinical center personnel and will be updated periodically throughout the study on the ANGEL-ASPECT website, as needed. A system composed of members of the executive committee and CRA will be implemented for the clinical centers to ask any procedural questions by phone, fax, or e-mail. The ANGEL-ASPECT executive committee and monitoring committee will formulate answers in consultation with the Steering Committee and will periodically distribute to the participating centers a set of frequently asked questions and answers. The members of the executive committee will manage and conduct site visits to ensure the integrity and validity of the data on the CRF. During the trial period, each site should be visited at least once. If there are data quality problems or recruitment problems, it should be visited as needed.

# 14. Study monitoring and quality assurance control

#### 14.1 Responsibilities of the investigator(s)

The Investigator(s) should conduct the Clinical Trial in accordance with the Clinical Trial Protocol, The International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human Use (ICH) guidelines for Good Clinical Practice and the applicable regulatory requirements.

The Investigator is required to ensure compliance with all procedures required by the Clinical Trial Protocol and with all study procedures provided by the Sponsor (including security rules). The Investigator should provide reliable data and all information requested by the Protocol (with the help of the CRF, Discrepancy Resolution Form or other appropriate instruments) in an accurate and legible manner and ensure direct access to source documents by Sponsor representatives.

The Investigator may appoint other individuals as Sub-Investigators, as he/she thinks appropriate. All Sub-Investigators shall be appointed and listed in a timely manner and will be supervised by the Investigator. The Investigator will provide them a copy of the Clinical Trial Protocol and all necessary information. The Sponsor is responsible for taking all reasonable steps to ensure the proper conduct of the Clinical Trial Protocol as regards to ethics, Clinical Trial Protocol compliance, integrity and validity of the data on the CRF.

## 14.2 Study monitoring

The main responsibility of the monitoring team is to help researchers to ensure that

all aspects of clinical trials are ethical, scientific, professional, and standardized. According to the ICH guidelines for Good Clinical Practice (GCP), the Monitoring Team must check the CRF entries according to the source documents, except for the pre-identified.

The monitoring team will regularly contact each center through site visits or an online webinar, and will send inspectors to evaluate the research progress, adherence of the investigators and patients to the research protocol and to solve urgent problems. During these inspection visits, the inspector will work together with the site-investigators. The main aspects of inspection and monitoring are as follows (not exclusive): patient's informed consent, patient recruitment and follow-up, documentation and reporting of SAEs and data quality.

## **15.** Data retention

The double reviewed CRF and imaging data will be sent to the trial-designated data management center by CRAs. The person in charge of the data management center will check and sign the receipt form. The CRF will be kept by the research center after data entry is completed.

# 16. Data Security Monitoring

The data safety monitoring board (DSMB) is established to monitor the safety of participants, protect participants and ensure the integrity of the study. All AEs should be recorded, handled and tracked until they are properly resolved or stabilized. Any SAEs and unexpected events should be reported in a timely manner to the ethics committee in accordance with the relevant provisions, the competent department, the sponsor and the supervisory and administrative departments. The principal researchers should regularly review all AEs and set up meetings to assess the risks and benefits of the study if necessary. An independent data safety monitoring committee will be

appointed to review safety data, evaluate the effectiveness of data monitoring, and decide whether to make new proposal.

During the clinical trial, the data of the subjects should be collected anonymously in the CRF. The subjects are identified only by the subject number and the abbreviation of the initials. Due to safety reason and administrative instructions, when the subject's identity is leaked, researchers shall share the responsibility of confidentiality. In the informed consent form, the patient allows authorized research staff, ethics committee, and the authority to refer directly to the relevant original data on the case report (such as the patient's medical file case, booking records, the original laboratory records, etc.). The above personnel shall comply with occupational confidentiality rules and must keep all patient identity and medical information confidential.

# 17. Registration and Publication

#### 17.1 Registration of study summary and results

The study representatives will register a study summary in ClinicalTrials.gov (https: //clinicaltrials.gov) before the start of the study and update the summary as appropriate according to changes in the protocol or progress of the study. When the study is completed, the study representatives will register a study result without delay.

#### **17.2 Publication of study results**

When the study is completed, the study database will be closed within one month after the last scheduled follow-up date of the last included patient. A manuscript which describes the study and the answer to the primary research question will be submitted to a major clinical journal within 3 months from closure of the database. The study representatives will publish the results of the study after taking necessary measures (e.g., to prevent identification of specific study patients) to protect the human rights of patients and related parties or the rights and benefits of patients and related parties. The manuscript will be shared with the financial sponsor(s) one month before submission, but the financial sponsor(s) will have no influence on its contents. Author(s) of the paper are determined by the study representatives according to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://www.icmje.org/) by the International Committee of Medical Journal Editors (ICMJE). All authors should review and agree to the details of the paper prior to submission. The same goes for authors of conference presentations.

# 18. Ownership and use of data

## 18.1 Ownership of the data

The results, data, intellectual property rights, etc. obtained in this study belong to the study representatives and not to the patients. Whether the intellectual property rights of the study representatives belong to the individual or to the study institution is determined by the agreement of the participating hospital.

## 18.2 Use of collected data

The study Steering Committee determines whether to use the data obtained in this study (hereinafter, "study data") for further study conducted by the Study representatives or sub-investigators as a secondary analysis.

If the analysis is judged to be beyond the scope of secondary analysis, or if the study data is used by a person except for the study representatives or sub-investigators of this study, the Study Steering Committee prepares a separate protocol and conducts the study after undergoing ethical review in accordance with relevant laws, regulations and ethical guidelines for medical research on human subjects.

# **19.** Funding and conflict of interest

The study was funded by unrestricted grants from Covidien Healthcare

International Trading (Shanghai) Co., Ltd., Johnson & Johnson MedTech, Genesis

MedTech (Shanghai) Co., Ltd. and Shanghai HeartCare Medical Technology Co., Ltd.

# 20. Reference

- Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2019;50(12):e344-e418. DOI: 10.1161/STR.00000000000211.
- Turc G, Bhogal P, Fischer U, et al. European Stroke Organisation (ESO)- European Society for Minimally Invasive Neurological Therapy (ESMINT) guidelines on mechanical thrombectomy in acute ischemic stroke. J Neurointerv Surg 2019;11(6):535-538. DOI: 10.1136/neurintsurg-2018-014568.
- 3. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;372(1):11-20. DOI: 10.1056/NEJMoa1411587.
- Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015;372(11):1009-18. DOI: 10.1056/NEJMoa1414792.
- Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015;372(11):1019-30. DOI: 10.1056/NEJMoa1414905.
- 6. Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015;372(24):2296-306. DOI: 10.1056/NEJMoa1503780.
- Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 2015;372(24):2285-95. DOI: 10.1056/NEJMoa1415061.
- Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med 2018;378(1):11-21. DOI: 10.1056/NEJMoa1706442.
- 9. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med 2018;378(8):708-718. DOI: 10.1056/NEJMoa1713973.
- Bracard S, Ducrocq X, Mas JL, et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. Lancet Neurol 2016;15(11):1138-47. DOI: 10.1016/S1474-4422(16)30177-6.
- 11. Gautheron V, Xie Y, Tisserand M, et al. Outcome After Reperfusion Therapies in Patients With Large Baseline Diffusion-Weighted Imaging Stroke Lesions: A THRACE Trial (Mechanical Thrombectomy After Intravenous Alteplase Versus Alteplase Alone After Stroke) Subgroup Analysis. Stroke 2018;49(3):750-753. DOI: 10.1161/STROKEAHA.117.020244.
- Deb-Chatterji M, Pinnschmidt H, Flottmann F, et al. Predictors of independent outcome of thrombectomy in stroke patients with large baseline infarcts in clinical practice: a multicenter analysis. J Neurointerv Surg 2020;12(11):1064-1068. DOI: 10.1136/neurintsurg-2019-015641.

- Roman LS, Menon BK, Blasco J, et al. Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data. Lancet Neurol 2018;17(10):895-904. DOI: 10.1016/S1474-4422(18)30242-4.
- 14. Campbell BCV, Majoie C, Albers GW, et al. Penumbral imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-level data. Lancet Neurol 2019;18(1):46-55. DOI: 10.1016/S1474-4422(18)30314-4.
- 15. Sarraj A, Hassan AE, Savitz S, et al. Outcomes of Endovascular Thrombectomy vs Medical Management Alone in Patients With Large Ischemic Cores: A Secondary Analysis of the Optimizing Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT) Study. JAMA Neurol 2019;76(10):1147-1156. DOI: 10.1001/jamaneurol.2019.2109.
- Cagnazzo F, Derraz I, Dargazanli C, et al. Mechanical thrombectomy in patients with acute ischemic stroke and ASPECTS </=6: a meta-analysis. J Neurointerv Surg 2020;12(4):350-355. DOI: 10.1136/neurintsurg-2019-015237.
- Sarraj A, Grotta JC, Pujara DK, Shaker F, Tsivgoulis G. Triage imaging and outcome measures for large core stroke thrombectomy - a systematic review and meta-analysis. J Neurointerv Surg 2020;12(12):1172-1179. DOI: 10.1136/neurintsurg-2019-015509.
- Rebello LC, Bouslama M, Haussen DC, et al. Endovascular Treatment for Patients With Acute Stroke Who Have a Large Ischemic Core and Large Mismatch Imaging Profile. JAMA Neurol 2017;74(1):34-40. DOI: 10.1001/jamaneurol.2016.3954.
- Broocks G, Flottmann F, Schonfeld M, et al. Incomplete or failed thrombectomy in acute stroke patients with Alberta Stroke Program Early Computed Tomography Score 0-5 - how harmful is trying? European journal of neurology 2020;27(10):2031-2035. DOI: 10.1111/ene.14358.
- Nicholson P, Hilditch CA, Neuhaus A, et al. Per-region interobserver agreement of Alberta Stroke Program Early CT Scores (ASPECTS). J Neurointerv Surg 2020;12(11):1069-1071. DOI: 10.1136/neurintsurg-2019-015473.
- 21. van Horn N, Kniep H, Broocks G, et al. ASPECTS Interobserver Agreement of 100 Investigators from the TENSION Study. Clin Neuroradiol 2021. DOI: 10.1007/s00062-020-00988-x.
- Demeestere J, Garcia-Esperon C, Garcia-Bermejo P, et al. Evaluation of hyperacute infarct volume using ASPECTS and brain CT perfusion core volume. Neurology 2017;88(24):2248-2253. DOI: 10.1212/WNL.000000000004028.
- Sarraj A, Hassan AE, Grotta J, et al. Optimizing Patient Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT): A Prospective, Multicenter Cohort Study of Imaging Selection. Ann Neurol 2020;87(3):419-433. DOI: 10.1002/ana.25669.
- 24. Mourand I, Abergel E, Mantilla D, et al. Favorable revascularization therapy in patients with ASPECTS </= 5 on DWI in anterior circulation stroke. J Neurointerv Surg 2018;10(1):5-9. DOI: 10.1136/neurintsurg-2017-013358.
- 25. Inoue M, Olivot JM, Labreuche J, et al. Impact of diffusion-weighted imaging Alberta stroke program early computed tomography score on the success of endovascular reperfusion therapy. Stroke 2014;45(7):1992-8. DOI: 10.1161/STROKEAHA.114.005084.
- 26. Han M, Choi JW, Rim NJ, et al. Cerebral infarct volume measurements to improve patient selection for endovascular treatment. Medicine (Baltimore) 2016;95(35):e4702. DOI:

10.1097/MD.00000000004702.

- 27. Manceau PF, Soize S, Gawlitza M, et al. Is there a benefit of mechanical thrombectomy in patients with large stroke (DWI-ASPECTS </= 5)? European journal of neurology 2018;25(1):105-110. DOI: 10.1111/ene.13460.
- Broocks G, Rajput F, Hanning U, et al. Highest Lesion Growth Rates in Patients With Hyperacute Stroke. Stroke 2018:STROKEAHA118023457. DOI: 10.1161/STROKEAHA.118.023457.
- 29. Goyal M, Fargen KM, Turk AS, et al. 2C or not 2C: defining an improved revascularization grading scale and the need for standardization of angiography outcomes in stroke trials. J Neurointerv Surg 2014;6(2):83-6. DOI: 10.1136/neurintsurg-2013-010665.
- 30. von Kummer R, Broderick JP, Campbell BC, et al. The Heidelberg Bleeding Classification: Classification of Bleeding Events After Ischemic Stroke and Reperfusion Therapy. Stroke; a journal of cerebral circulation 2015;46(10):2981-6. DOI: 10.1161/STROKEAHA.115.010049.
- 31. Zaidat OO, Yoo AJ, Khatri P, et al. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke; a journal of cerebral circulation 2013;44(9):2650-63. DOI: 10.1161/STROKEAHA.113.001972.
- 32. Boers AM, Marquering HA, Jochem JJ, et al. Automated cerebral infarct volume measurement in follow-up noncontrast CT scans of patients with acute ischemic stroke. AJNR Am J Neuroradiol 2013;34(8):1522-7. DOI: 10.3174/ajnr.A3463.
- 33. Liu L, Chen W, Zhou H, et al. Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of ischaemic cerebrovascular diseases. Stroke Vasc Neurol 2020;5(2):159-176. DOI: 10.1136/svn-2020-000378.
- 34. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990;16(3):199-208. DOI: 10.1016/0168-8510(90)90421-9.

# 21. Appendix

## Appendix Table 1. Modified Rankin Scale

The modified Rankin Scale (mRS) is an ordinal scale ranging from 0 to 5, with higher scores indicating more severe disability. A score of 6 indicates death.

Category	Short description	Long description	
0	No symptoms	No symptoms	
1	Symptoms, no disability	Minor symptoms that do not interfere with lifestyle	
2	Slight disability	Slight disability, symptoms that lead to some restriction in lifestyle, but do not interfere with the patient's capacity to look after himself.	
3	Moderate disability	Moderate disability, symptoms that significantly restrict lifestyle and prevent totally independent existence	
4	Moderately severe disability	Moderately severe disability, symptoms that clearly prevent independent existence though not needing constant attention	
5	Severe disability	Severe disability, totally dependent patient requiring constant attention day and night.	
6	Death	Death	

eTICI grade	Short description	Long description
0	No perfusion	No antegrade flow beyond the point of occlusion
1	Limited reperfusion	Antegrade reperfusion past the initial occlusion, but limited distal branch filling with little or slow distal reperfusion
2a	<50% reperfusion	Antegrade reperfusion of less than half of the occluded target artery previously ischemic territory (eg, in 1 major division of the MCA and its territory)
2b	≥50% and <90% reperfusion	Antegrade reperfusion of more than half of the previously occluded target artery ischemic territory (eg, in 2 major divisions of the MCA and its territories)
2c	≥90% reperfusion	Near complete antegrade reperfusion of the previously occluded target artery ischemic territory, except for slow flow or distal emboli in a few distal cortical vessels
3	100% reperfusion	Complete antegrade reperfusion of the previously occluded target artery ischemic territory, with absence of visualized occlusion in all distal branches

# Appendix Table 2. Extended Thrombolysis In Cerebral Ischemia (eTICI) Scale

MCA: middle cerebral artery; eTICI; extended thrombolysis in cerebral ischemia scale

## Appendix Table 3. National Institute of Health Stroke Scale (NIHSS)

The NIHSS is an ordinal scale to evaluate the severity of stroke by assessing a patient's performance in the neurological exam. Scores range from 0 to 42, with higher scores indicating a more severe deficit. Administer stroke scale items in the order listed. Record performance in each category after each subscale exam. Do not go back and change scores. Follow directions provided for each exam technique. Scores should reflect what the patient does, not what the clinician thinks the patient can do. The clinician should record answers while administering the exam and work quickly. Except where indicated, the patient should not be coached (i.e. repeated requests to patient to make a special effort).

Instructions	Scale definition		
	0 = Alert; keenly responsive.		
	1 = Not alert; but arousable by minor		
1a. Level of consciousness. The investigator must choose a	stimulation to obey, answer, or respond.		
response if a full evaluation is prevented by such obstacles as	2 = Not alert; required repeated stimulation to		
an endotracheal tube, language barrier, orotracheal	attend, or is obtunded and requires strong or		
trauma/bandages. A 3 is scored only if the patient makes no	painful stimulation to make movements (not		
movement (other than reflexive posturing) in response to	stereotyped).		
noxious stimulation.	3 = Responds only with reflex motor or		
	autonomic effects or totally unresponsive,		
	flaccid and areflexic.		
1b. LOC Questions: The patient is asked the month and			
his/her age. The answer must be correct – there is not partial			
credit for being close. Phasic and stuporous patients who do			
not comprehend the questions will score 2. Patients unable to			
speak because of endotracheal intubation, orotracheal trauma,	0 = Answers both questions correctly.		
severe dysarthria from any cause, language barrier, or any	1 = Answers one question correctly.		
other problem not secondary to aphasia are given a 1. It is	2 = Answers neither question correctly.		
important that only the initial answer be graded and that the			
examiners not "help" the patient with verbal or non-verbal			
clues.			
1c. LOC Commands: The patient is asked to open and close			
the eyes and then to grip and release the non-paretic hand.			
Substitute another one step command if the hand cannot be	0 = Performs both tasks correctly.		
used. Credit is given if an unequivocal attempt is made but not	1 = Performs one task correctly.		
completed due to weakness. If the patient does not respond to	2 = Performs neither task correctly.		
command, the task should be demonstrated to him or her			
(pantomime), and the result scored (i.e. follows none, one or			

	1
two commands). Patients with trauma, amputation, or other	
physical impediments should be given suitable one-step	
commands. Only the first attempt is scored.	
2. Best Gaze: Only horizontal eye movements will be tested.	
Voluntary or reflexive (oculocephalic) eye movements will be	
scored, but caloric testing is not done. If the patient has a	
conjugate deviation of the eyes that can be overcome by	0= Normal.
voluntary or reflexive activity, the score will be a 1. If a patient	
has an isolated peripheral nerve paresis (CN III, IV or VI),	1= Partial gaze palsy; gaze is abnormal in one or both eyes, but forced deviation or total gaze paresis is not present.
score a 1. Gaze is testable in all aphasic patients. Patients with	
ocular trauma, bandages, preexisting blindness, or other	
disorder of visual acuity or fields should be tested with	2= Forced deviation; or total gaze paresis not
reflexive movements, and a choice made by the investigator.	overcome by the oculocephalic maneuver.
Establishing eye contact and then moving about the patient	
from side to side will occasionally clarify the presence of a	
partial gaze palsy.	
3. Visual: Visual fields (upper and lower quadrants) are tested	
by confrontation, using finger counting or visual threat, as	
appropriate. Patients may be encouraged, but if they look at the	
side of the moving finger appropriately, this can be scored as	0= No visual loss.
normal. If there is unilateral blindness or enucleation, visual	1= Partial hemianopia.
fields in the remaining eye are scored. Score 1 only if a clear-	2= Complete hemianopia.
cut asymmetry, including quadrantanopia, is found. If patient is	3= Bilateral hemianopia (blind including
blind from any cause, score 3.	cortical blindness)
Double simultaneous stimulation is performed in this case.	
If there is extinction, the patient receives a 1, and the results are	
used to respond to item 11.	
	0 = Normal symmetrical movements.
<b>4. Facial palsy:</b> Ask or use pantomime to encourage the	1= Minor paralysis (flattened nasolabial fold,
patient to show teeth or raise eyebrows and close eyes. Score	asymmetry on smiling)
symmetry of grimace in response to noxious stimuli in the	2= Partial paralysis (total or near-total
poorly response or non-comprehending patient. If facial	paralysis of lower face)
trauma/bandages, orotracheal tube, tape or other physical	3= Complete paralysis of one or both sides
barriers obscure the face, these should be removed to the	(absence of facial movement in the upper and
extent possible.	lower face).
<b>5. Motor arm:</b> The limb is placed in the appropriate position:	0= No drift; limb holds 90 (or 45) degrees for
extend the arms (palms down) 90 degrees (if sitting) or 45	full 10 seconds.
degrees (if supine). Drift is scored if the arm falls before 10	1= Drift; limb holds 90 (or 45) degrees, but
seconds. The aphasic patient is encouraged using urgency in	drifts down before full 10 seconds; does not
the voice and pantomime, but not noxious stimulation. Each	hit bed or other support.
limb is tested in turn, beginning with the non-paretic arm.	2= Some effort against gravity; limb cannot
Only in the case of amputation or joint fusion at the shoulder,	get to or maintain (if cued) 90 (or 45) degrees,
the examiner should record the score as untestable (UN), and	drifts down to bed, but has some effort against

-leader mite the surface of the distance	
clearly write the explanation for this choice.	gravity.
	3= No effort against gravity; limb falls.
	4= No movement.
	UN = Amputation or joint fusion: explain:
	5a = Left Arm.
	5b = Right arm.
	0= No drift; leg holds 30-degree position for
	full 5 seconds.
<b>6. Motor leg:</b> The limb is placed in the appropriate position:	1= Drift; leg falls by the end of the 5-second
hold the leg at 30 degrees (always tested supine). Drift is scored	period but does not hit bed.
if the leg falls before 5 seconds. The aphasic patient is	2= Some effort against gravity; leg falls to bed
encouraged using urgency in the voice and pantomime, but not	by 5 seconds, but has some effort against
noxious stimulation. Each limb is tested in turn, beginning with	gravity.
the non-paretic leg. Only in the case of amputation or joint	3= No effort against gravity; leg falls to bed
fusion at the hip, the examiner should record the score as	immediately.
untestable (UN), and clearly write the explanation for this	4= No movement.
choice.	UN = Amputation or joint fusion: explain:
	6a. Left Leg
	6b. Right Leg.
<b>7. Limb ataxia:</b> This item is aimed at finding evidence of a unilateral cerebellar lesion. Test with eyes open. In case of visual defect, ensure testing is done in intact visual field. The finger-nose-finger and heel-shin tests are performed on both sides, and ataxia is scored only if present out of proportion to weakness. Ataxia is absent in the patient who cannot understand or is paralyzed. Only in the case of amputation or joint fusion, the examiner should record the score as untestable (UN), and clearly write the explanation for this choice. In case of blindness, test by having the patient touch nose from extended arm position.	0= Absent. 1= Present in one limb. 2= Present in two limbs. UN = Amputation or joint fusion: explain:
8. Sensory: Sensation or grimace to pinprick when tested, or	
withdrawal from noxious stimulus in the obtunded or aphasic	
patient. Only sensory loss attributed to stroke is scored as	0= Normal; no sensory loss.
abnormal and the examiner should test as many body areas	1= Mild-to-moderate sensory loss; patients
(arms [not hands], legs, trunk, face) as needed to accurately	feels pinprick is less sharp or is dull on the
check for hemisensory loss. A score of 2, 'severe or total sensory	affected side; or there is a loss of superficial
loss', should only be given when a severe or total loss of	pain with pinprick, but patient is aware of
sensation can be clearly demonstrated. Stuporous and aphasic	being touched.
patients will, therefore, probably score 1 or 0. The patient with	2= Severe to total sensory loss; patient is not
brainstem stroke who has bilateral loss of sensation is scored 2.	aware of being touched in the face, arm and
If the patient does not respond and is quadriplegic, score 2.	leg.
Patients in a coma (item 1a=3) are automatically given a 2 on	
this item.	
uno iwin.	

-

	0= No aphasia; normal
	1= Mild-to-moderate aphasia; some obvious
	loss of fluency or facility of comprehension,
9. Best language: A great deal of information about	without significant limitation on ideas
comprehension will be obtained during the preceding sections	expressed or form of expression. Reduction of
of the examination. For this scale item, the patient is asked to	speech and/or comprehension, however,
describe what is happening in the attached picture, to name the	makes
items on the attached naming sheet and to read from the	conservation about provided materials
attached list of sentences. Comprehension is judged from	difficult or impossible. For example, in
responses here, as well as to all of the commands in the	conversation about provided materials,
preceding general neurological exam. If visual loss interferes	examiner can identify picture or naming card
with the tests, ask the patient to identify objects placed in the	content from patient's response.
hand, repeat, and produce speech. The intubated patient should	2= Severe aphasia; all communication is
be asked to write. The patient in a coma (item 1a=3) will	through fragmentary expression; great need
automatically score 3 on this item. The examiner must choose	for inference, questioning, and guessing by the
a score for the patient with stupor or limited cooperation, but a	listener. Range of information that can be
score of 3 should be used only if the patient is mute and	exchanged is limited; listener carries burden
follows no one-step commands.	of communication. Examiner cannot identify
ionows no one-step commands.	materials provided from patient response.
	3 = Mute, global aphasia: no usable speech or
	auditory comprehension.
<b>10. Dysarthria:</b> If patient is thought to be normal, an adequate	0= Normal.
sample of speech must be obtained by asking patient to read or	1= Mild-to-moderate dysarthria; patient slurs
repeat words from the attached list. If the patient has severe	at least some words and, at worst, can be
aphasia, the clarity of articulation of spontaneous speech can	understood by some difficulty.
be rated. Only if patient is intubated or has other physical	2= Severe dysarthria: patient's speech is so
barriers to producing speech, the examiner should record the	slurred as to be unintelligible in the absence of
score as untestable (UN), and clearly write an explanation for	or out of proportion to any dysphasia, or is
this choice. Do not tell the patient why he or she is being	mute/anarthric.
tested.	UN = Intubated or other physical barrier.
11. Extinction and Inattention (formerly Neglect): Sufficient	
information to identify neglect may be obtained during the	0= No abnormality.
prior testing. If the patient has a severe visual loss preventing	1= Visual, tactile, auditory, spatial, or personal
visual double simultaneous stimulation, and the cutaneous	inattention or extinction to bilateral
stimuli are normal, the score is normal. If the patient has	simultaneous stimulation in one of the sensory
aphasia but does appear to attend to both sides, the score is	modalities.
normal. The presence of visual spatial neglect or anosagnosia	2= Profound hemi-inattention or extinction to
may also be taken as evidence of abnormality. Since the	more than one modality; does not recognize
abnormality is scored only if present, the item is never	own hand or orients to only one side of space.
untestable.	

#### Appendix Table 4. EuroQoL 5D-5L

Under each heading, please tick the ONE box that best describes your health TODAY.

#### Mobility

I have no problems in walking about

I have slight problems in walking about

I have moderate problems in walking about

I have severe problems in walking about

I am unable to walk about

#### Self-care

I have no problems washing or dressing myself

I have slight problems washing or dressing myself

I have moderate problems washing or dressing myself

I have severe problems washing or dressing myself

I am unable to wash or dress myself

#### Usual activities (e.g. work, study, housework, family or leisure activities)

I have no problems doing my usual activities

I have slight problems doing my usual activities

I have moderate problems doing my usual activities

I have severe problems doing my usual activities

I am unable to do my usual activities

#### Pain/discomfort

I have no pain or discomfort

I have slight pain or discomfort

I have moderate pain or discomfort

I have severe pain or discomfort

I have extreme pain or discomfort

#### Anxiety/depression

I am not anxious or depressed

I am slightly anxious or depressed

I am moderately anxious or depressed


I am severely anxious or depressed

I am extremely anxious or depressed

# • We would like to know how good or bad your health is TOADY.

- This scale is numbered from 0 to 100.
- 100 means the <u>best</u> health you can imagine.
  0 means the <u>worst</u> health you can imagine.
- Mark an X on the scale to indicate how your health is TODAY.
- Now, please write the number you marked on the scale in the box below.





#### Appendix Table 5. Heidelberg bleeding classification

Symptomatic intracranial hemorrhage (SICH): new intracranial hemorrhage detected by brain imaging associated with any of the items below:

 $1. \ge 4$  points decline in the total NIHSS at the time of diagnosis compared to immediately before worsening. Note that a 4 point change is not compared with the baseline admission NIHSS score but instead to the immediate predeterioration neurological status

2.  $\geq$ 2 point decline in one NIHSS category. The rationale for this is to capture new hemorrhages that produce new neurological symptoms, making them clearly symptomatic but not causing worsening in the original stroke territory. For example, a new remote hemorrhage in the contralateral occipital lobe may cause new hemianopia that is clearly symptomatic but the patient will not have worsening of  $\geq$ 4 points on the NIHSS score

Leading to intubation/hemicraniectomy/EVD placement or other major medical/surgical intervention.

Anatomic Description of Intracranial Hemorrhages


	Anatonne Desemption of intractantal remotinages		
Class	Туре	Description	
1	Hemorrhagic transformation of infarcted brain tissue		
1a	HI1	Scattered small petechiae, no mass effect	
1b	HI2	Confluent petechiae, no mass effect	
1c	PH1	Hematoma within infarcted tissue, occupying $<30\%$ , no substantive mass effect	
2	Intracerebral hem	norrhage within and beyond infarcted brain tissue	
	PH2	Hematoma occupying 30% or more of the infarcted tissue, with obvious mass effect	
3	Intracerebral hemorrhage outside the infarcted brain tissue or intracranial- extracerebral hemorrhage		
3a		Parenchymal hematoma remote from infarcted brain tissue	
3b		Intraventricular hemorrhage	
3c		Subarachnoid hemorrhage	
3d		Subdural hemorrhage	

3. Absence of alternative explanation for deterioration

HI indicates hemorrhagic infarction; and PH, parenchymatous hematoma.

#### Appendix Table 6. Alberta Stroke Program Early CT Score (ASPECTS)

The Alberta Stroke Program Early CT Score (ASPECTS) is a semiquantitative method of estimation of infarct size with non-contrast CT during the acute phase. The territory of the middle cerebral artery is allotted 10 points. 1 point is subtracted for an area of early ischaemic change, such as focal swelling, or parenchymal hypoattenuation, for each of the defined regions. A normal CT scan has an ASPECTS value of 10 points. A score of 0 indicates diffuse ischaemia throughout the territory of the middle cerebral artery.



A=anterior circulation; P=posterior circulation; C=caudate; L=lentiform; IC=internal capsule; I=insular ribbon; MCA=middle cerebral artery; M1=anterior MCA cortex; M2=MCA cortex lateral to insular ribbon; M3=posterior MCA cortex; M4, M5, and M6 are anterior, lateral, and posterior MCA territories immediately superior to M1, M2, and M3, rostral to basal ganglia.

Subcortical structures are allotted 3 points (C, L, and IC). MCA cortex is allotted 7 points (insular cortex, M1, M2, M3, M4, M5, and M6).

# Study of Endovascular Therapy in Acute Anterior Circulation Large VeSsel Occlusive Patients with a LargE InfarCT Core: A Multicenter, Prospective, Open-Label, Blinded-Endpoint, Randomized Controlled Trial (ANGEL-ASPECT)



# Protocol

Research team: Beijing Tiantan Hospital, Capital Medical University, Beijing, China Principal Investigator: Zhongrong Miao, MD, Professor of Neurology Co- Principal Investigator: Zeguang Ren, Vitor Mendes Pereira Protocol Version 7.1 Trial Registration: ClinicalTrials.gov NCT04551664 Date: May 18, 2021

# **Table of Contents**

Protocol Signature Page	70
ANGEL-ASPECT Protocol Synopsis	71
Abbreviations	77
1. Background	79
1.1 The rational of EVT for large infarct core volume	79
1.2 Image modality to identify large infarct core volume	81
1.3 ASPECTS and infarct core volume selection	
1.4 EVT time window for large infarct core volume	
1.5 ANGEL-ASPECT Trial design	
2. Study objective	84
2.1 Primary objective	84
2.2 Secondary objective	84
3. Study design	84
3.1 Study design	85
3.2 Randomization	85
3.3 Follow-up schedule	85
3.4 Blind design	86
4. Participant selection	86
4.1 Inclusion Criteria	86
4.1.1 Center Inclusion Criteria	86
4.1.2 Clinical Inclusion Criteria	86
4.1.3 Neuroimaging Inclusion Criteria	
4.2 Exclusion Criteria	
4.2.1 Center Exclusion Criteria	87
4.2.2 Clinical Exclusion Criteria	87
4.2.3 Neuroimaging Exclusion Criteria	
5. Imaging protocol	88
5.1 Baseline imaging	
5.2 Intraoperative and follow-up imaging:	

	5.3 Imaging core lab	91
6.	Treatments	91
	6.1 Endovascular Therapy (EVT)	91
	6.2 Best Medical Management (BMM)	92
7.	Study endpoints	93
	7.1 Primary efficacy endpoint	93
	7.2 Secondary efficacy endpoint	93
	7.3 Primary safety endpoint	93
	7.4 Secondary safety endpoint	93
8.	Data collection and Study procedure	94
	8.1 Screening and Inclusion	94
	8.2 Data to be collected during procedure	96
	8.3 Post Treatment (Through Hospital Discharge)	96
	8.4 Follow-up Visit at Day 30 (±3), Day 90 (±7) and 12 Months (±14 days)	97
	8.5 Unscheduled Follow-up Visit	97
	8.6 Schedule of activities and assessments	98
9.	Study risk pre-assessment and risk management	99
9.	Study risk pre-assessment and risk management         9.1 Monitoring of adverse events	
9.		99
9.	9.1 Monitoring of adverse events	99 99
9.	<ul><li>9.1 Monitoring of adverse events</li><li>9.2 Definitions of adverse events</li></ul>	99 99 99
9.	<ul> <li>9.1 Monitoring of adverse events</li></ul>	99 99 99 99
9.	<ul> <li>9.1 Monitoring of adverse events</li></ul>	99 99 99 99 
9.	<ul> <li>9.1 Monitoring of adverse events</li></ul>	99 99 99 99 
9.	<ul> <li>9.1 Monitoring of adverse events</li></ul>	
9.	<ul> <li>9.1 Monitoring of adverse events</li></ul>	
9.	<ul> <li>9.1 Monitoring of adverse events</li></ul>	
	<ul> <li>9.1 Monitoring of adverse events</li></ul>	
	<ul> <li>9.1 Monitoring of adverse events</li></ul>	
	<ul> <li>9.1 Monitoring of adverse events</li> <li>9.2 Definitions of adverse events.</li> <li>9.2.1 Adverse event (AE)</li> <li>9.2.2 Serious adverse event (SAE)</li> <li>9.3 Recording of adverse events</li> <li>9.4 Causal relationship between adverse events and study:</li> <li>9.5 Obligation of the investigator regarding safety reporting.</li> <li>9.5.1 Adverse events</li> <li>9.5.2 Serious adverse event</li> <li>9.5.3 Follow-up and risk management</li> <li>0. Statistical Analysis</li> </ul>	
	<ul> <li>9.1 Monitoring of adverse events</li> <li>9.2 Definitions of adverse events.</li> <li>9.2.1 Adverse event (AE)</li> <li>9.2.2 Serious adverse event (SAE)</li> <li>9.3 Recording of adverse events</li> <li>9.4 Causal relationship between adverse events and study:</li> <li>9.5 Obligation of the investigator regarding safety reporting.</li> <li>9.5.1 Adverse events.</li> <li>9.5.2 Serious adverse event</li> <li>9.5.3 Follow-up and risk management</li> <li>0. Statistical Analysis</li> <li>10.1 Sample size estimation</li> </ul>	
	<ul> <li>9.1 Monitoring of adverse events</li> <li>9.2 Definitions of adverse events</li> <li>9.2.1 Adverse event (AE)</li> <li>9.2.2 Serious adverse event (SAE)</li> <li>9.3 Recording of adverse events</li> <li>9.4 Causal relationship between adverse events and study:</li> <li>9.5 Obligation of the investigator regarding safety reporting</li> <li>9.5.1 Adverse events</li> <li>9.5.2 Serious adverse event</li> <li>9.5.3 Follow-up and risk management</li> <li>0. Statistical Analysis</li> <li>10.1 Sample size estimation</li> <li>10.2 Data collection and entry</li> </ul>	

	10.2.3 Submission to the EDC system after the approval of investigator	102
	10.2.4 Data monitoring and query by CRA via EDC	103
	10.2.5 Data exportation from the EDC system	103
1	0.3 Statistical considerations	103
	10.3.1 Analysis sets	103
	10.3.2 Statistical considerations	104
1	0.4 Interim analysis	105
11.	Ethical standards	106
1	1.1 Ethical standards	106
1	1.2 Law and regulations	107
1	1.3 Informed consent	107
1	1.4 Institutional review board/institutional ethics committee (IRB/IEC)	107
12.	Confidentiality and publication of research findings	108
13.	Study Organization	108
1	3.1 Constitution	108
1	3.2 Site training and certification	110
14.	Study monitoring and quality assurance control	112
1	4.1 Responsibilities of the investigator(s)	112
1	4.2 Study monitoring	112
15.	Data retention	113
16.	Data Security Monitoring	113
17.	Registration and Publication	114
1	7.1 Registration of study summary and results	114
1	7.2 Publication of study results	114
18.	Ownership and use of data	115
1	8.1 Ownership of the data	115
1	8.2 Use of collected data	115
10		
19.	Funding and conflict of interest	115
19. 20.	Funding and conflict of interest	
	Reference	115
20. 21.	Reference	115

Appendix Table 3. National Institute of Health Stroke Scale (NIHSS)	121
Appendix Table 4. EuroQoL 5D-5L	125
Appendix Table 5. Heidelberg bleeding classification	127
Appendix Table 6. Alberta Stroke Program Early CT Score (ASPECTS)	128

# **Protocol Signature Page**

I have read this protocol and agree to adhere to the requirements.

By signing this document we confirm that the clinical study will be conducted in accordance with the protocol and all applicable laws and regulations including, but not limited to, the International Conference on Harmonisation Guideline for Good Clinical Practice (GCP) and the ethical principles that have their origins in the Declaration of Helsinki.

Clinical Site

Site Principal Investigator Signature

Date

Official Title		Study of Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients with a Large Infarct Core: A Multicenter, Prospective, Open- Label, Blinded-Endpoint, Randomized Controlled Trial
Acronym		ANGEL-ASPECT
Sponsor		Beijing Tiantan Hospital, Capital Medical University
Study Center	rs	~50 centers in China
Statement of	Hypothesis	Best medical management (BMM) combined with endovascular Therapy (EVT) might be superior to BMM alone in acute anterior circulation large vessel occlusive (LVO) patients with a large infarct core.
Study	Primary objective	To estimate if acute ischemic stroke patients with anterior circulation LVO and large infarct core at 0-24 hours after stroke onset have improved neurological functional outcomes when treated with BMM plus EVT compared to BMM alone.
Objectives	Secondary objective	To estimate if acute ischemic stroke patients with anterior circulation LVO and large infarct core at 0-24 hours after stroke onset have increased the risk of symptomatic intracranial hemorrhage (sICH) when treated with BMM plus EVT compared to BMM alone.
Study settings		Multicenter, Prospective, Randomized, Open-label, Blinded End-point (PROBE) design
Randomization		Participants will be randomized in a 1:1 ratio based on simple randomization of the central network

# **ANGEL-ASPECT Protocol Synopsis**

		randomization system to receive BMM plus EVT or
		BMM alone.
		A total of 502 patients are planned to be enrolled.
~		Interim analysis will take place when 1/3 (168 cases)
Sample Size		and 2/3 (336 cases) have completed 3-month follow-
		up.
	Primary Endpoint	90 days (±7 days) modified Ranking Scale (mRS)
		(1) 90 days (±7 days) mRS 0-2
		(2) 90 days (±7 days) mRS 0-3
		(3) 36 hours ( $\pm 12$ hours) NIHSS 0-1 or decrease $\geq 10$
Effective		from baseline
Endpoints	Secondary	(4) Infarct core volume change from baseline, at 7
	Endpoints	days (±1 day) or at discharge assessed with
		NCCT or at 36 hours (±12 hours) assessed with
		MRI
		(5) 36 hours ( $\pm 12$ hours) target artery recanalization
		rate assessed with CTA or MRA
	Primary	Rate of sICH within 48 hours from randomization
	Safety	(Heidelberg Bleeding Classification)
	Endpoint	
Safaty		(1) All-cause mortality within 90 days ( $\pm$ 7 days)
Safety	Sacandawy	(2) Any intracranial hemorrhage within 48 hours
Endpoints	Secondary	from randomization (Heidelberg Bleeding
	Safety	Classification)
	Endpoints	(3) Decompressive hemicraniectomy during
		hospitalization
Dautiain (	Inclusion	Center Inclusion Criteria
Participants	Criteria	

(1) Equipped with emergency department and
neurology department for stroke patients
(2) Equipped with stroke team operating on 24/7
(3) Capable of EVT and intravenous (IV)
thrombolysis for acute ischemic stroke patients
Clinical Inclusion Criteria:
(1) Age 18-80 years
(2) Presenting with symptoms consistent with acute
ischemic stroke
(3) Pre-stroke mRS score 0-1
(4) NIHSS score 6-30 at the time of randomization
(5) Randomization can be finished within 24 hours
from stroke onset (stroke onset time is defined as
last known well time)
(6) Informed consent signed
Neuroimaging Inclusion Criteria:
(1) CTA or MRA proved occlusion of Internal
Carotid Artery (ICA) terminus or M1 segment of
Middle Cerebral Artery
(2) Imaging evidence of low Alberta Stroke Program
Early CT Score (ASPECTS) (based on non-
contrast CT) or large infarct Core (defined as
rCBF <30% on CT perfusion or ADC<620 on
MRI) fill one of the following criteria:
1) ASPECTS 3–5
2) ASPECTS >5 (6 h-24 h) with infarct core
volume 70-100 ml
3) ASPECTS <3 with infarct core volume 70-100
ml
1

	Center Exclusion Criteria
	(1) Centers in which the number of acute ischemic
	stroke cases treated with endovascular procedures
	are less than 20 per year;
	(2) Incapable of complying with the protocol to
	proceed with the research.
	Clinical Exclusion Criteria
	(1) Females who are pregnant, or those of
	childbearing, potential with positive urine or
	serum beta Human Chorionic Gonadotropin test
	(2) Known severe allergy (more severe than skin rash)
	to contrast agents uncontrolled by medications
	(3) Refractory hypertension that is difficult to be
	controlled by drugs (defined as persistent systolic
Exclusion	blood pressure >185 mmHg or diastolic blood
Criteria	pressure >110 mmHg)
	(4) Known hemorrhagic tendency (including but not
	limited to): Baseline platelet count $< 100 \times 10^{9}/L;$
	Heparin was administered within 48 hours with
	aPTT≥35s; on anticoagulant therapy with warfarin
	and International Normalized Ratio (INR) > 1.7
	(Patients with no history or suspected
	coagulopathy do not need to wait for laboratory
	results of INR or aPTT prior to enrollment)
	(5) Parenchymal organ surgery and biopsy were
	performed in the past one month
	(6) Any active bleeding or recent bleeding
	(gastrointestinal bleeding, urinary bleeding, etc.)
	in the past one month

		(7) Undergoing hemodialysis or peritoneal dialysis;
		Known severe renal insufficiency with glomerular
		filtration rate <30 ml/min or serum
		creatinine >220 mmol/L (2.5mg/dl)
		(8) Brain tumor (with mass effect)
		(9) The expected survival time is less than 1 year
		(such as comorbidity with malignant tumor,
		serious heart and lung diseases, etc.)
		(10)Participation in other interventional randomized
		clinical trials that may confound the outcome
		assessment of the trial
		(11)Other circumstances that the investigator
		considers inappropriate for participation in the
		trial or that may pose significant risks to patients
		(such as inability to understand and/or follow the
		study procedures and/or follow up due to mental
		disorders, cognitive or emotional disorders)
		Neuroimaging Exclusion Criteria
		(1) Midline shift or herniation, mass effect with
		effacement of the ventricles
		(2) Evidence of acute intracranial hemorrhage
		(3) Acute bilateral strokes or multiple intracranial
		vessels occlusions
	Study Arm	BMM plus EVT
Treatment		
Allocation	Control	BMM alone
	Arm	
Follow-up schedule		Study visits will take place on day of randomization,
ronow-up schedule		at 36 hours (± 12 hours), 7 days (±1 day)/at discharge

	which is earlier, 30 days (±3 days), 90 days (±7 days)
	and 12 months ( $\pm$ 14 days).
	Subgroup analysis will be performed based on the
	following variables:
	(1) Age (< 70 years vs. ≥70 years)
	(2) Weak-up stroke or not
	(3) Last known well to randomization time (< 6 h vs.
	$\geq 6 h$ )
	(4) Stroke severity before randomization (NIHSS<16
Subgroup analysis	points vs. NIHSS≥16 points)
	(5) IV thrombolysis or not
	(6) Occlusion site (intracranial ICA vs. M1 segment)
	(7) Ipsilateral carotid artery occlusion or not
	(8) ASPECT score (< 3 points vs. ≥3 points)
	(9) Infarct core volume (< 70ml vs. ≥70ml)
	(10) Etiological subtype of stroke (cardiac embolism
	vs. large artery atherosclerosis)
Study duration	August 2020 to October 2023 (enrolment completed
Study duration	at October 2022)

# Abbreviations

AE       Adverse Event         aPTT       Activated Partial Thromboplastin Time         ASPECTS       Alberta Stroke Program Early CT Score         BMM       Best Medical Management         CEC       Clinical Events Adjudication Committee         CI       Confidence Interval         CRA       Clinical Research Associate         CRC       Clinical research coordinator         CRF       Case Report Form         CSA       Chinese Stroke Association         CT       Computer Tomography Angiography         CTA       Computed Tomography Perfusion Imaging         DWI or CTP Assessment with Clinical Mismatch in the Triage of       Wake-Up and Late Presenting Strokes Undergoing         Neurointervention with Trevo       Endovascular Therapy Following Imaging Evaluation for Ischemic         DEFUSE 3       Endovascular Therapy Following in Medicine         DSA       Digital Subtraction Angiography         DSMB       Data Safety Monitoring Board         DWI       Diffusion Weighted Imaging         ECG       Electronic Data Capture         EQC       Electronic Data Capture         EVT       Endovascular Therapy         FAS       Full Analysis Set         FLAIR       FLuid Attenuated Inversion Recovery	ADC	Apparent Diffusion Coefficient
aPTT       Activated Partial Thromboplastin Time         ASPECTS       Alberta Stroke Program Early CT Score         BMM       Best Medical Management         CEC       Clinical Events Adjudication Committee         CI       Confidence Interval         CRA       Clinical Research Associate         CRC       Clinical research coordinator         CRF       Case Report Form         CSA       Chinese Stroke Association         CT       Computed Tomography         CTA       Computed Tomography Angiography         CTP       Computed Tomography Perfusion Imaging         DAWN       Wake-Up and Late Presenting Strokes Undergoing         Neurointervention with Trevo       Stroke 3         DICOM       Digital Imaging and Communications in Medicine         DSA       Digital Subtraction Angiography         DSMB       Data Safety Monitoring Board         DWI       Diffusion Weighted Imaging         ECG       Electrocardiogram         EDC       Electronic Data Capture         EQ-5D-5L       EuroQoL 5-Dimensions 5-Level questionnaire         eTICI       Expanded Thrombolysis in Cerebral Infarction         EVT       Endovascular Therapy         FAS       Full Analysis Sct		**
ASPECTS       Alberta Stroke Program Early CT Score         BMM       Best Medical Management         CEC       Clinical Events Adjudication Committee         CI       Confidence Interval         CRA       Clinical Research Associate         CRC       Clinical research coordinator         CRF       Case Report Form         CSA       Chinese Stroke Association         CT       Computer Tomography         CTA       Computed Tomography Angiography         CTP       Computed Tomography Perfusion Imaging         DAWN       Wake-Up and Late Presenting Strokes Undergoing         Neurointervention with Trevo       Neurointervention with Trevo         DEFUSE 3       Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3         DICOM       Digital Imaging and Communications in Medicine         DSA       Digital Subtraction Angiography         DSMB       Data Safety Monitoring Board         DWI       Diffusion Weighted Imaging         ECG       Electronic Data Capture         EQ-SD-5L       EuroQoL 5-Dimensions 5-Level questionnaire         eTICI       Expanded Thrombolysis in Cerebral Infarction         EVT       Endovascular Therapy         FAS       Full Analysis Set         FLAIR<		
BMM       Best Medical Management         CEC       Clinical Events Adjudication Committee         CI       Confidence Interval         CRA       Clinical Research Associate         CRC       Clinical research coordinator         CRF       Case Report Form         CSA       Chinese Stroke Association         CT       Computer Tomography Angiography         CTA       Computed Tomography Perfusion Imaging         DWI or CTP Assessment with Clinical Mismatch in the Triage of         DAWN       Wake-Up and Late Presenting Strokes Undergoing         Neurointervention with Trevo         DEFUSE 3         Endovascular Therapy Following Imaging Evaluation for Ischemic         Stroke 3         DICOM       Digital Imaging and Communications in Medicine         DSA       Digital Subtraction Angiography         DSMB       Data Safety Monitoring Board         DWI       Diffusion Weighted Imaging         ECG       Electrocardiogram         EDC       Electronic Data Capture         EQ-SD-SL       EuroQoL 5-Dimensions 5-Level questionnaire         eTICI       Expanded Thrombolysis in Cerebral Infarction         EVT       Endovascular Therapy         FAS       Full Analysis Set <t< td=""><td></td><td></td></t<>		
CECClinical Events Adjudication CommitteeCIConfidence IntervalCRAClinical Research AssociateCRCClinical research coordinatorCRFCase Report FormCSAChinese Stroke AssociationCTComputer TomographyCTAComputed Tomography AngiographyCTPComputed Tomography Perfusion ImagingDAWNWake-Up and Late Presenting Strokes Undergoing Neurointervention with TrevoDEFUSE 3Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3DICOMDigital Imaging and Communications in MedicineDSADigital Subtraction AngiographyDSMBData Safety Monitoring BoardDWIDiffusion Weighted ImagingECGElectrocardiogramEDCElectronic Data CaptureEQ-SD-SLEuroQoL 5-Dimensions 5-Level questionnaireeTICIExpanded Thrombolysis in Cerebral InfarctionEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICAInternational Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors		
CIConfidence IntervalCRAClinical Research AssociateCRCClinical research coordinatorCRFCase Report FormCSAChinese Stroke AssociationCTComputer TomographyCTAComputed Tomography AngiographyCTPComputed Tomography Perfusion ImagingDAWNWake-Up and Late Presenting Strokes Undergoing Neurointervention with TrevoDEFUSE 3Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3DICOMDigital Imaging and Communications in MedicineDSADigital Subtraction AngiographyDKIDiffusion Weighted ImagingECGElectrocardiogramEDCElectronic Data CaptureEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors		
CRAClinical Research AssociateCRCClinical research coordinatorCRFCase Report FormCSAChinese Stroke AssociationCTComputer TomographyCTAComputed Tomography AngiographyCTPComputed Tomography Perfusion ImagingDAWNDWI or CTP Assessment with Clinical Mismatch in the Triage ofWake-Up and Late Presenting Strokes Undergoing Neurointervention with TrevoDEFUSE 3Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3DICOMDigital Imaging and Communications in MedicineDSADigital Subtraction AngiographyDSMBData Safety Monitoring BoardDWIDiffusion Weighted ImagingECGElectronic Data CaptureEQGElectronic Data CaptureEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors		
CRCClinical research coordinatorCRFCase Report FormCSAChinese Stroke AssociationCTComputer TomographyCTAComputed Tomography AngiographyCTPComputed Tomography Perfusion ImagingDAWNDWI or CTP Assessment with Clinical Mismatch in the Triage ofWake-Up and Late Presenting Strokes Undergoing Neurointervention with TrevoDEFUSE 3Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3DICOMDigital Imaging and Communications in MedicineDSADigital Subtraction AngiographyDSMBData Safety Monitoring BoardDWIDiffusion Weighted ImagingECGElectronic Data CaptureEQ-5D-5LEuroQoL 5-Dimensions 5-Level questionnaire eTICIEXpanded Thrombolysis in Cerebral InfarctionEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICAInternational Council for Harmonisation of Technical Requirements for Pharmaccutical for Human UseICMJEInternational Committee of Medical Journal Editors		
CRFCase Report FormCSAChinese Stroke AssociationCTComputer TomographyCTAComputed Tomography AngiographyCTPComputed Tomography Perfusion ImagingDWI or CTP Assessment with Clinical Mismatch in the Triage ofDAWNWake-Up and Late Presenting Strokes Undergoing Neurointervention with TrevoDEFUSE 3Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3DICOMDigital Imaging and Communications in MedicineDSADigital Subtraction AngiographyDSMBData Safety Monitoring BoardDWIDiffusion Weighted ImagingECGElectrocardiogramEDCElectronic Data CaptureEQ-5D-5LEuroQoL 5-Dimensions 5-Level questionnaireeTICIExpanded Thrombolysis in Cerebral InfarctionEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICAInternational Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors		
CSAChinese Stroke AssociationCTComputer TomographyCTAComputed Tomography AngiographyCTPComputed Tomography Perfusion ImagingDWI or CTP Assessment with Clinical Mismatch in the Triage ofDAWNWake-Up and Late Presenting Strokes Undergoing Neurointervention with TrevoDEFUSE 3Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3DICOMDigital Imaging and Communications in MedicineDSADigital Subtraction AngiographyDSMBData Safety Monitoring BoardDWIDiffusion Weighted ImagingECGElectrocardiogramEDCElectronic Data CaptureEQ-5D-5LEuroQoL 5-Dimensions 5-Level questionnaireeTICIExpanded Thrombolysis in Cerebral InfarctionEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICAInternal Carotid ArteryICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors		
CTComputer TomographyCTAComputed Tomography AngiographyCTPComputed Tomography Perfusion ImagingDWI or CTP Assessment with Clinical Mismatch in the Triage ofWake-Up and Late Presenting Strokes Undergoing Neurointervention with TrevoDEFUSE 3Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3DICOMDigital Imaging and Communications in MedicineDSADigital Subtraction AngiographyDSMBData Safety Monitoring BoardDWIDiffusion Weighted ImagingECGElectrocardiogramEDCElectronic Data CaptureEQ-5D-5LEuroQoL 5-Dimensions 5-Level questionnaireeTICIExpanded Thrombolysis in Cerebral InfarctionEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICAInternal Carotid ArteryICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors		
CTAComputed Tomography AngiographyCTPComputed Tomography Perfusion ImagingDWI or CTP Assessment with Clinical Mismatch in the Triage ofWake-Up and Late Presenting Strokes Undergoing Neurointervention with TrevoDEFUSE 3Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3DICOMDigital Imaging and Communications in MedicineDSADigital Subtraction AngiographyDSMBData Safety Monitoring BoardDWIDiffusion Weighted ImagingECGElectrocardiogramEDCElectronic Data CaptureEQ-5D-5LEuroQoL 5-Dimensions 5-Level questionnaireeTICIExpanded Thrombolysis in Cerebral InfarctionEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICAInternal Carotid ArteryICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors		
CTPComputed Tomography Perfusion ImagingDWI or CTP Assessment with Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention with TrevoDEFUSE 3Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3DICOMDigital Imaging and Communications in MedicineDSADigital Subtraction AngiographyDSMBData Safety Monitoring BoardDWIDiffusion Weighted ImagingECGElectrocardiogramEDCElectronic Data CaptureEQ-5D-5LEuroQoL 5-Dimensions 5-Level questionnaireeTICIExpanded Thrombolysis in Cerebral InfarctionEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICAInternal Carotid ArteryICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors		
DWI or CTP Assessment with Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention with TrevoDEFUSE 3Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3DICOMDigital Imaging and Communications in MedicineDSADigital Subtraction AngiographyDSMBData Safety Monitoring BoardDWIDiffusion Weighted ImagingECGElectrocardiogramEDCElectronic Data CaptureEQ-5D-5LEuroQoL 5-Dimensions 5-Level questionnaireeTICIExpanded Thrombolysis in Cerebral InfarctionEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICAInternal Carotid ArteryICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors		
DAWNWake-Up and Late Presenting Strokes Undergoing Neurointervention with TrevoDEFUSE 3Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3DICOMDigital Imaging and Communications in MedicineDSADigital Subtraction AngiographyDSMBData Safety Monitoring BoardDWIDiffusion Weighted ImagingECGElectrocardiogramEDCElectronic Data CaptureEQ-5D-5LEuroQoL 5-Dimensions 5-Level questionnaireeTICIExpanded Thrombolysis in Cerebral InfarctionEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors		
Neurointervention with TrevoDEFUSE 3Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3DICOMDigital Imaging and Communications in MedicineDSADigital Subtraction AngiographyDSMBData Safety Monitoring BoardDWIDiffusion Weighted ImagingECGElectrocardiogramEDCElectronic Data CaptureEQ-5D-5LEuroQoL 5-Dimensions 5-Level questionnaireeTICIExpanded Thrombolysis in Cerebral InfarctionEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICAInternal Carotid ArteryICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors	DAWN	•
DEFUSE 3Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3DICOMDigital Imaging and Communications in MedicineDSADigital Subtraction AngiographyDSMBData Safety Monitoring BoardDWIDiffusion Weighted ImagingECGElectrocardiogramEDCElectronic Data CaptureEQ-5D-5LEuroQoL 5-Dimensions 5-Level questionnaireeTICIExpanded Thrombolysis in Cerebral InfarctionEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors	DAWN	
DEFUSE 3Stroke 3DICOMDigital Imaging and Communications in MedicineDSADigital Subtraction AngiographyDSMBData Safety Monitoring BoardDWIDiffusion Weighted ImagingECGElectrocardiogramEDCElectronic Data CaptureEQ-5D-5LEuroQoL 5-Dimensions 5-Level questionnaireeTICIExpanded Thrombolysis in Cerebral InfarctionEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors		
DICOMDigital Imaging and Communications in MedicineDSADigital Subtraction AngiographyDSMBData Safety Monitoring BoardDWIDiffusion Weighted ImagingECGElectrocardiogramEDCElectronic Data CaptureEQ-5D-5LEuroQoL 5-Dimensions 5-Level questionnaireeTICIExpanded Thrombolysis in Cerebral InfarctionEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors	DEFUSE 3	
DSADigital Subtraction AngiographyDSMBData Safety Monitoring BoardDWIDiffusion Weighted ImagingECGElectrocardiogramEDCElectronic Data CaptureEQ-5D-5LEuroQoL 5-Dimensions 5-Level questionnaireeTICIExpanded Thrombolysis in Cerebral InfarctionEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICAInternal Carotid ArteryICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors	DICOM	
DSMBData Safety Monitoring BoardDWIDiffusion Weighted ImagingECGElectrocardiogramEDCElectronic Data CaptureEQ-5D-5LEuroQoL 5-Dimensions 5-Level questionnaireeTICIExpanded Thrombolysis in Cerebral InfarctionEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICAInternal Carotid ArteryICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors	DSA	
DWIDiffusion Weighted ImagingECGElectrocardiogramEDCElectronic Data CaptureEQ-5D-5LEuroQoL 5-Dimensions 5-Level questionnaireeTICIExpanded Thrombolysis in Cerebral InfarctionEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICAInternal Carotid ArteryICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors	DSMB	
ECGElectrocardiogramEDCElectronic Data CaptureEQ-5D-5LEuroQoL 5-Dimensions 5-Level questionnaireeTICIExpanded Thrombolysis in Cerebral InfarctionEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICAInternal Carotid ArteryICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors		
EDCElectronic Data CaptureEQ-5D-5LEuroQoL 5-Dimensions 5-Level questionnaireeTICIExpanded Thrombolysis in Cerebral InfarctionEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICAInternal Carotid ArteryICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors	ECG	
EQ-5D-5LEuroQoL 5-Dimensions 5-Level questionnaireeTICIExpanded Thrombolysis in Cerebral InfarctionEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICAInternal Carotid ArteryICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors	EDC	
eTICIExpanded Thrombolysis in Cerebral InfarctionEVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICAInternal Carotid ArteryICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors	EQ-5D-5L	=
EVTEndovascular TherapyFASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICAInternal Carotid ArteryICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors		
FASFull Analysis SetFLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICAInternal Carotid ArteryICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors	EVT	
FLAIRFLuid Attenuated Inversion RecoveryGCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICAInternal Carotid ArteryICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors	FAS	1 °
GCPGood Clinical PracticeGREGradient Recalled EchoGSR-ETGerman Stroke Registry – Endovascular TreatmentICAInternal Carotid ArteryICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors	FLAIR	-
GSR-ETGerman Stroke Registry – Endovascular TreatmentICAInternal Carotid ArteryICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors	GCP	
ICAInternal Carotid ArteryICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors	GRE	Gradient Recalled Echo
ICAInternal Carotid ArteryICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors		German Stroke Registry – Endovascular Treatment
ICHThe International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human UseICMJEInternational Committee of Medical Journal Editors		
Requirements for Pharmaceutical for Human Use         ICMJE       International Committee of Medical Journal Editors		
ICMJE International Committee of Medical Journal Editors	ICH	Requirements for Pharmaceutical for Human Use
IEC Institutional Ethios Committee	ICMJE	
IEC Institutional Etnics Committee	IEC	Institutional Ethics Committee
INR International Normalized Ratio	INR	International Normalized Ratio

ITTIntention-To-TreatIVIntravenousLICVLarge Infarct Core VolumeLLCLimited Liability CompanyLVOLarge Vessel OcclusiveMCAMiddle Cerebral ArteryMMMedical ManagementMRAMagnetic Resonance AngiographyMRIMagnetic Resonance ImagingmRSModified Rankin ScaleNCCTNon-contrast computed tomographyNRSNumber Cruncher Statistical SystemNIHSSNational Institute of Health stroke scaleNMPANational Institute of Health stroke scaleNMPANational Medical Products AdministrationOROdd RatioPASSPower Analysis and Sample SizePROBEProspective, Randomized, Open-label, Blinded End-pointPWIperfusion weighted imagingSAESerious Adverse EventSAPStatistical Analysis SetSELECTOptimizing Patient's Selection for Endovascular Treatment in AcuteIschemic StrokeslcHSICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versusalteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of ExcellenceTOASTTrial of ORG 10172 in Acute Stroke Treatment	IRB	Institutional Review Board
LICVLarge Infarct Core VolumeLLCLimited Liability CompanyLVOLarge Vessel OcclusiveMCAMiddle Cerebral ArteryMMMedical ManagementMRAMagnetic Resonance AngiographyMRIMagnetic Resonance ImagingmRSModified Rankin ScaleNCCTNon-contrast computed tomographyNIHSSNational Institute of Health stroke scaleNMPANational Institute of Health stroke scaleNMPANational Medical Products AdministrationOROdd RatioPASSPower Analysis and Sample SizePPSPer Protocol SetPROBEProspective, Randomized, Open-label, Blinded End-pointPWIperfusion weighted imagingSAESerious Adverse EventSAPStatistical Analysis PlanSASSafety Analysis SetSELECTOptimizing Patient's Selection for Endovascular Treatment in Acute Ischemic StrokeSICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence		
LLCLimited Liability CompanyLVOLarge Vessel OcclusiveMCAMiddle Cerebral ArteryMMMedical ManagementMRAMagnetic Resonance AngiographyMRIMagnetic Resonance ImagingmRSModified Rankin ScaleNCCTNon-contrast computed tomographyNKSNumber Cruncher Statistical SystemNIHSSNational Institute of Health stroke scaleNMPANational Institute of Health stroke scaleNMPANational Medical Products AdministrationOROdd RatioPASSPower Analysis and Sample SizePPSPer Protocol SetPROBEProspective, Randomized, Open-label, Blinded End-pointPWIperfusion weighted imagingSAESerious Adverse EventSAPStatistical Analysis PlanSASSafety Analysis SetSELECTOptimizing Patient's Selection for Endovascular Treatment in Acute Ischemic StrokesICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	IV	Intravenous
LLCLimited Liability CompanyLVOLarge Vessel OcclusiveMCAMiddle Cerebral ArteryMMMedical ManagementMRAMagnetic Resonance AngiographyMRIMagnetic Resonance ImagingmRSModified Rankin ScaleNCCTNon-contrast computed tomographyNKSNumber Cruncher Statistical SystemNIHSSNational Institute of Health stroke scaleNMPANational Institute of Health stroke scaleNMPANational Medical Products AdministrationOROdd RatioPASSPower Analysis and Sample SizePPSPer Protocol SetPROBEProspective, Randomized, Open-label, Blinded End-pointPWIperfusion weighted imagingSAESerious Adverse EventSAPStatistical Analysis PlanSASSafety Analysis SetSELECTOptimizing Patient's Selection for Endovascular Treatment in Acute Ischemic StrokesICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	LICV	Large Infarct Core Volume
LVOLarge Vessel OcclusiveMCAMiddle Cerebral ArteryMMMedical ManagementMRAMagnetic Resonance AngiographyMRIMagnetic Resonance ImagingmRSModified Rankin ScaleNCCTNon-contrast computed tomographyNCSSNumber Cruncher Statistical SystemNIHSSNational Institute of Health stroke scaleNMPANational Medical Products AdministrationOROdd RatioPASSPower Analysis and Sample SizePPSPer Protocol SetPROBEProspective, Randomized, Open-label, Blinded End-pointPWIperfusion weighted imagingSAESerious Adverse EventSAPStatistical Analysis PlanSASSafety Analysis SetSELECTOptimizing Patient's Selection for Endovascular Treatment in AcuteIschemic StrokeSiICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence		
MCAMiddle Cerebral ArteryMMMedical ManagementMRAMagnetic Resonance AngiographyMRIMagnetic Resonance ImagingmRSModified Rankin ScaleNCCTNon-contrast computed tomographyNCSSNumber Cruncher Statistical SystemNIHSSNational Institute of Health stroke scaleNMPANational Medical Products AdministrationOROdd RatioPASSPower Analysis and Sample SizePPSPer Protocol SetPROBEProspective, Randomized, Open-label, Blinded End-pointPWIperfusion weighted imagingSAESerious Adverse EventSAPStatistical Analysis PlanSASSafety Analysis SetSELECTOptimizing Patient's Selection for Endovascular Treatment in Acute Ischemic StrokeSICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	LVO	
MRAMagnetic Resonance AngiographyMRIMagnetic Resonance ImagingmRSModified Rankin ScaleNCCTNon-contrast computed tomographyNCSSNumber Cruncher Statistical SystemNIHSSNational Institute of Health stroke scaleNMPANational Medical Products AdministrationOROdd RatioPASSPower Analysis and Sample SizePPSPer Protocol SetPROBEProspective, Randomized, Open-label, Blinded End-pointPWIperfusion weighted imagingSAESerious Adverse EventSAPStatistical Analysis PlanSASSafety Analysis SetSELECTOptimizing Patient's Selection for Endovascular Treatment in Acute Ischemic StrokeSICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	MCA	
MRIMagnetic Resonance ImagingmRSModified Rankin ScaleNCCTNon-contrast computed tomographyNCSSNumber Cruncher Statistical SystemNIHSSNational Institute of Health stroke scaleNMPANational Medical Products AdministrationOROdd RatioPASSPower Analysis and Sample SizePPSPer Protocol SetPROBEProspective, Randomized, Open-label, Blinded End-pointPWIperfusion weighted imagingSAESerious Adverse EventSAPStatistical Analysis PlanSASSafety Analysis SetSELECTOptimizing Patient's Selection for Endovascular Treatment in Acute Ischemic StrokeTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	MM	Medical Management
mRSModified Rankin ScaleNCCTNon-contrast computed tomographyNCSSNumber Cruncher Statistical SystemNIHSSNational Institute of Health stroke scaleNMPANational Medical Products AdministrationOROdd RatioPASSPower Analysis and Sample SizePPSPer Protocol SetPROBEProspective, Randomized, Open-label, Blinded End-pointPWIperfusion weighted imagingSAESerious Adverse EventSAPStatistical Analysis PlanSASSafety Analysis SetSELECTOptimizing Patient's Selection for Endovascular Treatment in Acute Ischemic StrokeSICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	MRA	Magnetic Resonance Angiography
NCCTNon-contrast computed tomographyNCSSNumber Cruncher Statistical SystemNIHSSNational Institute of Health stroke scaleNMPANational Medical Products AdministrationOROdd RatioPASSPower Analysis and Sample SizePPSPer Protocol SetPROBEProspective, Randomized, Open-label, Blinded End-pointPWIperfusion weighted imagingSAESerious Adverse EventSAPStatistical Analysis PlanSASSafety Analysis SetSELECTOptimizing Patient's Selection for Endovascular Treatment in Acute Ischemic StrokeTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	MRI	Magnetic Resonance Imaging
NCSSNumber Cruncher Statistical SystemNIHSSNational Institute of Health stroke scaleNMPANational Medical Products AdministrationOROdd RatioPASSPower Analysis and Sample SizePPSPer Protocol SetPROBEProspective, Randomized, Open-label, Blinded End-pointPWIperfusion weighted imagingSAESerious Adverse EventSAPStatistical Analysis PlanSASSafety Analysis SetSELECTOptimizing Patient's Selection for Endovascular Treatment in Acute Ischemic StrokeSICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	mRS	Modified Rankin Scale
NIHSSNational Institute of Health stroke scaleNMPANational Medical Products AdministrationOROdd RatioPASSPower Analysis and Sample SizePPSPer Protocol SetPROBEProspective, Randomized, Open-label, Blinded End-pointPWIperfusion weighted imagingSAESerious Adverse EventSAPStatistical Analysis PlanSASSafety Analysis SetSELECTOptimizing Patient's Selection for Endovascular Treatment in Acute Ischemic StrokeSICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	NCCT	Non-contrast computed tomography
NMPANational Medical Products AdministrationOROdd RatioPASSPower Analysis and Sample SizePPSPer Protocol SetPROBEProspective, Randomized, Open-label, Blinded End-pointPWIperfusion weighted imagingSAESerious Adverse EventSAPStatistical Analysis PlanSASSafety Analysis SetSELECTOptimizing Patient's Selection for Endovascular Treatment in Acute Ischemic StrokeSICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	NCSS	Number Cruncher Statistical System
OROdd RatioPASSPower Analysis and Sample SizePPSPer Protocol SetPROBEProspective, Randomized, Open-label, Blinded End-pointPWIperfusion weighted imagingSAESerious Adverse EventSAPStatistical Analysis PlanSASSafety Analysis SetSELECTOptimizing Patient's Selection for Endovascular Treatment in Acute Ischemic StrokeSICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	NIHSS	National Institute of Health stroke scale
PASSPower Analysis and Sample SizePPSPer Protocol SetPROBEProspective, Randomized, Open-label, Blinded End-pointPWIperfusion weighted imagingSAESerious Adverse EventSAPStatistical Analysis PlanSASSafety Analysis SetSELECTOptimizing Patient's Selection for Endovascular Treatment in Acute Ischemic StrokeSICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	NMPA	National Medical Products Administration
PPSPer Protocol SetPROBEProspective, Randomized, Open-label, Blinded End-pointPWIperfusion weighted imagingSAESerious Adverse EventSAPStatistical Analysis PlanSASSafety Analysis SetSELECTOptimizing Patient's Selection for Endovascular Treatment in Acute Ischemic StrokeSICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	OR	Odd Ratio
PROBEProspective, Randomized, Open-label, Blinded End-pointPWIperfusion weighted imagingSAESerious Adverse EventSAPStatistical Analysis PlanSASSafety Analysis SetSELECTOptimizing Patient's Selection for Endovascular Treatment in Acute Ischemic StrokeSICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	PASS	Power Analysis and Sample Size
PWIperfusion weighted imagingSAESerious Adverse EventSAPStatistical Analysis PlanSASSafety Analysis SetSELECTOptimizing Patient's Selection for Endovascular Treatment in Acute Ischemic StrokeSICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	PPS	Per Protocol Set
SAESerious Adverse EventSAPStatistical Analysis PlanSASSafety Analysis SetSELECTOptimizing Patient's Selection for Endovascular Treatment in Acute Ischemic StrokeSICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	PROBE	Prospective, Randomized, Open-label, Blinded End-point
SAPStatistical Analysis PlanSASSafety Analysis SetSELECTOptimizing Patient's Selection for Endovascular Treatment in Acute Ischemic StrokeSICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	PWI	perfusion weighted imaging
SASSafety Analysis SetSELECTOptimizing Patient's Selection for Endovascular Treatment in Acute Ischemic StrokesICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	SAE	Serious Adverse Event
SELECTOptimizing Patient's Selection for Endovascular Treatment in Acute Ischemic StrokesICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	SAP	Statistical Analysis Plan
SELECTIschemic StrokesICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	SAS	Safety Analysis Set
Ischemic StrokesICHSymptomatic intracranial hemorrhageTHRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence		
THRACEMechanical thrombectomy after intravenous alteplase versus alteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence		
IHRACEalteplase alone after strokeTICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	sICH	
TICIThrombolysis In Cerebral InfarctionT-NICETiantan Neuroimaging Center of Excellence	THRACE	
T-NICE Tiantan Neuroimaging Center of Excellence	TICI	
66		
	TOAST	

# 1. Background

Large clinical trials on early and late window stroke patients have helped to establish the indications for endovascular treatment (EVT) of acute ischemic stroke (AIS) patients with large vessel occlusion (LVO). <sup>1,2</sup> This includes Alberta Stroke Program Early CT Scores (ASPECTS) score  $\geq 6$  patients within 6 hours,<sup>3-7</sup> and patients meeting DWI or CTP Assessment with Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention with Trevo (DAWN) and Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke (DEFUSE 3) trial imaging criteria patient at 6-16 or 24 hours.<sup>8,9</sup> Since then, many clinical trials have undergone an expanding the indications of EVT for AIS patients with LVO. Whether patients with large infarct core volume (LICV) are suitable for EVT is one of the unanswered questions.

#### 1.1 The rational of EVT for large infarct core volume

Several retrospective studies, prospective studies, and meta-analyses suggest that patients with LICV may benefit from EVT. The Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE) trial was one of these early randomized trials to enroll patients with ASPECTS<6.<sup>10</sup> A subgroup analysis of THRACE trial showed among 53 subjects with a diffusion-weighted imaging (DWI) volume of >70 ml, 12 (22.6%) patients of the EVT group had good clinical outcomes (mRS  $\leq$  2 at 90 days).<sup>11</sup> The prospective German Stroke Registry – Endovascular Treatment (GSR-ET) also showed that 22% of 152 thrombectomy patients with ASPECTS <6 achieved independence with mRS 0-2 at 90 days.<sup>12</sup> The Highly Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials (HERMES) collaboration pooled the data from the six trials. It showed a benefit of EVT over control was observed in patients with ASPECTS 0–4 or DWI-determined infarct core volume  $\geq$  70 ml. Functional improvement (mRS 0-2 at 90 days) rates in the EVT group compared with the control group were 25% vs. 14% and 30% vs.20%,

respectively.13,14

In the Optimizing Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT) trial, the prespecified secondary analysis of 105 patients (of whom 62 received EVT) with ASPECTS  $\leq 5$  or CTP-determined ischemic core volume  $\geq 50$  ml showed that functional independence was achieved in 31% in the EVT group vs. 14% in the control group.<sup>15</sup> Incidence rates of death, neurologic decline, and symptomatic intracerebral hemorrhage (sICH) were similar in both groups. In addition, EVT was also associated with less infarct growth (44 vs. 98 mL; p=0.006) and smaller final infarct volume (97 vs. 190 mL; p=0.001) than medical management (MM).

One meta-analysis including 17 studies and 1378 patients with ASPECTS 0–6 (1194 EVT, 184 MT) found that mRS 0–2 was achieved in 30.1% of cases after EVT and in 3.2% after MM (OR 4.76, p=0.01).<sup>16</sup> The marked lower rate in the MM group compared to previous RCTs (HERMES: 14%, SELECT: 14%) is likely due to the imbalance of baseline characteristics of the patients in these retrospective studies . for example, the patients in MM group were older (75 years vs 68.7 years), had higher NIHSS scores (19 vs. 18), lower rate of intravenous (IV) thrombolysis (47.8% vs. 56.8%) and longer symptoms onset to admission time (130 min vs. 115 min). Successful recanalization (Thrombolysis in Cerebral Infarction (TICI) grade 2b–3) gave higher odds of mRS 0–2 than unsuccessful reperfusion (OR 5.2, p=0.001). Another pooled random-effect meta-analysis, including 12 studies of large core patients (ASPECTS <6 or ischemic core volume  $\geq$  50 ml), demonstrated increased functional independence (mRS 0–2) rates with EVT (25% vs 7%; pooled OR: 4.39, 95% CI: 2.53 to 7.64), and decreased mortality (23% vs. 33%; pooled OR: 0.53, 95% CI: 0.40 to 0.71).<sup>17</sup>

In a matched case-control study of 56 patients (28 pairs) with ICA, M1 and M2 occlusion and CTP-determined infarct core > 50mL, EVT led to higher rates of functional independence (90-day mRS 0-2, 25% vs 0%; p=0.04), and smaller final infarct volumes (87 vs 242 mL; p <0.001).<sup>18</sup> One control (4%) and two treatment patients (7%) developed a parenchymal hematoma type 2 (p>0.99). The rates of hemicraniectomy (7% vs 21%; p=0.10) and 90-day mortality (29% vs 48%; p=0.75)

were lower in the EVT arm. Sensitivity analysis for patients with a baseline infarct core volume greater than 70 mL (12 pairs) revealed a significant reduction in final infarct volumes (110 vs. 319 mL; p<0.001) but only a nonsignificant improvement in the overall distribution of mRS scores favoring the treatment group (p=0.18).

Interestingly, one observational cohort study included a consecutive sample of 170 patients with anterior circulation stroke and initial ASPECTS  $\leq$  5 (99 patients in the EVT group, 71 patients in the MM group). The study showed that clinical outcome after failed or incomplete EVT (TICI 0–2b) was significantly better compared to patients with MM only (median mRS 5, interquartile range 4–6 vs. 5–6, p=0.03). Failed EVT (TICI 0–2a) was not associated with a worse outcome than MM.<sup>19</sup>

## 1.2 Image modality to identify large infarct core volume

Generally speaking, there were two imaging evaluation methods for large infarct core, one is a semi-quantitative evaluation based on CT/MRI-ASPECTS, and the other was a quantitative evaluation based on CTP/MRI with the aid of automated artificial intelligence software. ASPECTS is a widely accepted tool used to assess infarct volume. In general, ASPECTS < 6 is regarded as a "large core infarct." However, multiple studies have shown low interrater agreement with ASPECTS.<sup>20,21</sup> An inaccurate ASPECTS can mis-assign patients between the EVT and control groups, weakening any trial conclusions. Quantitative determination of infarct core volume using CTP/MRI could compensate for poor consistency of ASPECTS.

Notably, the correlation between the CTP/MRI-determined infarct core volume and ASPECTS is not well established. Therefore, the optimal imaging modality for evaluating patients with LICV in clinical trials remains to be explored. The subgroup analysis in a meta-analysis comparing outcomes between these two imaging modalities did not find significant heterogeneity in the results when LICV was defined based on ASPECTS or ischemic core volume of CTP.<sup>17</sup> While one study<sup>22</sup> found a good correlation between ASPECTS and CTP/MRI volume, others found them to be discordant.<sup>15,17,23</sup> To expedite enrollment, this study allowed the use of non-contrast CT

(NCCT)-ASPECTS and/or CTP/MRI imaging modalities to screen patients with LICV.

# 1.3 ASPECTS and infarct core volume selection

A recent meta-analysis of 17 studies and 1378 patients reported mRS 0-2 was achieved by 37.7%, 33.3%, 22.1%, and 17.1% of patients with ASPECTS 6, 5, 4 and 0-4 respectively.<sup>16</sup> The studies by Mourand et al.<sup>24</sup> and Inoue et al.<sup>25</sup> showed favorable outcomes in between 16% and 20% of patients with ASPECTS 0–3 after EVT. Another meta-analysis showed that ASPECT 0-2 favored MM instead of EVT.<sup>13</sup> The benefit of EVT gradually declined with decreasing in ASPECTS, especially when ASPECTS < 3, because the infarct core volume was very large and there was less salvageable brain tissue, which might make EVT ineffective.<sup>13,26,27</sup> Therefore, this study limited the ASPECTS of enrolled patients to 3-5.

There is some debate about whether "large core" should be defined as 50ml vs. 70ml on CTP. In ANGEL-ASPECT, the infarct core volume > 70 ml was defined as LICV. Similar to patients with ASPECTS 0-2, patients with excessive infarct core volume may also be less likely to benefit from EVT. Previous studies showed a lack of benefit if CTP-determined core volume exceeded 100 ml and 150 ml.<sup>14,15</sup> Therefore, when patients were enrolled only based on the infarct core volume as assessed by CTP/MRI, this study limited the infarct core volume to 70 ml-100 ml.

## 1.4 EVT time window for large infarct core volume

Patients in the hyperacute phase of stroke showed increased ASPECTS lesion growth from imaging to recanalization, suggesting a benefit of faster recanalization in these patients.<sup>28</sup> A meta-analysis by Cagnazzo et al. demonstrated that a shorter time from onset to reperfusion was associated with a higher probability of functional independence after EVT in patients with ASPECTS 0–6.<sup>16</sup> The SELECT trial found that patients with LICV had a gradual decline in functional outcomes with prolonged treatment time, with a lower likelihood of benefit from EVT after 12 hours.<sup>15</sup> This

suggested that for LICV patients, the earlier EVT may be more beneficial. However, a recent meta-analysis found that patients with LICV did not show a significant difference in outcomes among studies reporting <6 hours, <12 hours, and <24 hours for stroke to EVT time windows.<sup>17</sup> This may be because most LICV patients presented in the early time window, reducing the power to detect the difference between early and late windows. The reason may also be that the efficacy of MM declines over time, thus preserving the efficacy of EVT. In this context, it is important to study whether EVT also benefits patients with LICV in the late time window, therefore the time window of ANGEL-ASPECT is 0-24 hours.

## **1.5 ANGEL-ASPECT Trial design**

ANGEL-ASPECT trial is a PROBE study initiated by researchers to explore the effectiveness and safety of EVT in patients with anterior circulation large vessel occlusion with ASPECTS 3-5 or infarction core volume 70-100ml within 24 hours. ANGEL-ASPECT trial allows multiple imaging modalities to screen for LICV patients, but at the same time imposes certain limitations on the range of ASEPCTS or infarct core volume. The main purpose was to reduce the risk of EVT while enrolling as many LICV patients as possible. The primary image inclusion criteria of ANGEL-ASPECT was NCCT-ASPECTS 3-5, and the infarct core volume 70 ml-100 ml was used as auxiliary inclusion criteria. Briefly, the inclusion criteria for LICV are: (1) If NCCT-ASPECTS is 3-5 and presentation is within 24 hours of onset, patients are enrolled without limitation of infarct core volume. (2) For NCCT-ASPECTS 0-2 and core infarction volume 70 ml-100 ml, patients are enrolled. (3) If NCCT-ASPECTS is >5 and between 6 to 24 hours from symptom onset, only patients with infarct core volume 70 ml-100 ml are enrolled.

Subgroup analysis will focus on age, LKW to randomization time, NIHSS score, IV thrombolysis, occlusion site, ASPECTS, infarct core volume, and stroke etiology.

ANGEL-ASPECT is the only randomized controlled trial conducted in China for LICV patients so far. The results of this trial will clarify whether EVT is effective and

safe in Chinese LICV patients.

# 2. Study objective

## 2.1 Primary objective

To estimate if acute ischemic stroke patients with anterior circulation LVO and large infarct core at 0-24 hours after stroke onset have improved neurological functional outcomes when treated with BMM plus EVT compared to BMM alone.

# 2.2 Secondary objective

To estimate if acute ischemic stroke patients with anterior circulation LVO and large infarct core at 0-24 hours after stroke onset have increased the risk of sICH when treated with BMM plus EVT compared to BMM alone.

# 3. Study design

## 3.1 Study design

Multicenter, Prospective, Randomized, Open-label, Blinded End-point (PROBE) trial design (Figure 1).




Figure 1. Study design: randomization algorithm

## **3.2 Randomization**

The random code will be generated by a central network randomization system with 24h real-time online service based on the simple randomization method. The researcher in each center will obtain the random code from the central network randomization system according to the enrollment order. Patients who meet the inclusion criteria and in whom written informed consent can be obtained, will be randomly assigned to the following treatment groups in a 1:1 ratio:

- BMM plus EVT group: patients will receive EVT with stent retriever or contact aspiration as first-line devices for thrombectomy plus BMM;
- BMM group: Patients will receive BMM alone.

# 3.3 Follow-up schedule

- Face-to-face visit: day of randomization, 36 hours (±12 hours), 7 days (±1 day) /at discharge whichever is earlier
- (2) Telephone visit: 30 days ( $\pm$ 3 days), 90 days ( $\pm$ 7 days), and 12 months  $\pm$ 14 days

# 3.4 Blind design

(1) Only the patient and the treating physician are aware of the randomization

information, and the evaluation of information at baseline and in-hospital visits that relate to the study endpoints should be evaluated by an investigator who is not aware of the patient group assignment and the treatment received.

- (2) The primary endpoint visits are standardized visits conducted by trained third party personnel who are not aware of the patient's randomization assignment and their actual treatment status. All follow-up calls were recorded, and a follow-up report was formed.
- (3) All imaging data related to the study will be collected for central interpretation. The images at each visit site were interpreted independently by a core lab, and the readers were unaware of the patient's baseline information, treatment received (except EVT angiography images), and prognosis.

# 4. Participant selection

#### 4.1 Inclusion Criteria

#### 4.1.1 Center Inclusion Criteria

- (1) Equipped with an emergency department and neurology department for stroke patients
- (2) Equipped with a stroke team operating 24/7
- (3) Capable of endovascular therapy and IV thrombolysis for acute ischemic stroke patients

#### 4.1.2 Clinical Inclusion Criteria

- (1) 18 to 80 years of age
- (2) Presenting with symptoms consistent with an acute ischemic stroke
- (3) Pre-stroke mRS score 0-1
- (4) NIHSS score 6-30 at the time of randomization
- (5) Randomization can be finished within 24 hours of stroke onset (stroke onset time is defined as last known well time)
- (6) Informed consent signed by the patient or legally authorized representative

#### 4.1.3 Neuroimaging Inclusion Criteria

- CTA or MRA proven occlusion of the Internal Carotid Artery (ICA) terminus or M1 segment of the Middle Cerebral Artery (MCA)
- (2) Imaging evidence of low ASPECTS (based on NCCT) or large infarct Core (defined as rCBF <30% on CT perfusion or ADC<620 on MRI) fulfill one of the following criteria:</p>
  - 4) ASPECTS 3-5
  - 5) ASPECTS >5 (6h-24 h) with infarct core volume 70-100 ml
  - 6) ASPECTS <3 with infarct core volume 70-100 ml

#### 4.2 Exclusion Criteria

#### 4.2.1 Center Exclusion Criteria

- Centers in which the number of acute ischemic stroke cases treated with endovascular procedures are less than 20
- (2) Centers that are unable to comply with the research protocol

#### 4.2.2 Clinical Exclusion Criteria

- Females who are pregnant, or those of childbearing potential with positive urine or serum beta Human Chorionic Gonadotropin test
- (2) Known severe allergy (more than a rash) to contrast media uncontrolled by medication
- (3) Refractory hypertension that is difficult to control by medication (defined as persistent systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg)
- (4) Known hemorrhagic tendency (including but not limited to): Baseline platelet count < 100×10<sup>9</sup>/L; Heparin was administered within 48 hours with aPTT≥35s; on anticoagulant therapy with warfarin and International Normalized Ratio (INR) > 1.7 (Patients with no history or suspected coagulopathy do not need to wait for laboratory results of INR or aPTT prior to enrollment)
- (5) Parenchymal organ surgery and biopsy were performed in the past one month
- (6) Any active bleeding or recent bleeding (gastrointestinal bleeding, urinary bleeding, etc.)

in the past one month

- (7) Undergoing hemodialysis or peritoneal dialysis; Known severe renal insufficiency with glomerular filtration rate <30ml/min or serum creatinine >220mmol/L (2.5mg/dl)
- (8) Brain tumor (with mass effect)
- (9) The expected survival time is less than 1 year (such as comorbidity with malignant tumor, advanced heart or lung disease, etc.)
- (10) Participation in another interventional randomized clinical trials that may confound outcome assessment of the study
- (11) Other circumstances that the investigator considers inappropriate for participation in the study or that may pose significant risks to patients (such as inability to understand and/or follow the study procedures and/or follow up due to mental disorders, cognitive or emotional disorders)

#### 4.2.3 Neuroimaging Exclusion Criteria

- (1) Midline shift or herniation, mass effect with effacement of the ventricles
- (2) Evidence of acute intracranial hemorrhage
- (3) Acute bilateral strokes or multiple intracranial vessel occlusion

# 5. Imaging protocol

#### 5.1 Baseline imaging

All researchers were trained in the course of the imaging protocol and the use of RAPID software, and participated in the network training, simulation test and examination of NCCT-ASPECTS before enrollment. The ASPECTS training and test are conducted through the online training system of the trial website (http://angel-aspect.org). Those who pass the exam (accuracy rate more than 80%) will obtain the ASPECTS assessment qualification certificate and be qualified for imaging assessment. During imaging screening, researchers in the sub-center with imaging evaluation qualifications and two trained neuroradiologists from the trial team will conduct real-

time online image evaluation of ASPECTS, occlusion site, infarct core volume to ensure the accuracy of the imaging assessment (Figure 2).

- (1) ASPECTS: All patients presenting within 24h of symptom onset will undergo a plain CT scan. After the preliminary screening of ASPECTS by trained clinicians in research centers, two dedicated clinicians (insert initials here / names) from the trial team will conduct real-time online evaluation of the prospective patient. When the ASPECTS score reaches a consensus that is between 3 to 5 between the site and central core lab investigators, the patient is then deemed suitable for enrollment into ANGEL-ASPECT. NCCT-ASPECTS will be manually determined independently before RAPID ASPECTS<sup>®</sup> (version 5.0.4, iSchemaView, CA, USA) assessment.
- (2) Infarct core volume: The infarct core volume was automatically evaluated by iSchemaView automated RAPID<sup>®</sup> software (version 5.0.4, iSchemaView, CA, USA), and the infarction core volume was defined as rCBF<30% based on CTP or ADC<620  $\times 10^{-6}$  mm<sup>2</sup>/s based on MRI. For patients who present with NCCT-ASPECTS 0-2 within 6 hours from symptom onset, if the infarct core volume is between 70ml and 100ml, then the patient is eligible for enrollment. If the infarct core volume is between 70ml and 100ml in an extend time window (6-24 hours) of stroke onset, the patient is also suitable for inclusion regardless of ASPECTS.
- (3) Target occlusion vascular: The occluded arterial was determined by CTA or MRA. Occlusion of the ICA or M1 segment of the MCA is suitable for enrollment. Patients with ipsilateral extracranial internal carotid artery occlusion or stenosis with the above artery occlusion will also be included in this trial. As a tandem lesion can be difficult to distinguish on CTA or MRA, patients with tandem lesion in the EVT group will be confirmed during angiography.




Figure 2. Imaging evaluation working flow

#### 5.2 Intraoperative and follow-up imaging:

- (1) Intraoperative imaging: In the EVT group, preoperative DSA was required to determine the site of vascular occlusion and eTICI score,<sup>29</sup> and postoperative angiography was required to evaluate the eTICI score. It is recommended to conduct NCCT or cone-beam CT immediately after EVT to exclude bleeding.
- (2) Imaging evaluation of hemorrhage: The NCCT scan 36 hours ( $\pm 12$  hours) after randomization was taken as the main criterion for the judgment of hemorrhage, and

Heidelberg Bleeding Classification was used to evaluate the classification of hemorrhage.<sup>30</sup>

- (3) **Vascular imaging follow-up:** Vascular imaging (CTA/MRA) was conducted with 36 hours (±12 hours) h after randomization to determine vascular patentability.<sup>31</sup>
- (4) Evaluation of postoperative infarct volume: The infarct core volume was determined at 7 days (±1 day) or at discharge assessed with NCCT or at 36 hours (±12 hours) assessed with MRI, and the infarct core volume was determined manually by imaging core lab using validated automated software.<sup>32</sup>

#### 5.3 Imaging core lab

Tiantan Neuroimaging Center of Excellence (T-NICE) is the imaging core lab of this trial. During the period from onset to discharge, all imaging data (CT, CTA, CTP, MRI, MRA, PWI, DSA) were collected by CRO in DICOM format. T-NICE will conduct quality control. All images will be quality controlled, rendered anonymous and sent to T-NICE for central adjudication. The final results will be reviewed and confirmed by the imaging assessment committee, and then input into the database system.

# 6. Treatments

Patients meeting the eligibility criteria and signing the informed consent will be randomized. Patients randomized to the interventional arm will receive BMM plus EVT. Artery puncture should be performed within 1 hour of randomization. Patients randomized to the medical arm will receive BMM.

#### 6.1 Endovascular Therapy (EVT)

When the patient's condition permits, local anesthesia is the first choice for rapid initiation of puncture and endovascular therapy. If the condition requires, sedation can be used, and intubation can be considered for patients at high risk of airway collapse. If the patient is expected to have poor intraoperative cooperation even with sedation or is at high risk of using sedation or airway conditions due to the patient's illness, general anesthesia should be used. Return to the Neuro-Intensive Care Unit (NICU) with intubation or not should be determined according to the surgical results.

Systemic heparinization is not recommended for preoperative and intraoperative treatment. Femoral artery is suggested for arterial puncture, and long sheath, guiding catheter or balloon guiding catheter can be used. Stent retriever (Solitaire, EMBOTRAP, Reco, Captor or other first-line stent retriever systems) and/or contact aspiration (Penumbra aspiration system or other first-line aspiration system) are recommended as the first choice for thrombectomy. If successful reperfusion (eTICI 2b50-3) is not achieved after routine thrombectomy, other techniques are allowed for rescue treatment, including replacement of thrombectomy technique, replacement of thrombectomy device, intra-arterial thrombolysis, balloon angioplasty or stent implantation, etc. The need for rescue treatment is defined (including, but not limited to, a decision made by the investigator based on intraoperative conditions) as follows: three times of thrombectomy with the same thrombectomy device (stent or suction catheter) without successful recanalization; Target vessels were successfully recanalized and reoccluded again; Target vessel dissection or stenosis ≥70%, with any degree of forward blood flow disturbance; New lumen/stent thrombosis resulted in a decreased of eTICI score.

All the above operations should be performed using devices approved by the National Medical Products Administration (NMPA) and should be performed in accordance with the approved intended use and operating instructions.

#### 6.2 Best Medical Management (BMM)

All enrolled patients should receive BMM in accordance with the recommendation of "Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders" by Chinese Stroke Association (CSA).<sup>33</sup> This includes IV thrombolysis therapy for patients meeting the guidelines. Patients who plan to undergo or are undergoing IV thrombolysis therapy can decide whether to terminate IV thrombolysis

therapy in advance according to the investigator's judgment after enrollment. Patients who had completed IV thrombolysis prior to randomization are also eligible for inclusion in this study. All patients will be required to record the name, dosage and time of IV thrombolysis medication in detail. Antiplatelet agents are not recommended within 24 hours after IV thrombolysis unless the patient has undergone balloon dilatation or stent implantation, at which time the antithrombotic strategy is determined by the investigator. Based on the time window and infarct core volume for ANGEL-ASPECT, it is anticipated that most patients enrolled in ANGEL-ASPECT will not have received IV thrombolysis prior to randomization. Non-IV thrombolysis patients will be treated with aspirin, unless an indication for early anticoagulation is present.

# 7. Study endpoints

# 7.1 Primary efficacy endpoint

90 days (±7 days) modified Ranking Scale (mRS)

# 7.2 Secondary efficacy endpoint

- (1) 90 days ( $\pm$ 7 days) mRS 0-2
- (2) 90 days (±7 days) mRS 0-3
- (3) 36 hours ( $\pm 12$  hours) NIHSS 0-1 or decrease  $\geq 10$  from baseline
- (4) Infarct core volume change from baseline, at 7 days (±1 day) or at discharge assessed with NCCT or at 36 hours (±12 hours) assessed with MRI
- (5) 36 hours (±12 hours) target artery recanalization rate assessed with CTA or MRA

# 7.3 Primary safety endpoint

Rate of sICH within 48 hours from randomization (Heidelberg Bleeding Classification, Appendix 5)

## 7.4 Secondary safety endpoint

- (1) All-cause mortality within 90 days ( $\pm$ 7 days)
- (2) Any intracranial hemorrhage within 48 hours from randomization (Heidelberg Bleeding Classification)
- (3) Decompressive hemicraniectomy during hospitalization

# 8. Data collection and Study procedure

Investigator(s) should keep a record, the eligibility Case Report Form (CRF), of subjects who enter pre-study screening. The sub-center number must be indicated. The screening table will be used to analyze and determine whether the enrolled patients in different study sites are representative. Referring to the procedure manual and data collection guidelines, investigators should guarantee the input of CRF is precise, complete and timely, and answer the queries in time. Brain imaging which includes: CT, CTA, CTP, MRI (T1+T2+DWI+FLAIR+ADC+GRE-T2\*/SWI+MRA±PWI) and DSA will be collected as DICOM format. Laboratory results will be collected in photocopies of the reports.

## 8.1 Screening and Inclusion

- Basic data collection: hospital name, name of patient identification, age, sex, allergy to contrast agent.
- History of present event: time of onset (time of last known well), time of arrival at the hospital, type of onset, IV thrombolysis after onset (initial time, name and dose of the drug).

• Medical history and medication before onset

Medical histories (smoking, drinking, hypertension, diabetes, dyslipidemia, cardiac arrhythmia, valvular heart disease, cardiac insufficiency, coronary atherosclerotic heart disease, peripheral arterial disease, TIA, cerebral infarction, cerebral hemorrhage, intracranial tumors), pre-stroke mRS;

Combination therapy: Antiplatelet drugs (aspirin, clopidogrel, cilostazol, prasugrel, ticagrelor, ticlopidine, etc.), anticoagulants (warfarin, dabigatran, rivaroxaban, apixaban, edoxaban, heparin, argatroban, etc.), statins (atorvastatin, pitavastatin, rosuvastatin, pravastatin, simvastatin, fluvastatin, etc.).

• Physical examination

Height and weight, blood pressure, pulse, neurological evaluation (NIHSS and Glasgow scale), 12-lead electrocardiogram (ECG).

• Emergency laboratory examinations

Emergency blood routine, emergency renal function, emergency liver function (transaminase), emergency coagulation, random blood glucose, etc.

• Imaging

A head CT is required to rule out hemorrhage and perform ASPECTS evaluation; a CTA or MRA is essential to confirm the occlusion artery; a CTP or MRI is required to calculate the infarct core volume

- All participants or his/her need to sign a written informed consent form
- Included subjects will be randomized

## 8.2 Data to be collected during procedure

- General anesthesia with intubation or conscious sedation with local anesthesia at start of procedure
- Procedure times: groin puncture time, time of each pass finish, time of initial flow restoration, time of successful recanalization and the end of the procedure
- eTICI score: pre-procedure and post-procedure
- Details of procedure: Accessory and adjunctive devices used (guide catheter, guidewire, intermediate catheter, microcatheter), number and type of devices for thrombectomy, number of recanalization attempt deployments, rescue procedures with medications besides thrombectomy
- Medication during the procedure: heparin, tirofiban, alteplase, urokinase.
- Intraprocedural complications: Presence of vasospasm (time of onset, vessels involved, time resolved, treatment required), evidence of clot migration or embolization, dissections, perforations, etc.

## 8.3 Post Treatment (Through Hospital Discharge)

A face-to-face observation will be performed at 36 hours ( $\pm 12$  hours) and 7 days ( $\pm 1$  day)/at discharge which is earlier after randomization.

- Brain imaging performed at 36 (±12) hours after randomization: CT/CTA or MRI/MRA.
- A physical exam, as well as clinical and neurological assessments, will be completed at 36 (±12) hours and 7 (±1) days/at discharge which is earlier after randomization. Data to be collected include: vital signs (blood pressure and heart rate), relevant concomitant medications (including antiplatelet, anticoagulant, and antihypertensive agents), significant findings from clinical assessment and physical exam (i.e. all new, worsening, or improved conditions), all significant neurological findings, NIHSS Score (both), mRS (7 days or discharge only), and adverse event (AE).
- Head CT evaluation is needed at 7 days (±1 day) or at discharge whichever is earlier

Laboratory examinations will be collected at 24 hours (±12 hours) and 7 days (±1 day) or at discharge whichever is earlier after randomization, including: blood routine, renal function, liver function, coagulation, fasting blood glucose, etc.

## 8.4 Follow-up Visit at Day 30 (±3), Day 90 (±7) and 12 Months (±14 days)

These follow-up evaluations can be performed via telephone if it's not convenient for an in-person visit at the investigational site. All subjects entered into the study will undergo a standard neurological assessment by experienced physicians who are blinded to treatment assignment. Data to be collected include:

- mRS
- Patient-reported functional health status and quality of life using EuroQoL 5-Dimensions 5-Level questionnaire (EQ-5D-5L)<sup>34</sup>
- Relevant concomitant medications
- Significant findings from clinical assessment and physical exam (i.e. all new, worsening, or improved conditions since discharge)

## 8.5 Unscheduled Follow-up Visit

If an unscheduled follow-up visit occurs after randomization at the investigational site during the study, the incidence of any new or unresolved AEs will be assessed. If the visit is due to a change in neurological status, NIHSS and mRS will be completed by a certified rater.

### 8.6 Schedule of activities and assessments

Measurements	Baseline	36-hour	7±1 day	30-day (±3	90 days	12-month ±14
		(±12 hours)	/at discharge	days) visit	(±7 days)	days visit
		visit	visit		visit	
Informed Consent	х					
Inclusion/Exclusion	Х					
Randomization	Х					
Demographic characteristics	х					
History of present illness	х					
Past medical history	х					
Relevant Concomitant Medications	х	Х	Х	Х	Х	х
mRS	Х		Х	Х	х	х
NIHSS	Х	Х	Х			
Head CT	Х		x <sup>3</sup>			
CTA±CTP or	$\mathbf{x}^1$					
MRI*+MRA±PWI						
CT+CTA or MRI*+SWI+MRA		x <sup>2</sup>				
Carotid CTA/MRA/ultrasound		x <sup>4</sup>				
ASPECTS on CT	х					
Ischemic volume on CTP/DWI	х	x <sup>5</sup>	x <sup>5</sup>			
Laboratory examinations	х	Х	х			
Electrocardiogram	х					
TOAST			Х			
EQ-5D-5L scale				Х	Х	Х
AE/SAE		Х	Х	Х	Х	х

<sup>1</sup> For all enrolled cases, CT+CTA+CTP examination was the first choice before randomization

 $^{2}$  All the enrolled cases should be reviewed with multi-mode imaging 24-48 hours after randomization, and the image evaluation method should be the same as before randomization

<sup>3</sup> All enrolled cases should be examined by head CT at 7 days ( $\pm 1$  day) after randomization or at discharge which is earlier

<sup>4</sup> It was only applicable to patients in the standard medical treatment group who did not undergo cervical angiography prior to randomization

<sup>5</sup> Based on head CT or MRI, determined by the core imaging laboratory

\*MRI sequence includes T1+T2+DWI+ADC+FLAIR sequence

ADC: apparent diffusion coefficient; AE: adverse event; ASPECTS: Alberta stroke program early computed tomography score; CT: computed tomography; CTA: computed tomography angiography; CTP: computed tomography perfusion; EQ-5D-5L: EuroQoL 5-Dimensions 5-Level questionnaire; FLAIR: fluid attenuated inversion recovery; MRA: magnetic resonance angiography; MRI: magnetic resonance imaging; mRS: modified Rankin scale; NIHSS: National Institutes of Health Stroke Scale; PWI: perfusion weighted imaging; SAE: serious adverse event; SWI: susceptibility weighting imaging; TOAST: Trial of ORG 10172 in Acute Stroke Treatment.

## 9. Study risk pre-assessment and risk management

### 9.1 Monitoring of adverse events

All AEs will be managed and reported in compliance with all applicable regulations and will be included in the final Clinical Study Report (CSR).

## 9.2 Definitions of adverse events

### 9.2.1 Adverse event (AE)

Adverse Events, as long as they occur from the first visit planned in the Clinical Trial Protocol/signature of the informed consent (i.e., occurring during the washout period) to the last visit planned in the protocol, are adverse medical events or deterioration of qualifying event. AEs include symptoms (ie, nausea, chest pain), signs (ie, tachycardia, liver enlargement) and abnormal laboratory results (ie, laboratory or ECG abnormalities). AEs can be classified as serious adverse events (SAEs) and non-serious AEs.

### 9.2.2 Serious adverse event (SAE)

A Serious adverse event is refers to :

- Results in death, or
- Is life-threatening, or

Note: The term "life-threatening" in the definition of "serious" refers to an event in which the patient is at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it was more severe.

- Requires inpatient hospitalization or prolongation of existing hospitalization, or
- Results in persistent or significant disability/incapacity, or
- Is a congenital anomaly/birth defect, or
- Is a medically important event

### 9.3 Recording of adverse events

Non-serious AE: Only some of the non-serious AEs will be collected from time of randomization throughout the treatment/follow-up periods to the Study Closure Visit. Other non-serious AEs are up to the investigator to decide whether to collect.

SAE: All SAEs will be collected and recorded.

#### 9.4 Causal relationship between adverse events and study:

Attribution of: (1) Definite; (2) Probably; (3) Possibly; (4) Unlikely; (5) Not related; (6) Not applicable.

### 9.5 Obligation of the investigator regarding safety reporting

### 9.5.1 Adverse events

All AEs will be recorded on the corresponding page(s) in the CRF. Whenever possible, symptoms should be grouped as a single syndrome or diagnosis. The Investigator should specify the date of onset, intensity, action taken with respect to Investigational Product, corrective treatment/therapy given, outcome and his/her opinion about whether it is possible that the AE is caused by the study intervention, related to the index stroke, other cause, or intercurrent condition.

#### 9.5.2 Serious adverse event

For SAEs, the investigator must immediately take corresponding measures:

Immediately notify the representative of the Monitoring Team, send the signed and dated corresponding pages of in the CRF to the representative of the Monitoring Team, and attach a photocopy of all examinations conducted and the examination dates. For laboratory results, include the laboratory normal ranges. The contact information (name, address and fax number) of the representative is on the Clinical Trial Protocol. These measures should be completed no later than **24 hours** after SAE.

Care should be taken to ensure that the patient's identity is protected and the patient's identifiers in the Clinical Trial are properly noted on all copies of source documents provided to the Sponsor.

#### 9.5.3 Follow-up and risk management

The Investigator should take all appropriate measures to ensure the safety of the patients.

Screening of subjects should strictly follow the inclusion and exclusion criteria of the study. If an AE occurs during the study period, relevant evaluations will be performed, including blood routine examination, coagulation, creatinine, hepatic function, renal function, arterial blood gas analysis, ultrasound and computer tomography. Targeted treatment and necessary consultation should be carried out in a timely manner. When dealing with SAEs, it is important to make sure patient's airway is clear, respiration, blood pressure and heart rate is steady.

Notably, the investigator should follow up the outcome of any AEs (clinical signs, laboratory values or other, etc.) until the patient's condition returns to normal or stabilizes. The follow-up will continue even if the patient withdraws from the clinical trial, and the patient will be interviewed by telephone or face-to-face at the scheduled visit time. The monitoring team may request additional visits and investigations.

### **10.** Statistical Analysis

#### 10.1 Sample size estimation

In this study, a multicenter, open, randomized, parallel control design method was used. The primary measure of efficacy was mRS score at 90 days ( $\pm$ 7 days) after enrollment (considered as ordered variable). According to the literature data and clinical experts' opinions, the parameters were set as follows: (1) The proportion of mRS score 0-6 in control group was 3%, 4%, 10%, 17%, 16%, 12% and 38%, respectively; (2) The average treatment effect of EVT improved the outcome with the common OR value for improvement of mRS reached 1.73; (3) Two Interim analysis were considered. Adjusted level  $\alpha$ =0.046 (two-sided) and power 1- $\beta$ =0.90. (4) The randomization was allocated to the intervention group and the control group in a 1:1 ratio. Based on these parameters, the total sample size was 452. Considering 10% attrition rate,

the final total sample size was 502 cases, 251 cases in each group.

Interim analysis will be conducted when 1/3 (168) and 2/3 (336) of patients have completed 3-month follow-up. The O'Brien-Fleming boundaries will be used at the interim analysis with a two-sided alpha of 0.0002 (stage 1), 0.0123 (stage 2) and 0.046 (stage 3, final analysis).

The PASS software (NCSS, LLC, version 11) was used to calculate the sample size.

### **10.2 Data collection and entry**

Paper-based CRF and electronic data capture (EDC) system will be used for data collection and input. All the content required by the protocol in the system must be filled, the unfilled content should be explained, and the reason needs to be marked in the EDC system.

### 10.2.1 Paper-based CRF filled out by the investigator

Site investigators should use black or blue-black recording pens to fill out the paper-based CRF neatly and clearly to ensure that the data is clear and readable. If the paper-based CRF information needs to be modified, it should not be altered or overwritten. The correct information should be written next to the original information, signed and dated by the person who modified it. The clinical research monitor (Clinical Research Associate, CRA) will review the completeness and accuracy of the CRF and guide the investigator to make necessary corrections and supplements.

### 10.2.2 Data entry to the EDC system by CRC

After the paper-based CRF is completed, the Clinical research coordinator (CRC) will input the content of the paper CRF into the EDC system.

### 10.2.3 Submission to the EDC system after the approval of the investigator

The paper-based CRF is will be submitted after the investigator has approves it. After the data is submitted, all data revisions and feedback are carried out through the EDC system. If the EDC system has submitted a form that needs to be modified, contact the CRA of this center.

After the CRA opens the form, the investigator can guide the CRC to modify the data in EDC system.

### 10.2.4 Data monitoring and query by CRA via EDC

#### 10.2.5 Data exportation from the EDC system

After the data from the EDC system is exported to the database, it will be proofread by the data administrator. Obvious errors will be corrected by the data administrator. Other errors or missing values will be filled in the data query form, and the query form will be sent to the participating center for solutions through email, express, telephone or WeChat.

The participating centers are responsible for correcting the data in the EDC system after verifying the original data and related information. Site investigators must answer these queries by verifying or modifying relevant information or data.

#### **10.3 Statistical considerations**

This section is an overview of the statistical considerations. It provides the general specifications for the analysis of the data to be collected and presented in the CSR. A final Statistical Analysis Plan (SAP) will be issued prior to database lockdown and before code breaking. The SAP will define all "pre-specified, planned analyses."

All programming will be performed using SAS Version 9.4.

### 10.3.1 Analysis sets

#### (1) Full Analysis Set (FAS):

Based on the principles of the Intent-to-Treat (ITT) analysis, all randomized subjects, either treated with medication or with EVT will be included in the FAS. The primary efficacy endpoint analysis of this study will be performed on the FAS.

### (2) Per Protocol Set (PPS)

The PPS is a subset that includes all subjects who were treated with the treatment

assignment to which they were randomized and there are no clinically meaningful deviations from the protocol. Severe deviations from the protocol will be finally defined during the data auditing process, including but not limited to the followings:

1) The subject is not in line with the inclusion criteria.

2) There are other treatments that potentially confound the appraisal of efficacy of the planned treatment.

3) Poor compliance.

4) Follow-up interval exceeds the required time window.

Secondary analysis will be conducted on the PPS. If its result are not consistent with that of the FAS, a detailed analysis to examine the difference(s) will be required.

### (3) Safety Analysis Set (SAS)

The SAS consists of all subjects who received treatment with at least one evaluation of the safety outcome.

### **10.3.2 Statistical considerations**

### (1) Baseline characteristics comparisons

T-test or Wilcoxon rank sum test will be used for comparison between continuous variables, and Chi-squared tests, Fisher's exact test or Wilcoxon sum rank test will be used for comparison between categorical variables.

### (2) Efficacy Analysis

Primary efficacy endpoint: Based on an ITT basis, an ordinal logistic regression model is used to calculate the common odds ratio between the two treatment groups. All statistics will be two-sided with p < 0.046 considered significant.

Secondary Efficacy Analyses: Endpoints including the 90-day mRS 0-2 will be analyzed using a binary logistic regression model. The infarct core volume change from baseline will be analyzed using student t-test or Wilcoxon rank sum test as appropriate.

### (3) Safety Analysis

Safety events in the two treatment groups will be described based on the SAS dataset. Logistic regression will be used to compare the differences in safety endpoints such as intracranial bleeding events between the two groups. Chi-square test and Fisher's exact test will be used to compare the differences in the incidence of AEs and SAEs between the two groups.

### (4) Subgroup analysis

The mRS at 90 days will be presented for each level of the covariates listed below:

- (1) Age (< 70 vs.  $\geq$ 70)
- (2) Weak-up stroke or not
- (3) Last known well to randomization time ( $< 6h \text{ vs.} \ge 6h$ )
- (4) Stroke severity before randomization (NIHSS<16 vs. NIHSS≥16)
- (5) IV thrombolysis or not
- (6) Occlusion site (ICA vs. M1 segment)
- (7) Ipsilateral carotid artery occlusion or not
- (8) ASPECTS (< 3 points vs.  $\geq$ 3 points)
- (9) Infarct core volume (< 70ml vs.  $\geq 70$ ml)
- (10) Etiological stroke subtype (Cardiac embolism vs. large artery atherosclerosis)

#### **10.4 Interim analysis**

Interim analysis will take place when 1/3 (168 cases) and 2/3 (336 cases) have completed 3-month follow-up. The O'Brien-Fleming boundaries will be used at the interim analysis as follows:

There are no established techniques for the assessment of interim trial efficacy boundaries using an ordinal logistic regression model (proportional odds model). Instead, we will revert to a simple dichotomous analysis of the mRS score at 0-2 defined at 90 days from randomization. The Z-statistic for this analysis shall be derived from the normal approximation of the binomial distribution as an unadjusted two-sample test of proportions. For an RCT comparing two treatment groups with respect to a binary outcome and two interim analysis, corresponding significance levels based on the O'Brien & Fleming boundary are two-sided 0.0002 (stage 1), 0.0123 (stage 2) and 0.046 (stage 3, final analysis).

With the result of interim analysis, DSMB will make the decision to continue or halt the study according to the test boundaries. The study will stop prematurely for futility if the result from the interim analysis indicate that we can't achieve an effective conclusion with the current sample size. Premature stopping for early success will be achieved if the interim analysis result has already proved the effect of intervention at significance level. Otherwise, the study will be continued until the predefined termination date. In interim analysis, the final sample size is allowed to be adjusted if the estimation of the primary outcome is drastically different from the actual data.

## 11. Ethical standards

#### 11.1 Ethical standards

This Clinical Trial will be conducted in accordance with the principles laid down by the 18th World Medical Assembly (Helsinki, 1964) and all applicable amendments laid down by the World Medical Assemblies and the ICH guidelines for Good Clinical Practice. Prior to initiating the study, each site will obtain Institutional review board (IRB) or institutional ethics committee (IEC) approval for the protocol, informed consent forms and materials used to recruit subjects. Before each subject is enrolled, the investigator is responsible for fully and comprehensively introducing the purpose, procedures and possible risks of the study to the subject or his/her agent, signing a written informed consent form, and informing the subjects that he has the right to withdraw from this study at any time. The informed consent should be kept as a clinical study document for future reference. The personal privacy and data confidentiality of subjects will be protected during the study process.

### 11.2 Law and regulations

This Clinical Trial will be conducted in compliance with all international laws and regulations, and Chinese laws and regulations, as well as any applicable guidelines.

### 11.3 Informed consent

The Investigator/sub-investigator should fully inform the patient of all pertinent aspects of the Clinical Trial, including the written information approved/preferred by the Ethics Committee (IRB/IEC). The Informed Consent Form used by the Investigator for obtaining the patient's informed consent must be reviewed and approved by the Sponsor and then submitted to the Ethics Committee (IRB/IEC) for approval.

All participants should be informed to the fullest extent possible about the study, in language and terms they are able to understand. Prior to a patient's participation in the Clinical Trial, informed Consent Form should be signed and dated by the patient or by the patient's legal representative and by the person who conducted the informed consent discussion. A copy of the signed and dated Informed Consent Form will be provided to the patient.

### 11.4 Institutional review board/ Institutional ethics committee (IRB/IEC)

The Investigator or the Sponsor must submit this Clinical Trial Protocol to the appropriate Ethics Committee (IRB/IEC), and the Ethics Committee is required to forward to the Sponsor a copy of the written approval/favorable opinion signed and dated by the Chairman with Ethics Committee (IRB/IEC) composition.

The Clinical Trial (study number, Clinical Trial Protocol title and version number), the documents reviewed (Clinical Trial Protocol, Informed Consent Form, Investigator's Brochure, Investigator's CV, etc.), the list of voting members along with their qualification and the date of the review should be clearly stated on the written (IRB/IEC) approval/favorable opinion.

During the Clinical Trial, any amendment or modification to the Clinical Trial Protocol should be submitted to the Ethics Committee (IRB/IEC). It should also be informed of any event likely to affect the safety of patients or the continued conduct of the Clinical Trial, in particular any change in safety. All updates to the Investigator's Brochure will be sent to the Ethics Committee (IRB/IEC). If requested, annual progress report, as well as final summary of the Clinical Trial's outcome at the end of the Clinical Trial, will also be sent to the Ethics Committee (IRB/IEC).

## **12.** Confidentiality and publication of research findings

The principal investigator has complete intellectual property rights. The entire research process and data analysis process will strictly protect the subjects' information. Publication of the results of this trial will be governed by the policies and procedures developed by the Executive Committee. The trial results will be published as soon as possible after database lockdown. This trial will produce detailed data on treatment effects, medical care, and outcomes. Biostatisticians will be consulted to ensure that it is impossible to uniquely identify any participant. Diskettes with the data in comma-delimited text format, along with a data dictionary in a text file, will be sent to interested parties.

## 13. Study Organization

## **13.1** Constitution

## • The steering committee

- ✓ The steering committee will provide scientific and strategic direction for the trial and will have overall responsibility for its design, execution, and publication.
- ✓ The steering committee will also be responsible for ensuring that study execution and management are of the highest quality.
- ✓ It will approve the protocol and the operational guidelines of the trial prior to its commencement.
- ✓ The steering committee will meet regularly by teleconference or face-to-face meetings to discuss and report the progress of the study.
- ✓ The composition of the steering committee and its responsibilities are described in a charter which will be finalized before the start of the trial.

Member	Department	Hospital
Yongjun Wang	Department of Neurology	Beijing Tiantan Hospital, Capital
Tongjun wang	Department of Neurology	Medical University

### **Steering Committee**

Yilong Wang	Department of Neurology	Beijing Tiantan Hospital, Capital Medical University
Liping Liu Department of Neurology		Beijing Tiantan Hospital, Capital Medical University
David S. Liebeskind Department of Neurology		University of California at Los Angeles
Zhongrong Miao Department of Interventional Neuroradiology		Beijing Tiantan Hospital, Capital Medical University
Zeguang Ren Department of Neurosurgery		The Affiliated Hospital of Guizhou Medical University
Vitor Mendes	Department of Neurosurgery, Division of	St Michael's Hospital, University of
Pereira	Surgery	Toronto

## • Executive committee

The executive committee is responsible for reviewing the status of the trial and available blinded data and will take appropriate actions regarding the conduct of the study. Executive Committee meetings will be organized to make major decisions. The composition of the Executive Committee and its responsibilities are described in a charter which will be finalized before the start of the trial.

## • Data safety and monitoring board (DSMB)

The DSMB will meet regularly and monitor the study progress to ensure that the study meets the highest standards of ethics and patient safety. It is composed of Academic Members, including an independent statistician, who does not otherwise participate in the trial. A DSMB charter including membership, role and responsibilities will be approved by both the DSMB and the Executive Committee before the start of the trial.

Written recommendations and their rationale will be provided to the Chairs of the Steering Committee immediately after each DSMB meeting.

Member	Department	Hospital
Jianmin Liu	Neurovascular Center	Changhai Hospital, Naval Medical University
Chen Yao	Department of Medical Statistics	Peking University First Hospital
Kan anina Chan	Demonstration of Neurole and	The Southwest Hospital of Army Medical
Kangning Chen Department of Neurology		University

Data s	safety	and	monitoring	board
--------	--------	-----	------------	-------

## • Clinical event committee (CEC)

Clinical events and safety endpoint will be reviewed by CEC. A CEC charter including membership, role and responsibilities will be approved before the start of the trial by the CEC and the Executive Committee.

Member	Department	Hospital
Kun Fang	Department of Neurology	Huashan Hospital, Fudan University
Bo Song	Department of Neurology	The First Affiliated Hospital of Zhengzhou University
Yi Dong	Department of Neurology	Huashan Hospital, Fudan University

## **Clinical event committee**

### • Imaging assessment committee

Name	Department	Hospital
Jing Jing	Tiantan Neuroimaging Center of	China National Clinical Research Center
	Excellence (T-NICE)	for Neurological Diseases
Zhe Zhang	Tiantan Neuroimaging Center of	China National Clinical Research Center
	Excellence (T-NICE)	for Neurological Diseases
Yingkui Zhang	Tiantan Neuroimaging Center of	China National Clinical Research Center
	Excellence (T-NICE)	for Neurological Diseases
Wei Wu	Department of Neurology	Qilu Hospital, Shandong University

### 13.2 Site training and certification

Executive committee will provide training to their participating sites in Good Clinical Practice Guidelines and in some outcome assessments. Prior to initiation of patient enrollment, Site Investigators and Coordinators must complete all training programs.

The training programs that need to be completed are as follows:

- (1) Study procedures
- (2) ANGEL-ASPECT eligibility criteria
- (3) mRS
- (4) NIHSS
- (5) ASPECTS

- (6) iSchemaView automated RAPID® software
- (7) eTICI
- (8) TOAST etiology subtyping
- (9) Heidelberg Bleeding Classification
- (10) Collecting DICOM imaging data

Successful completion of the training program is a must before a site begin to enroll patients. The conference call will be held intermittently, and PI and key staff will be available to answer questions.

A detailed Manual of Procedures will serve as the primary document describing all study related procedures. It will serve as a guide to train clinical center personnel and will be updated periodically throughout the study on the ANGEL-ASPECT website, as needed. A system composed of members of executive committee and CRA will be implemented for the clinical centers to ask any procedural questions by phone, fax, or e-mail. The ANGEL-ASPECT executive committee and monitoring committee will formulate answers in consultation with the Steering Committee and will periodically distribute to the participating centers a set of frequently asked questions and answers.

The members of executive committee will manage and conduct site visits to ensure the integrity and validity of the data on the CRF. During the trial period, each site should be visited at least once. If there are data quality problems or recruitment problems, it should be visited as needed.

## 14. Study monitoring and quality assurance control

### 14.1 Responsibilities of the investigator(s)

The Investigator(s) should conduct the Clinical Trial in accordance with the Clinical Trial Protocol, The International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human Use (ICH) guidelines for Good Clinical Practice and the applicable regulatory requirements.

The Investigator is required to ensure compliance with all procedures required by the Clinical Trial Protocol and with all study procedures provided by the Sponsor (including security rules). The Investigator should provide reliable data and all information requested by the Protocol (with the help of the CRF, Discrepancy Resolution Form or other appropriate instruments) in an accurate and legible manner and ensure direct access to source documents by Sponsor representatives.

The Investigator may appoint other individuals as Sub-Investigators, as he thinks appropriate. All Sub-Investigators shall be appointed and listed in a timely manner and will be supervised by the Investigator. The Investigator will provide them a copy of the Clinical Trial Protocol and all necessary information. The Sponsor is responsible for taking all reasonable steps to ensure the proper conduct of the Clinical Trial Protocol as regards ethics, Clinical Trial Protocol compliance, and integrity and validity of the data on the CRF.

## 14.2 Study monitoring

The main responsibility of the monitoring team is to help researchers to ensure that all aspects of clinical trials are ethical, scientific, professional, and standardized. According to the ICH guidelines for Good Clinical Practice (GCP), the Monitoring Team must check the CRF entries according to the source documents, except for the pre-identified.

The monitoring team will regularly contact each center through site visits or online webinar, and will send inspectors to evaluate the research progress, adherence of the investigators and patients to the research protocol and to solve urgent problems. During these inspection visits, the inspector will work together with the site-investigators. The main aspects of inspection and monitoring are as follows (not exclusive): patient's informed consent, patient recruitment and follow-up, documentation and reporting of SAEs and data quality.

## 15. Data retention

The double reviewed CRF and imaging data will be sent to the trial-designated data management center by CRAs. The person in charge of the data management center will check and sign the receipt form. The CRF will be kept by the research center after data entry is completed.

## 16. Data Security Monitoring

The data safety monitoring board (DSMB) is established to monitor the safety of participants, protect participants and ensure the integrity of the study. All AEs should be recorded, handled and tracked until they are properly resolved or stabilized. Any SAEs and unexpected events should be reported in a timely manner to the ethics committee in accordance with the relevant provisions, the competent department, the sponsor and the supervisory and administrative departments. The principal researchers should regularly review all AEs and set up meetings to assess the risks and benefits of the study if necessary. An independent data safety monitoring committee will be appointed to review safety data, evaluate the effectiveness of data monitoring, and decide whether to make new proposal.

During the clinical trial, the data of the subjects should be collected anonymously in the CRF. The subjects are identified only by the subject number and the abbreviation of the initials. Due to safety reason and administrative instructions, when the subject's identity is leaked, researchers shall share the responsibility of confidentiality. In the informed consent form, the patient allows authorized research staff, ethics committee, and the authority to refer directly to the relevant original data on the case report (such as the patient's medical file case, booking records, the original laboratory records, etc.). The above personnel shall comply with occupational confidentiality rules and must keep all patient's identity and medical information confidential.

## 17. Registration and Publication

## 17.1 Registration of study summary and results

The study representatives register a study summary in ClinicalTrials.gov (https: //clinicaltrials.gov) before the start of the study and update the summary as appropriate according to changes in the protocol or progress of the study. When the study is completed, the study representatives register a study result without delay.

## **17.2 Publication of study results**

When the study is completed, the study database will be closed within one month after the last scheduled follow-up date of the last included patient. A manuscript which describes the study and the answer to the primary research question will be submitted to a major clinical journal within 3 months from closure of the database. The study representatives publish the results of the study after taking necessary measures (e.g., to prevent identification of specific study patients) to protect the human rights of patients and related parties or the rights and benefits of patients and related parties.

The manuscript will be shared with the financial sponsor(s) one month before submission, but the financial sponsor(s) will have no influence on its contents. Author(s) of the paper are determined by the study representatives according to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://www.icmje.org/) by the International Committee of Medical Journal Editors (ICMJE). All authors should review and agree to the details of the paper prior to submission. The same goes for authors of conference presentations.

## 18. Ownership and use of data

## 18.1 Ownership of the data

The results, data, intellectual property rights, etc. obtained in this study belong to

the study representatives and not to the patients. Whether the intellectual property rights of the study representatives belong to the individual or to the study institution is determined by the agreement of the participating hospital.

## 18.2 Use of collected data

The study Steering Committee determines whether to use the data obtained in this study (hereinafter, "study data") for further study conducted by the Study representatives or sub-investigators as a secondary analysis of this study.

If the analysis is judged to be beyond the scope of secondary analysis, or if the study data is used by a person except for the study representatives or sub-investigators, the Study Steering Committee prepares a separate protocol and conducts the study after undergoing ethical review in accordance with relevant laws, regulations and ethical guidelines for medical research on human subjects.

## **19.** Funding and conflict of interest

The study was funded by untrestricted grants from Covidien Healthcare International Trading (Shanghai) Co., Ltd., Johnson & Johnson MedTech, Genesis MedTech (Shanghai) Co., Ltd. and Shanghai HeartCare Medical Technology Co., Ltd.

## 20. Reference

- Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2019;50(12):e344-e418. DOI: 10.1161/STR.00000000000211.
- Turc G, Bhogal P, Fischer U, et al. European Stroke Organisation (ESO)- European Society for Minimally Invasive Neurological Therapy (ESMINT) guidelines on mechanical thrombectomy in acute ischemic stroke. J Neurointerv Surg 2019;11(6):535-538. DOI: 10.1136/neurintsurg-2018-014568.
- 3. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;372(1):11-20. DOI: 10.1056/NEJMoa1411587.

- Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015;372(11):1009-18. DOI: 10.1056/NEJMoa1414792.
- Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015;372(11):1019-30. DOI: 10.1056/NEJMoa1414905.
- 6. Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015;372(24):2296-306. DOI: 10.1056/NEJMoa1503780.
- Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 2015;372(24):2285-95. DOI: 10.1056/NEJMoa1415061.
- Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med 2018;378(1):11-21. DOI: 10.1056/NEJMoa1706442.
- 9. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med 2018;378(8):708-718. DOI: 10.1056/NEJMoa1713973.
- Bracard S, Ducrocq X, Mas JL, et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. Lancet Neurol 2016;15(11):1138-47. DOI: 10.1016/S1474-4422(16)30177-6.
- Gautheron V, Xie Y, Tisserand M, et al. Outcome After Reperfusion Therapies in Patients With Large Baseline Diffusion-Weighted Imaging Stroke Lesions: A THRACE Trial (Mechanical Thrombectomy After Intravenous Alteplase Versus Alteplase Alone After Stroke) Subgroup Analysis. Stroke 2018;49(3):750-753. DOI: 10.1161/STROKEAHA.117.020244.
- Deb-Chatterji M, Pinnschmidt H, Flottmann F, et al. Predictors of independent outcome of thrombectomy in stroke patients with large baseline infarcts in clinical practice: a multicenter analysis. J Neurointerv Surg 2020;12(11):1064-1068. DOI: 10.1136/neurintsurg-2019-015641.
- Roman LS, Menon BK, Blasco J, et al. Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data. Lancet Neurol 2018;17(10):895-904. DOI: 10.1016/S1474-4422(18)30242-4.
- 14. Campbell BCV, Majoie C, Albers GW, et al. Penumbral imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-level data. Lancet Neurol 2019;18(1):46-55. DOI: 10.1016/S1474-4422(18)30314-4.
- 15. Sarraj A, Hassan AE, Savitz S, et al. Outcomes of Endovascular Thrombectomy vs Medical Management Alone in Patients With Large Ischemic Cores: A Secondary Analysis of the Optimizing Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT) Study. JAMA Neurol 2019;76(10):1147-1156. DOI: 10.1001/jamaneurol.2019.2109.
- Cagnazzo F, Derraz I, Dargazanli C, et al. Mechanical thrombectomy in patients with acute ischemic stroke and ASPECTS </=6: a meta-analysis. J Neurointerv Surg 2020;12(4):350-355. DOI: 10.1136/neurintsurg-2019-015237.
- Sarraj A, Grotta JC, Pujara DK, Shaker F, Tsivgoulis G. Triage imaging and outcome measures for large core stroke thrombectomy - a systematic review and meta-analysis. J Neurointerv Surg 2020;12(12):1172-1179. DOI: 10.1136/neurintsurg-2019-015509.
- Rebello LC, Bouslama M, Haussen DC, et al. Endovascular Treatment for Patients With Acute Stroke Who Have a Large Ischemic Core and Large Mismatch Imaging Profile. JAMA Neurol

2017;74(1):34-40. DOI: 10.1001/jamaneurol.2016.3954.

- 19. Broocks G, Flottmann F, Schonfeld M, et al. Incomplete or failed thrombectomy in acute stroke patients with Alberta Stroke Program Early Computed Tomography Score 0-5 how harmful is trying? European journal of neurology 2020;27(10):2031-2035. DOI: 10.1111/ene.14358.
- Nicholson P, Hilditch CA, Neuhaus A, et al. Per-region interobserver agreement of Alberta Stroke Program Early CT Scores (ASPECTS). J Neurointerv Surg 2020;12(11):1069-1071. DOI: 10.1136/neurintsurg-2019-015473.
- van Horn N, Kniep H, Broocks G, et al. ASPECTS Interobserver Agreement of 100 Investigators from the TENSION Study. Clin Neuroradiol 2021. DOI: 10.1007/s00062-020-00988-x.
- 22. Demeestere J, Garcia-Esperon C, Garcia-Bermejo P, et al. Evaluation of hyperacute infarct volume using ASPECTS and brain CT perfusion core volume. Neurology 2017;88(24):2248-2253. DOI: 10.1212/WNL.00000000004028.
- Sarraj A, Hassan AE, Grotta J, et al. Optimizing Patient Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT): A Prospective, Multicenter Cohort Study of Imaging Selection. Ann Neurol 2020;87(3):419-433. DOI: 10.1002/ana.25669.
- 24. Mourand I, Abergel E, Mantilla D, et al. Favorable revascularization therapy in patients with ASPECTS </= 5 on DWI in anterior circulation stroke. J Neurointerv Surg 2018;10(1):5-9. DOI: 10.1136/neurintsurg-2017-013358.
- 25. Inoue M, Olivot JM, Labreuche J, et al. Impact of diffusion-weighted imaging Alberta stroke program early computed tomography score on the success of endovascular reperfusion therapy. Stroke 2014;45(7):1992-8. DOI: 10.1161/STROKEAHA.114.005084.
- Han M, Choi JW, Rim NJ, et al. Cerebral infarct volume measurements to improve patient selection for endovascular treatment. Medicine (Baltimore) 2016;95(35):e4702. DOI: 10.1097/MD.00000000004702.
- 27. Manceau PF, Soize S, Gawlitza M, et al. Is there a benefit of mechanical thrombectomy in patients with large stroke (DWI-ASPECTS </= 5)? European journal of neurology 2018;25(1):105-110. DOI: 10.1111/ene.13460.
- Broocks G, Rajput F, Hanning U, et al. Highest Lesion Growth Rates in Patients With Hyperacute Stroke. Stroke 2018:STROKEAHA118023457. DOI: 10.1161/STROKEAHA.118.023457.
- 29. Goyal M, Fargen KM, Turk AS, et al. 2C or not 2C: defining an improved revascularization grading scale and the need for standardization of angiography outcomes in stroke trials. J Neurointerv Surg 2014;6(2):83-6. DOI: 10.1136/neurintsurg-2013-010665.
- 30. von Kummer R, Broderick JP, Campbell BC, et al. The Heidelberg Bleeding Classification: Classification of Bleeding Events After Ischemic Stroke and Reperfusion Therapy. Stroke; a journal of cerebral circulation 2015;46(10):2981-6. DOI: 10.1161/STROKEAHA.115.010049.
- Zaidat OO, Yoo AJ, Khatri P, et al. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke; a journal of cerebral circulation 2013;44(9):2650-63. DOI: 10.1161/STROKEAHA.113.001972.
- 32. Boers AM, Marquering HA, Jochem JJ, et al. Automated cerebral infarct volume measurement in follow-up noncontrast CT scans of patients with acute ischemic stroke. AJNR Am J Neuroradiol 2013;34(8):1522-7. DOI: 10.3174/ajnr.A3463.
- 33. Liu L, Chen W, Zhou H, et al. Chinese Stroke Association guidelines for clinical management

of cerebrovascular disorders: executive summary and 2019 update of clinical management of ischaemic cerebrovascular diseases. Stroke Vasc Neurol 2020;5(2):159-176. DOI: 10.1136/svn-2020-000378.

34. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990;16(3):199-208. DOI: 10.1016/0168-8510(90)90421-9.

# 21. Appendix

### Appendix Table 1. Modified Rankin Scale

The modified Rankin Scale (mRS) is an ordinal hierarchical scale ranging from 0 to 5, with higher scores indicating more severe disability. A score of 6 has been added to signify death.

Category	Short description	Long description
0	No symptoms	No symptoms
1	Symptoms, no disability	Minor symptoms that do not interfere with lifestyle
2	Slight disability	Slight disability, symptoms that lead to some restriction in lifestyle, but do not interfere with the patient's capacity to look after himself.
3	Moderate disability	Moderate disability, symptoms that significantly restrict lifestyle and prevent totally independent existence
4	Moderately severe disability	Moderately severe disability, symptoms that clearly prevent independent existence though not needing constant attention
5	Severe disability	Severe disability, totally dependent patient requiring constant attention day and night.
6	Death	Death

eTICI grade	Short description	Long description
0	No perfusion	No antegrade flow beyond the point of occlusion
1	Limited reperfusion	Antegrade reperfusion past the initial occlusion, but limited distal branch filling with little or slow distal reperfusion
2a	<50% reperfusion	Antegrade reperfusion of less than half of the occluded target artery previously ischemic territory (eg, in 1 major division of the MCA and its territory)
2b	≥50% and <90% reperfusion	Antegrade reperfusion of more than half of the previously occluded target artery ischemic territory (eg, in 2 major divisions of the MCA and its territories)
2c	≥90% reperfusion	Near complete antegrade reperfusion of the previously occluded target artery ischemic territory, except for slow flow or distal emboli in a few distal cortical vessels
3	100% reperfusion	Complete antegrade reperfusion of the previously occluded target artery ischemic territory, with absence of visualized occlusion in all distal branches

## Appendix Table 2. Extended Treatment In Cerebral Ischemia (eTICI) Scale

MCA: middle cerebral artery; eTICI; extended treatment in cerebral ischemia scale

### Appendix Table 3. National Institute of Health Stroke Scale (NIHSS)

The NIHSS is an ordinal hierarchical scale to evaluate the severity of stroke by assessing a patient's performance. Scores range from 0 to 42, with higher scores indicating a more severe deficit. Administer stroke scale items in the order listed. Record performance in each category after each subscale exam. Do not go back and change scores. Follow directions provided for each exam technique. Scores should reflect what the patient does, not what the clinician thinks the patient can do. The clinician should record answers while administering the exam and work quickly. Except where indicated, the patient should not be coached (i.e. repeated requests to patient to make a special effort).

Instructions	Scale definition
	0 = Alert; keenly responsive.
	1 = Not alert; but arousable by minor
1a. Level of consciousness. The investigator must choose a	stimulation to obey, answer, or respond.
response if a full evaluation is prevented by such obstacles as	2 = Not alert; required repeated stimulation to
an endotracheal tube, language barrier, orotracheal	attend, or is obtunded and requires strong or
trauma/bandages. A 3 is scored only if the patient makes no	painful stimulation to make movements (not
movement (other than reflexive posturing) in response to	stereotyped).
noxious stimulation.	3 = Responds only with reflex motor or
	autonomic effects or totally unresponsive,
	flaccid and areflexic.
<b>1b. LOC Questions:</b> The patient is asked the month and his/her	
age. The answer must be correct – there is not partial credit for	
being close. Phasic and stuporous patients who do not	
comprehend the questions will score 2. Patients unable to speak	0 = Answers both questions correctly.
because of endotracheal intubation, orotracheal trauma, severe	1 = Answers one question correctly.
dysarthria from any cause, language barrier, or any other	2 = Answers neither question correctly.
problem not secondary to aphasia are given a 1. It is important	
that only the initial answer be graded and that the examiners not	
"help" the patient with verbal or non-verbal clues.	
1c. LOC Commands: The patient is asked to open and close	
the eyes and then to grip and release the non-paretic hand.	
Substitute another one step command if the hand cannot be	
used. Credit is given if an unequivocal attempt is made but not	0 = Performs both tasks correctly.
completed due to weakness. If the patient does not respond to	1 = Performs one task correctly.
command, the task should be demonstrated to him or her	2 = Performs neither task correctly.
(pantomime), and the result scored (i.e. follows none, one or	
two commands). Patients with trauma, amputation, or other	
physical impediments should be given suitable one-step	

n one
l gaze
is not
er.
uding
fold,
-total
sides
r and
es for
s, but
es not
annot
grees,
gainst
n:

	5a = Left Arm.
	5b = Right arm.
	0= No drift; leg holds 30-degree position for
	full 5 seconds.
<b>6. Motor leg:</b> The limb is placed in the appropriate position:	1= Drift; leg falls by the end of the 5-second
hold the leg at 30 degrees (always tested supine). Drift is scored	period but does not hit bed.
if the leg falls before 5 seconds. The aphasic patient is	2= Some effort against gravity; leg falls to bed
encouraged using urgency in the voice and pantomime, but not	by 5 seconds, but has some effort against
noxious stimulation. Each limb is tested in turn, beginning with	gravity.
the non-paretic leg. Only in the case of amputation or joint	3= No effort against gravity; leg falls to bed
fusion at the hip, the examiner should record the score as	immediately.
untestable (UN), and clearly write the explanation for this	4= No movement.
choice.	UN = Amputation or joint fusion: explain:
	6a. Left Leg
	6b. Right Leg.
7. Limb ataxia: This item is aimed at finding evidence of a	00
unilateral cerebellar lesion. Test with eyes open. In case of	
visual defect, ensure testing is done in intact visual field. The	
finger-nose-finger and heel-shin tests are performed on both	
	0=Absent.
sides, and ataxia is scored only if present out of proportion to	1= Present in one limb.
weakness. Ataxia is absent in the patient who cannot understand	2= Present in two limbs.
or is paralyzed. Only in the case of amputation or joint fusion,	UN = Amputation or joint fusion: explain:
the examiner should record the score as untestable (UN), and	
clearly write the explanation for this choice. In case of	
blindness, test by having the patient touch nose from extended	
arm position.	
8. Sensory: Sensation or grimace to pinprick when tested, or	
withdrawal from noxious stimulus in the obtunded or aphasic	
patient. Only sensory loss attributed to stroke is scored as	0= Normal; no sensory loss.
abnormal and the examiner should test as many body areas	1= Mild-to-moderate sensory loss; patients
(arms [not hands], legs, trunk, face) as needed to accurately	feels pinprick is less sharp or is dull on the
check for hemisensory loss. A score of 2, 'severe or total sensory	affected side; or there is a loss of superficial
loss', should only be given when a severe or total loss of	pain with pinprick, but patient is aware of
sensation can be clearly demonstrated. Stuporous and aphasic	being touched.
patients will, therefore, probably score 1 or 0. The patient with	2= Severe to total sensory loss; patient is not
brainstem stroke who has bilateral loss of sensation is scored 2.	aware of being touched in the face, arm and
If the patient does not respond and is quadriplegic, score 2.	leg.
Patients in a coma (item 1a=3) are automatically given a 2 on	
this item.	
9. Best language: A great deal of information about	0= No aphasia; normal
comprehension will be obtained during the preceding sections	1= Mild-to-moderate aphasia; some obvious
of the examination. For this scale item, the patient is asked to	loss of fluency or facility of comprehension,
describe what is happening in the attached picture, to name the	without significant limitation on ideas
items on the attached naming sheet and to read from the attached	expressed or form of expression. Reduction of

list of sentences. Comprehension is judged from responses here, as well as to all of the commands in the preceding general neurological exam. If visual loss interferes with the tests, ask the patient to identify objects placed in the hand, repeat, and produce speech. The intubated patient should be asked to write. The patient in a coma (item 1a=3) will automatically score 3 on this item. The examiner must choose a score for the patient with stupor or limited cooperation, but a score of 3 should be used only if the patient is mute and follows no one-step commands.	<ul> <li>speech and/or comprehension, however, makes</li> <li>conservation about provided materials</li> <li>difficult or impossible. For example, in</li> <li>conversation about provided materials,</li> <li>examiner can identify picture or naming card</li> <li>content from patient's response.</li> <li>2= Severe aphasia; all communication is</li> <li>through fragmentary expression; great need</li> <li>for inference, questioning, and guessing by the</li> <li>listener. Range of information that can be</li> <li>exchanged is limited; listener carries burden</li> <li>of communication. Examiner cannot identify</li> <li>materials provided from patient response.</li> <li>3 = Mute, global aphasia: no usable speech or</li> <li>auditory comprehension.</li> </ul>
<ul> <li>10. Dysarthria: If patient is thought to be normal, an adequate sample of speech must be obtained by asking patient to read or repeat words from the attached list. If the patient has severe aphasia, the clarity of articulation of spontaneous speech can be rated. Only if patient is intubated or has other physical barriers to producing speech, the examiner should record the score as untestable (UN), and clearly write an explanation for this choice. Do not tell the patient why he or she is being tested.</li> <li>11. Extinction and Inattention (formerly Neglect): Sufficient information to identify neglect may be obtained during the prior testing. If the patient has a severe visual loss preventing visual double simultaneous stimulation, and the cutaneous stimuli are normal, the score is normal. If the patient has aphasia but does appear to attend to both sides, the score is normal. The presence of visual spatial neglect or anosagnosia may also be taken as evidence of abnormality. Since the abnormality is scored only if</li> </ul>	<ul> <li>0= Normal.</li> <li>1= Mild-to-moderate dysarthria; patient slurs at least some words and, at worst, can be understood by some difficulty.</li> <li>2= Severe dysarthria: patient's speech is so slurred as to be unintelligible in the absence of or out of proportion to any dysphasia, or is mute/anarthric.</li> <li>UN = Intubated or other physical barrier.</li> <li>0= No abnormality.</li> <li>1= Visual, tactile, auditory, spatial, or personal inattention or extinction to bilateral simultaneous stimulation in one of the sensory modalities.</li> <li>2= Profound hemi-inattention or extinction to more than one modality; does not recognize</li> </ul>

## Appendix Table 4. EuroQoL 5D-5L


Under each heading, please tick the ONE box that best describes your health TODAY.

### Mobility

I have no problems in walking about I have slight problems in walking about I have moderate problems in walking about I have severe problems in walking about I am unable to walk about Self-care I have no problems washing or dressing myself I have slight problems washing or dressing myself I have moderate problems washing or dressing myself I have severe problems washing or dressing myself I am unable to wash or dress myself Usual activities (e.g. work, study, housework, family or leisure activities) I have no problems doing my usual activities I have slight problems doing my usual activities I have moderate problems doing my usual activities I have severe problems doing my usual activities I am unable to do my usual activities Pain/discomfort I have no pain or discomfort I have slight pain or discomfort I have moderate pain or discomfort I have severe pain or discomfort I have extreme pain or discomfort Anxiety/depression I am not anxious or depressed I am slightly anxious or depressed I am moderately anxious or depressed I am severely anxious or depressed I am extremely anxious or depressed

- We would like to know how good or bad your health is TOADY.
- This scale is numbered from 0 to 100.
- 100 means the <u>best</u> health you can imagine.
  0 means the <u>worst</u> health you can imagine.
- Mark an X on the scale to indicate how your health is TODAY.
- Now, please write the number you marked on the scale in the box below.





### Appendix Table 5. Heidelberg bleeding classification

Symptomatic intracranial hemorrhage (SICH): new intracranial hemorrhage detected by brain imaging associated with any of the items below:

 $1. \ge 4$  points decline in the total NIHSS at the time of diagnosis compared to immediately before worsening. Note that a 4 points change is not compared with the baseline admission NIHSS score but instead to the immediate predeterioration neurological status

2.  $\geq$ 2 point decline in one NIHSS category. The rationale for this is to capture new hemorrhages that produce new neurological symptoms, making them clearly symptomatic but not causing worsening in the original stroke territory. For example, a new remote hemorrhage in the contralateral occipital lobe may cause new hemianopia that is clearly symptomatic but the patient will not have worsening of  $\geq$ 4 points on the NIHSS score

Leading to intubation/hemicraniectomy/EVD placement or other major medical/surgical intervention.

Anatomic Description of Intracranial Hemorrhages


	Anatomic Description of intractainal Hemorinages		
Class	Туре	Description	
1	1 Hemorrhagic transformation of infarcted brain tissue		
1a	HI1	Scattered small petechiae, no mass effect	
1b	HI2	Confluent petechiae, no mass effect	
1c	PH1	Hematoma within infarcted tissue, occupying $<30\%$ , no substantive mass effect	
2	Intracerebral hemorrhage within and beyond infarcted brain tissue		
	PH2	Hematoma occupying 30% or more of the infarcted tissue, with obvious mass effect	
3	3 Intracerebral hemorrhage outside the infarcted brain tissue or intracranial- extracerebral hemorrhage		
3a	Parenchymal hematoma remote from infarcted brain tissue		
3b	Intraventricular hemorrhage		
3c	Subarachnoid hemorrhage		
3d		Subdural hemorrhage	

3. Absence of alternative explanation for deterioration

HI indicates hemorrhagic infarction; and PH, parenchymatous hematoma.

### Appendix Table 6. Alberta Stroke Program Early CT Score (ASPECTS)

The Alberta Stroke Program Early CT Score (ASPECTS) is a semiquantitative method of estimation of infarct size with non-contrast CT during the acute phase. The territory of the middle cerebral artery is allotted 10 points. 1 point is subtracted for an area of early ischaemic change, such as focal swelling, or parenchymal hypoattenuation, for each of the defined regions. A normal CT scan has an ASPECTS value of 10 points. A score of 0 indicates diffuse ischaemia throughout the territory of the middle cerebral artery.



A=anterior circulation; P=posterior circulation; C=caudate; L=lentiform; IC=internal capsule; I=insular ribbon; MCA=middle cerebral artery; M1=anterior MCA cortex; M2=MCA cortex lateral to insular ribbon; M3=posterior MCA cortex; M4, M5, and M6 are anterior, lateral, and posterior MCA territories immediately superior to M1, M2, and M3, rostral to basal ganglia. Subcortical structures are allotted 3 points (C, L, and IC). MCA cortex is allotted 7 points (insular cortex, M1, M2, M3, M4, M5, and M6).

# Summary of changes

ANGEL-ASPECT Protocol V6.0-20200723 (original version)

ANGEL-ASPECT Protocol V7.0-20210412 (amended version)

ANGEL-ASPECT Protocol V7.1-20210518 (final version)

Version	Date of	Changed	Reasons for change
	revised		
V7.0	2021/04/12	Added Trial Registration number	Finished Trial Registration in
		(cover page): ClinicalTrials.gov	Clinical trials.gov after the
		NCT04551664	study was approved by
			the Ethics Committee of the
			hospital.
		Delete Neuroimaging Inclusion	There is no need to use
		Criteria (4.1.3):	mismatch ratio select patients.
		"(3) Mismatch ratio on CT perfusion or MRI (Tmax>6s volume / Ischemic core volume) >1.2"	
		Add subgroup analyses (8.2.4):	To indicate more specifically
		"(2) Weak-up stroke or not" and "(7) Ipsilateral carotid artery occlusion or not"	the subgroup for studies by add important subgroup in the research protocol prior to data fixation.
V7.1	2021/05/18	Extension of the Study duration	Prolonged duration because
		(cover page) : "August 2020 to	of delayed enrollment.
		October 2022 (enrolment completed at	
		October 2021)" $\rightarrow$ "August 2020 to	
		October 2023 (enrolment completed at October 2022)"	

Added committee tables of Study	Detailed tables of committee
Organization (13.1):	member.
"Steering Committee, Data safety and	
monitoring board, Clinical event	
committee, Imaging assessment	
committee	
The parameters were refined, the	The parameters were refined,
interim analysis was adjusted (10.1):	the interim analysis was
"(2) The average treatment effect of	adjusted, and the sample size
EVT improved the outcome with the	was recalculated.
common OR value for improvement of	
mRS reached 1.74; (3) Two Interim	
analysis were considered. Adjusted	
level $\alpha$ =0.050 and power 1- $\beta$ =0.90."	
$\rightarrow$ "(2) The average treatment effect of	
EVT improved the outcome with the	
common OR value for improvement of	
mRS reached 1.73; (3) Two Interim	
analysis were considered. Adjusted	
level $\alpha$ =0.046 (two-sided) and power 1-	
β=0.90."	
The sample size was recalculated	
(10.1):	
"(4) The sample size was allocated to	
the intervention group and the control	
group in a 1:1 ratio. Based on these	
parameters, the sample size was 219 in	
each group. Considering 10% attrition	
rate, the final total sample size was 488	
cases, 244 cases in each group."	
$\rightarrow$ "(4) The sample size was allocated	
to the intervention group and the	
control group in a 1:1 ratio. Based on	
these parameters, the total sample size	
was 452. Considering 10% attrition	
rate, the final total sample size was 502	
cases, 251 cases in each group."	

<b>Replaced Figure 1 (3.1):</b> Study design:	The figure of the study design
	6 7 6
randomization algorithm	was replaced because the
	sample size was recalculated
Refined parameters (10.3.2):	The parameters were refined.
"All statistics will be with p<0.050	
considered significant."	
$\rightarrow$ "All statistics will be two-sided with	
p<0.046 considered significant."	
Revised interim analyses plan (10.4):	Revise the interim analyses
"Interim analysis will take place when	plan according to DSMB's
1/2 (244 cases) and 3/4 (366 cases)	suggestion.
have completed 3-month follow-up."	
and "corresponding significance levels	
based on O'Brien & Fleming boundary	
are 0.003 (stage 1), 0.018 (stage 2) and	
0.044 (stage 3, final analysis)."	
$\rightarrow$ "Interim analysis will take place	
when 1/3 (168 cases) and 2/3 (336	
cases) have completed 3-month follow-	
up." and "corresponding significance	
levels based on O'Brien & Fleming	
boundary are two-sided 0.0002 (stage	
1), 0.0123 (stage 2) and 0.046 (stage 3,	
final analysis)."	

# Study of Endovascular Therapy in Acute Anterior Circulation Large VeSsel Occlusive Patients with a LargE InfarCT Core: A Multicenter, Prospective, Open-Label, Blinded-Endpoint, Randomized Controlled Trial (ANGEL-ASPECT)

## **Statistical Analysis Plan**

## **Principal Investigator**

Zhongrong Miao, MD

Beijing Tiantan Hospital, Capital Medical University, Beijing, China

## Prepared by

Yuesong Pan, PhD

Aoming Jin, PhD

Xianglong Xiang, MD

Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Version 1.0

July 23, 2020

1.	Introduction	134
2.	Study Objective	
3.	Study Endpoint(s)	
	Primary Efficacy Endpoints: Secondary Efficacy Endpoint: Primary Safety Endpoint.	134 134 135
4.	Secondary Safety Endpoint Statistical Hypotheses	
5.	Design	135
6.	Sample size estimates	137
7.	Analysis populations	138
8.	Full Analysis Set (FAS) Per Protocol Set (PPS) Safety Analysis Set (SAS) Treatment comparisons	139 139
9.	General considerations for data analyses	139
10.	Examination of Subgroups Multiple Comparisons and Multiplicity Data handling conventions	139
11.	Premature Withdrawal and Missing Data Event Rates Study Population	140 140
12.	Disposition of Subjects Protocol Deviations Demographic and Baseline Characteristics Efficacy Analyses	141 142
13.	Primary Efficacy Analysis Secondary Efficacy Analyses Safety Analyses	142 143
14.	References	145

## Table of Contents

## 1. Introduction

This statistical analysis plan (SAP) documents the planned statistical analyses for the ANGEL-ASPECT trial and is based on the protocol, together with any subsequent amendments.

This SAP is intended for the use of project team members and should be read in conjunction with the aforementioned protocol.

## 2. Study Objective

The primary objective of the study is to establish the efficacy of endovascular therapy (EVT) in Acute Anterior Circulation Large Vessel Occlusive (LVO) Patients with a large infarct core.

## **3.** Study Endpoint(s)

Primary Efficacy Endpoints:

The 90 ( $\pm$ 7) day modified Ranking scale.

Secondary Efficacy Endpoint:

1) 90 (±7) day mRS 0-2.

2) 90 (±7) day mRS 0-3.

3) 36h (24-48h) NIHSS 0-1 or decrease  $\geq 10$  from baseline.

4) 36h (24-48h) infarct volume change (by CT or MRI).

5) 36h (24-48h) target artery recanalization rate (by CTA or MRA).

## Primary Safety Endpoint

•Rate of symptomatic intracranial hemorrhage within 48 hours from randomization (Heidelberg Bleeding Classification).

## Secondary Safety Endpoint

1) All-cause mortality within 90 days.

2) Any intracranial hemorrhage within 48 hours from randomization (Heidelberg Bleeding Classification).

3) Decompressive hemicraniectomy during hospitalization.

## 4. Statistical Hypotheses

The primary outcome will be a shift of one or more categories (proportional odds analysis) on the modified Rankin scale determined at 90 days from randomization. The primary hypothesis is:

H<sub>A</sub>: Subjects in the group of best medical management plus EVT will have greater odds of showing improvement on the mRS at 90 days.

## 5. Design

This is a prospective, randomized, controlled, open label, blinded-endpoint (PROBE) study to compare the efficacy and safety of best medical management plus EVT compared to best medical management alone in Acute Anterior Circulation Large Vessel Occlusive (LVO) Patients with a large infarct core up to 24 hours from symptom onset or last seen well.

Patients who meet the inclusion criteria will be randomized to one of the following two treatment arms: best medical management plus EVT or best medical management alone. Endpoints in this prospective open label study will be assessed blinded to the treatment assignment of the patient (PROBE design). This study will be conducted in approximately 50 sites in China.

Best medical management plus EVT group: Patients randomized to experimental group will receive EVT plus to best medical management. According to the pathological characteristics of patients and the judgment of researchers, the following treatment methods can be selected: Mechanical thrombectomy, angioplasty and arterial thrombolysis. Stent thrombectomy (Solitaire\*, EMBOTRAP#, Trevo or Reco or other first-line stent thrombectomy systems) or aspiration (Penumbra system) is recommended as the first choice. If the recanalization is not successful, it can be replaced with balloon angioplasty or intracranial stent deployment. The need for rescue treatment is defined (including, but not limited to, a decision made by the investigator based on intraoperative conditions) as follows: three times of thrombectomy with the same thrombectomy device (stent or aspiration catheter) without successful recanalization; Target vessel was successfully recanalized and then reoccluded. Target vessel dissection or stenosis degree  $\geq$ 70%, with any degree of forward flow disturbance; lumen/stent thrombus resulted in a decreased eTICI score.

**Best medical management group:** All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplanet or anticoagulant determined by treating physician) therapy if appropriate. Intravenous thrombolysis (IVT) will be performed before EVT for patients who were eligible in compliance with the existing guideline.

The planned sample size is 488 cases, and two analyses will be conducted when the 90-day follow-up of 1/2 (244 cases) and 3/4 (366 cases) of the total sample size is completed, and the study may be terminated in advance based on clear validity or ineffectiveness. The expected duration of each subject's enrollment is approximately 1 year. Subjects will be followed with assessments at 36 (24-48) hours, hospital discharge (or 7±1 days),  $30\pm3$  days,  $90\pm7$  days and 12 months ±14 days post randomization.

A blinded core laboratory will assess baseline imaging to confirm vessel occlusion

and determine ASPECT score, 36 (24-48) hours post-randomization to assess presence of ICH, and to measure core infarct volume and determine angiographical variables such as final reperfusion status and residual stenosis.

## 6. Sample size estimates

In this study, a multicenter, open, randomized, parallel control design method was used. The primary measure of efficacy was mRS score at 90±7 days after enrollment (considered as ordered variable). According to the literature data and clinical experts' opinions, the parameters were set as follows: (1) The proportion of mRS score 0-6 in control group was 3%, 4%, 10%, 17%, 16%, 12% and 38%, respectively; (2) The average treatment effect of EVT improved the outcome with the common OR value for improvement of mRS reached 1.74; (3) Two Interim analysis were considered. Adjusted level  $\alpha$ =0.05 and power 1- $\beta$ =0.90. (4) The sample size was allocated to the intervention group and the control group in a 1:1 ratio. Based on these parameters, the total sample size was 438. Considering 10% attrition rate, the final total sample size was 488 cases, 244 cases in each group.

Interim analysis will take place when 1/2 (244 cases) and 3/4 (366 cases) have completed 3-month follow-up. O'Brien-Fleming boundaries will be used at the interim analysis as follows:

There are no established techniques for the assessment of interim trial efficacy boundaries using an ordinal logistic regression model (proportional odds model). Instead, we will revert to a simple dichotomous analysis of the mRS score at 0-2 defined at 90 days from randomization. The Z-statistic for this analysis shall be derived from the normal approximation of the binomial distribution as an unadjusted two-sample test of proportions. For an RCT comparing two treatment groups with respect to a binary outcome and two interim analysis, corresponding significance levels based on O'Brien & Fleming boundary are two-sided 0.003 (stage 1), 0.018 (stage 2) and 0.044 (stage 3, final analysis).

With the result of interim analysis, DSMB will make the decision to continue or

halt the study according to the test boundaries. The study will stop prematurely for futility if the result from the interim analysis indicate that we can't achieve an effective conclusion with the current sample size. Premature stopping for early success will be achieved if the interim analysis result has proven the effect of intervention at significance level. Otherwise, the study will be continued until the predefined termination date. In interim analysis, the final sample size is allowed to be adjusted if the estimation of the primary outcome is drastically different from the actual data.

## 7. Analysis populations

### Full Analysis Set (FAS)

Based on the principles of Intention-to-Treat analysis (ITT), all randomized subjects, either treated with medication or with EVT will be included in the full analysis set. The primary effectiveness endpoint analysis of this study will be performed on the FAS.

### **Per Protocol Set (PPS)**

The PPS is a subset that includes all subjects who were treated with the treatment to which they were randomized and there are no clinically meaningful deviations from the protocol. Severe derivations from the protocol will be finally defined during the data auditing process, including but not limited to the followings:

1) The subject is not in line with the inclusion criteria.

2) There exist other treatments that potentially confound the appraisal of efficacy of the planned treatment.

3) Poor compliance.

4) Follow-up interval exceeds the required time window.

Secondary analysis will be conducted on the PPS, whenever its result is not consistent with the one from the FAS, a detailed analysis of the difference is needed.

### Safety Analysis Set (SAS)

The safety analysis set consists of all subjects who received treatment with at least one time evaluation of safety outcome.

## 8. Treatment comparisons

The treatment comparison of interest in this study is to assess the safety and efficacy of best medical management plus EVT compared to best medical management alone in patients with AIS due to LVO in anterior circulation up to 24 hours from symptom onset or last seen well.

## 9. General considerations for data analyses

All analyses will be performed using SAS Version 9.4. All analysis output will use the treatment group naming of best medical management plus EVT group and best medical management group. All statistics were two sided with a P<0.05 considered significant.

## Examination of Subgroups

The extent to which the treatment effect of improvement in modified Ranking scale varies across levels of each subgroup will be assessed through interaction tests.

## Multiple Comparisons and Multiplicity

A single primary efficacy variable has been defined for this study, with all other efficacy variables identified as secondary or other. Similarly, only one treatment comparison is of interest in the study and therefore there are no requirements to adjust for multiple comparisons or multiple endpoints within this study.

## **10.Data handling conventions**

#### Premature Withdrawal and Missing Data

If any subject withdraws prematurely from the study (prior to the final visit D90±7 days assessment), they are required to complete the withdrawal visit in the CRF. The reasons for withdrawal will be presented in a summary table. For the purposes of summaries and analysis of clinic visit data, this visit will be assigned to the next scheduled clinic visit for that subject, regardless of whether the date falls within the next visit window.

Subjects who withdraw before the end of the study, but who do provide at least one post-baseline measure for a particular endpoint, will be included in the analysis. Subjects who do not attend any visits after randomization will be excluded from analysis of any endpoint, as no post-baseline data will be available.

Outlier values will be evaluated for their validity; all data will be included unless judged to be invalid (e.g., deemed incompatible with life by Medical Monitor and/or deemed invalid by the DSMB).

Efforts will be undertaken at study sites to reduce the amount of missing data. Due to the severity of the condition and the short 90-day follow-up period, very little loss to follow-up is anticipated. For the primary efficacy endpoint, complete data will be used and missing data will not be imputed in the main analysis. Also, sensitivity analyses with missing data imputed by LOCF (Last Observation Carry Forward) and WCCF (Worst Case Carry Forward) methods will be undertaken to explore the effect of missing data on the endpoint and test the robustness of the estimate.

#### **Event Rates**

The number of events should be recorded in detail and showing the event rate in 90 days of each treatment group in summary statement.

The event rate for each treatment group will be calculated as: the sum of number of event for all the patients / the sum of number of treatment periods for all the patients.

## **11.Study Population**

## **Disposition of Subjects**

The number of subjects in each analysis population will be presented, subjects to be excluded from the Per Protocol population will be listed, and the total number of subjects attending each clinic visit will also be summarized by treatment group.

The number of subjects randomized, completed and prematurely withdrawn from the study will be presented for each treatment group. The primary reasons for withdrawal both prior to and post randomization will also be presented.

A data display listing and summary of deviations from the inclusion/exclusion criteria will be presented for all subjects who were either entered or randomized into the trial.

### **Protocol Deviations**

Subject data will be examined for evidence of protocol violators in order to assess how well the protocol was followed. Inclusion and exclusion criteria are detailed in the study protocol.

Subjects who commit protocol violations will be included in the FAS Population but excluded from the Per Protocol Population. These protocol violations will be shown in a listing. Subjects can either be full or partial protocol violators. A full protocol violator is completely excluded from the Per Protocol Population. A partial protocol violator has only some data excluded. For subjects who violated the protocol during the treatment period due to unpermitted changes in the medication or prohibited concurrent medication, the analysis will only use data recorded prior to the violation. For all violations which reference the treatment period, the treatment start date will be used as the reference date.

A listing of all possible protocol violators will be produced for clinical review. The final list of subjects who are protocol violators and are therefore excluded from the Per-Protocol population will be agreed by the study team.

## Demographic and Baseline Characteristics

The following demographic information will be listed and summarized for subjects in each treatment group: age, sex, medical history, smoking history, weak-up stroke, randomization time, NIHSS score, intravenous thrombolysis, occlusion site, ipsilateral carotid artery occlusion, ASPECT score, infarct core volume and stroke subtype.

The continuous data followed normal distribution will be presented as mean and standard deviation, and the continuous data followed skewed distribution will be presented as median and interquartile range; categorical data will be presented as n(%). T-test or Wilcoxon rank sum test will be used for comparison between continuous variables, and Chi-squared tests, Fisher's exact test or Wilcoxon sum rank test will be used for comparison between categorical variables.

## **12.Efficacy Analyses**

## Primary Efficacy Analysis

The primary endpoint is the modified Ranking scale at 90-day. FAS will be the primary population for efficacy analyses. PPS will be used as secondary population for the efficacy analyses. If the results in the PPS population are inconsistent with the FAS population, detailed analysis of the inconsistent results is required.

### Main Model

Based on an intention-to-treat basis, an ordinal logistic regression model with site as a random effect will be used to calculate the common odds ratio between the two treatment groups. If the proportional odds assumption for ordinal logistic regression were not satisfied, the Wilcoxon-Mann-Whitney generalized odds ratio will be calculated using assumption-free ordinal analysis. All statistics will be two-sided with p<0.046 considered significant.

#### **Interactions with Subgroups**

Summary tables will be produced for the predefined subgroups and interactions between treatment and these subgroups will be investigated, using an ordinal logistic regression model. A separate model will be used for each interaction to determine its significance. This will also be presented graphically on a forest plot.

The predefined subgroups including:

- Age (< 75 vs.  $\geq$ 75)
- Last known well to randomization time (< 6h vs.  $\geq$  6h)
- Stroke severity before randomization (NIHSS<16 vs. NIHSS>16)
- · Intravenous thrombolysis or not
- · Occlusion site (ICA vs. M1 segment)
- ASPECT score (< 3 points vs.  $\geq$ 3 points)
- Infarct core volume (< 70ml vs. ≥70ml)
- Etiological stroke subtype (cardiac embolism vs. large artery atherosclerosis)

## Secondary Efficacy Analyses

#### 90-day mRS 0-2

The proportion of 90-day mRS 0-2 will be analyzed using a binary logistic regression model with site as a random effect. The odds ratio with 95% CI will be reported.

#### 90-day mRS 0-3

The proportion of 90-day mRS 0-3 will be analyzed using a binary logistic regression model with site as a random effect. The odds ratio with 95% CI will be reported.

#### 36h (24-48h) NIHSS 0-1 or decrease ≥10 from baseline

The proportion of 36h (24-48h) NIHSS 0-1 or decrease  $\geq$ 10 points from baseline will be analyzed using a binary logistic regression model with site as a random effect. The odds ratio with 95% CI will be reported.

### 36h (24-48h) infarct volume change (by CT or MRI)

The change of 36h (24-48h) infarct volume change (by CT or MRI) will be analyzed using student t-test or Wilcoxon rank sum test as appropriate.

#### 36h (24-48h) target artery recanalization rate (by CTA or MRA)

The 36h (24-48h) target artery recanalization rate (by CTA or MRA) will be analyzed using a logistic regression model with site as a random effect. The odds ratio with 95% CI will be reported.

## **13.Safety Analyses**

All analyses of safety data will be carried out using the safety set (SS) population.

## **Primary Safety Endpoints**

Rate of symptomatic intracranial hemorrhage within 48 hours from randomization (Heidelberg Bleeding Classification).

### **Secondary Safety Endpoints**

All-cause mortality within 90 days.

Rate of any intracranial hemorrhage within 48 hours from randomization (Heidelberg Bleeding Classification).

Rate of decompressive hemicraniectomy during hospitalization.

For most bleeding events, the binary logistic model with site as a random effect will be used to compare the odds ratio between the two treatments, or Poisson regression or negative binomial regression which are more appropriate for the analysis of rare event. For all-cause mortality within 90 days, the Cox proportional hazards model with site as a random effect will be used to compare the hazard ratio between the two treatments.

#### **Adverse Events**

Adverse events (AEs) will be coded using the MedDRA coding dictionary (Version 6.0 or a later release) and grouped by system organ class (as detailed in the study protocol). Separate data display listings and summaries will be presented for adverse events that start prior to first dose of study medication (pre-treatment), whilst on study medication

(during treatment) and after the last dose of study medication (post-treatment).

Within each treatment group, the number and percentage of subjects experiencing an AE will be summarized by system organ class and preferred term and Fisher's Exact test will be used to compare the number of each grouped AE event between treatment groups. In addition, a separate summary will be provided for AEs experienced by more than 5% of subjects in either of the treatment groups.

## **Serious Adverse Events**

Summary tables and data displays will be provided for serious adverse events (as detailed in the study protocol). In addition, all deaths and serious AE's will be documented in a case narrative format in the clinical study report.

The number of adverse events or serious adverse events occurring over the treatment period will be summarized and Fisher's Exact test will be used to compare between treatment groups.

## 14.References

- De Mets DL, Furberg CD, Friedman LM. Data monitoring in clinical trials. New York: Springer; 2006.
- Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials. New York: Chapman & Hall; 2000.
- Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372(11):1019-103

# Study of Endovascular Therapy in Acute Anterior Circulation Large VeSsel Occlusive Patients with a LargE InfarCT Core: A Multicenter, Prospective, Open-Label, Blinded-Endpoint, Randomized Controlled Trial (ANGEL-ASPECT)

## **Statistical Analysis Plan**

## **Principal Investigator**

Zhongrong Miao, MD

Beijing Tiantan Hospital, Capital Medical University, Beijing, China

## Prepared by

Yuesong Pan, PhD

Aoming Jin, PhD

Xianglong Xiang, MD

Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Version 2.0

May 18, 2021

1.	Table of Contents           Introduction	124
2.	Study Objective	134
3.	Study Endpoint(s)	134
	Primary Efficacy Endpoints: Secondary Efficacy Endpoint: Primary Safety Endpoint. Secondary Safety Endpoint.	134 135
4.	Statistical Hypotheses	
5.	Design	135
6.	Sample size estimates	137
7.	Analysis populations	138
8.	Full Analysis Set (FAS) Per Protocol Set (PPS) Safety Analysis Set (SAS) Treatment comparisons	138 139
9.	General considerations for data analyses	139
10.	Examination of Subgroups Multiple Comparisons and Multiplicity Data handling conventions	139
11.	Premature Withdrawal and Missing Data Event Rates Study Population	140 140
12.	Disposition of Subjects Protocol Deviations Demographic and Baseline Characteristics Efficacy Analyses	141 142
13.	Primary Efficacy Analysis Secondary Efficacy Analyses Safety Analyses	142 143
14.	References	

## Table of C

## 1. Introduction

This statistical analysis plan (SAP) documents the planned statistical analyses for the ANGEL-ASPECT trial and is based on the protocol, together with any subsequent amendments.

This SAP is intended for the use of project team members and should be read in conjunction with the aforementioned protocol.

# 2. Study Objective

The primary objective of the study is to establish the efficacy of endovascular therapy (EVT) in Acute Anterior Circulation Large Vessel Occlusive (LVO) Patients with a large infarct core.

# 3. Study Endpoint(s)

Primary Efficacy Endpoints:

The 90 ( $\pm$ 7) day modified Ranking scale.

Secondary Efficacy Endpoint:

1) 90 (±7) day mRS 0-2.

2) 90 (±7) day mRS 0-3.

3) 36h (24-48h) NIHSS 0-1 or decrease  $\geq 10$  from baseline.

4) 36h (24-48h) infarct volume change (by CT or MRI).

5) 36h (24-48h) target artery recanalization rate (by CTA or MRA).

## Primary Safety Endpoint

•Rate of symptomatic intracranial hemorrhage within 48 hours from randomization (Heidelberg Bleeding Classification).

#### Secondary Safety Endpoint

1) All-cause mortality within 90 days.

2) Any intracranial hemorrhage within 48 hours from randomization (Heidelberg Bleeding Classification).

3) Decompressive hemicraniectomy during hospitalization.

## 4. Statistical Hypotheses

The primary outcome will be a shift of one or more categories (proportional odds analysis) on the modified Rankin scale determined at 90 days from randomization. The primary hypothesis is:

H<sub>A</sub>: Subjects in the group of best medical management plus EVT will have greater odds of showing improvement on the mRS at 90 days.

## 5. Design

This is a prospective, randomized, controlled, open label, blinded-endpoint (PROBE) study to compare the efficacy and safety of best medical management plus EVT compared to best medical management alone in Acute Anterior Circulation Large Vessel Occlusive (LVO) Patients with a large infarct core up to 24 hours from symptom onset or last seen well.

Patients who meet the inclusion criteria will be randomized to one of the following two treatment arms: best medical management plus EVT or best medical management alone. Endpoints in this prospective open label study will be assessed blinded to the treatment assignment of the patient (PROBE design). This study will be conducted in approximately 50 sites in China.

Best medical management plus EVT group: Patients randomized to experimental group will receive EVT plus to best medical management. According to the pathological characteristics of patients and the judgment of researchers, the following treatment methods can be selected: Mechanical thrombectomy, angioplasty and arterial thrombolysis. Stent thrombectomy (Solitaire\*, EMBOTRAP#, Trevo or Reco and other first-line stent thrombectomy systems) and aspiration (Penumbra system) is recommended as the first choice. If the recanalization is not successful, it can be replaced with thrombus, balloon angioplasty or stent implantation. The need for rescue treatment is defined (including, but not limited to, a decision made by the investigator based on intraoperative conditions) as follows: three times of thrombectomy with the same thrombectomy device (stent or aspiration catheter) without successful recanalization; Target vessels were successfully recanalized and then occluded. Target vessel dissection or stenosis degree  $\geq$ 70%, with any degree of forward flow disturbance; lumen/stent thrombous resulted in a decreased eTICI score.

**Best medical management group:** All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplanet or anticoagulant determined by treating physician) therapy if appropriate. Intravenous thrombolysis (IVT) will be performed before EVT for patients who were eligible in compliance with the existing guideline.

The planned sample size is 502 cases, and two analyses will be conducted when the 90-day follow-up of 1/3 (168 cases) and 2/3 (336 cases) of the total sample size is completed, and the study may be terminated in advance based on clear validity or ineffectiveness. The expected duration of each subject's enrollment is approximately 1 year. Subjects will be followed with assessments at 36 (24-48) hours, hospital discharge (or 7±1 days),  $30\pm3$  days,  $90\pm7$  days and 12 months ±14 days post randomization.

A blinded core laboratory will assess baseline imaging to confirm vessel occlusion

and determine ASPECT score, 36 (24-48) hours post-randomization to assess presence of ICH, and to measure core infarct volume and determine angiographical variables such as final reperfusion status and residual stenosis.

## 6. Sample size estimates

In this study, a multicenter, open, randomized, parallel control design method was used. The primary measure of efficacy was mRS score at 90±7 days after enrollment (considered as ordered variable). According to the literature data and clinical experts' opinions, the parameters were set as follows: (1) The proportion of mRS score 0-6 in control group was 3%, 4%, 10%, 17%, 16%, 12% and 38%, respectively; (2) The average treatment effect of EVT improved the outcome with the common OR value for improvement of mRS reached 1.73; (3) Two Interim analysis were considered. Adjusted level  $\alpha$ =0.046 (two-sided) and power 1- $\beta$ =0.90. (4) The sample size was allocated to the intervention group and the control group in a 1:1 ratio. Based on these parameters, the total sample size was 452. Considering 10% attrition rate, the final total sample size was 502 cases, 251 cases in each group.

Interim analysis will take place when 1/3 (168 cases) and 2/3 (336 cases) have completed 3-month follow-up. O'Brien-Fleming boundaries will be used at the interim analysis as follows:

There are no established techniques for the assessment of interim trial efficacy boundaries using an ordinal logistic regression model (proportional odds model). Instead, we will revert to a simple dichotomous analysis of the mRS score at 0-2 defined at 90 days from randomization. The Z-statistic for this analysis shall be derived from the normal approximation of the binomial distribution as an unadjusted two-sample test of proportions. For an RCT comparing two treatment groups with respect to a binary outcome and two interim analysis, corresponding significance levels based on O'Brien & Fleming boundary are two-sided 0.0002 (stage 1), 0.0123 (stage 2) and 0.046 (stage 3, final analysis).

With the result of interim analysis, DSMB will make the decision to continue or

halt the study according to the test boundaries. The study will stop prematurely for futility if the result from the interim analysis indicate that we can't achieve an effective conclusion with the current sample size. Premature stopping for early success will be achieved if the interim analysis result has already proved the effect of intervention at significance level. Otherwise, the study will be continued until the predefined termination date. In interim analysis, the final sample size is allowed to be adjusted if the estimation of the primary outcome is drastically different from the actual data.

## 7. Analysis populations

### Full Analysis Set (FAS)

Based on the principles of Intention-to-Treat analysis (ITT), all randomized subjects, either treated with medication or with EVT will be included in the full analysis set. The primary effectiveness endpoint analysis of this study will be performed on the FAS.

### **Per Protocol Set (PPS)**

The PPS is a subset that includes all subjects who were treated with the treatment to which they were randomized and there are no clinically meaningful deviations from the protocol. Severe derivations from the protocol will be finally defined during the data auditing process, including but not limited to the followings:

1) The subject is not in line with the inclusion criteria.

2) There exist other treatments that potentially confound the appraisal of efficacy of the planned treatment.

3) Poor compliance.

4) Follow-up interval exceeds the required time window.

Secondary analysis will be conducted on the PPS, whenever its result is not consistent with the one from the FAS, a detailed analysis of the difference is needed.

#### Safety Analysis Set (SAS)

The safety analysis set consists of all subjects who received treatment with at least one time evaluation of safety outcome.

## 8. Treatment comparisons

The treatment comparison of interest in this study is to assess the safety and efficacy of best medical management plus EVT compared to best medical management alone in patients with AIS due to LVO in anterior circulation up to 24 hours from symptom onset or last seen well.

## 9. General considerations for data analyses

All analyses will be performed using SAS Version 9.4. All analysis output will use the treatment group naming of best medical management plus EVT group and best medical management group. All statistics were two sided with a P<0.05 considered significant.

## Examination of Subgroups

The extent to which the treatment effect of improvement in modified Ranking scale varies across levels of each subgroup will be assessed through interaction tests.

## Multiple Comparisons and Multiplicity

A single primary efficacy variable has been defined for this study, with all other efficacy variables identified as secondary or other. Similarly, only one treatment comparison is of interest in the study and therefore there are no requirements to adjust for multiple comparisons or multiple endpoints within this study.

## **10.Data handling conventions**

#### Premature Withdrawal and Missing Data

If any subject withdraws prematurely from the study (prior to the final visit D90±7 days assessment), they are required to complete the withdrawal visit in the CRF. The reasons for withdrawal will be presented in a summary table. For the purposes of summaries and analysis of clinic visit data, this visit will be assigned to the next scheduled clinic visit for that subject, regardless of whether the date falls within the next visit window.

Subjects who withdraw before the end of the study, but who do provide at least one post-baseline measure for a particular endpoint, will be included in the analysis. Subjects who do not attend any visits after randomization will be excluded from analysis of any endpoint, as no post-baseline data will be available.

Outlier values will be evaluated for their validity; all data will be included unless judged to be invalid (e.g., deemed incompatible with life by Medical Monitor and/or deemed invalid by the DSMB).

Efforts will be undertaken at study sites to reduce the amount of missing data. Due to the severity of the condition and the short 90-day follow-up period, very little loss to follow-up is anticipated. For the primary efficacy endpoint, complete data will be used and missing data will not be imputed in the main analysis. Also, sensitivity analyses with missing data imputed by LOCF (Last Observation Carry Forward) and WCCF (Worst Case Carry Forward) methods will be undertaken to explore the effect of missing data on the endpoint and test the robustness of the estimate.

#### **Event Rates**

The number of events should be recorded in detail and showing the event rate in 90 days of each treatment group in summary statement.

The event rate for each treatment group will be calculated as: the sum of number of event for all the patients / the sum of number of treatment periods for all the patients.

## **11.Study Population**

## **Disposition of Subjects**

The number of subjects in each analysis population will be presented, subjects to be excluded from the Per Protocol population will be listed, and the total number of subjects attending each clinic visit will also be summarized by treatment group.

The number of subjects randomized, completed and prematurely withdrawn from the study will be presented for each treatment group. The primary reasons for withdrawal both prior to and post randomization will also be presented.

A data display listing and summary of deviations from the inclusion/exclusion criteria will be presented for all subjects who were either entered or randomized into the trial.

### **Protocol Deviations**

Subject data will be examined for evidence of protocol violators in order to assess how well the protocol was followed. Inclusion and exclusion criteria are detailed in the study protocol.

Subjects who commit protocol violations will be included in the FAS Population but excluded from the Per Protocol Population. These protocol violations will be shown in a listing. Subjects can either be full or partial protocol violators. A full protocol violator is completely excluded from the Per Protocol Population. A partial protocol violator has only some data excluded. For subjects who violated the protocol during the treatment period due to unpermitted changes in the medication or prohibited concurrent medication, the analysis will only use data recorded prior to the violation. For all violations which reference the treatment period, the treatment start date will be used as the reference date.

A listing of all possible protocol violators will be produced for clinical review. The final list of subjects who are protocol violators and are therefore excluded from the Per-Protocol population will be agreed by the study team.

## Demographic and Baseline Characteristics

The following demographic information will be listed and summarized for subjects in each treatment group: age, sex, medical history, smoking history, weak-up stroke, randomization time, NIHSS score, intravenous thrombolysis, occlusion site, ipsilateral carotid artery occlusion, ASPECT score, infarct core volume and stroke subtype.

The continuous data followed normal distribution will be presented as mean and standard deviation, and the continuous data followed skewed distribution will be presented as median and interquartile range; categorical data will be presented as n(%). T-test or Wilcoxon rank sum test will be used for comparison between continuous variables, and Chi-squared tests, Fisher's exact test or Wilcoxon sum rank test will be used for comparison between categorical variables.

## **12.Efficacy Analyses**

## Primary Efficacy Analysis

The primary endpoint is the modified Ranking scale at 90-day. FAS will be the primary population for efficacy analyses. PPS will be used as secondary population for the efficacy analyses. If the results in the PPS population are inconsistent with the FAS population, detailed analysis of the inconsistent results is required.

### **Main Model**

Based on an intention-to-treat basis, an ordinal logistic regression model with site as a random effect will be used to calculate the common odds ratio between the two treatment groups. If the proportional odds assumption for ordinal logistic regression were not satisfied, the Wilcoxon-Mann-Whitney generalized odds ratio will be calculated using assumption-free ordinal analysis. All statistics will be two-sided with p<0.046 considered significant.

## Interactions with Subgroups

Summary tables will be produced for the predefined subgroups and interactions between treatment and these subgroups will be investigated, using an ordinal logistic regression model. A separate model will be used for each interaction to determine its significance. This will also be presented graphically on a forest plot.

The predefined subgroups including:

- Age (< 75 vs. ≥75)
- $\cdot$  Weak-up stroke or not
- Last known well to randomization time (< 6h vs.  $\geq$  6h)
- Stroke severity before randomization (NIHSS<16 vs. NIHSS≥16)
- · Intravenous thrombolysis or not
- Occlusion site (ICA vs. M1 segment)
- · Ipsilateral carotid artery occlusion or not
- ASPECT score (< 3 points vs.  $\geq$ 3 points)
- Infarct core volume (< 70ml vs. ≥70ml)
- Etiological stroke subtype (cardiac embolism vs. large artery atherosclerosis)

## Secondary Efficacy Analyses

## 90-day mRS 0-2

The proportion of 90-day mRS 0-2 will be analyzed using a binary logistic regression model with site as a random effect. The odds ratio with 95% CI will be reported.

## 90-day mRS 0-3

The proportion of 90-day mRS 0-3 will be analyzed using a binary logistic regression model with site as a random effect. The odds ratio with 95% CI will be reported.

## 36h (24-48h) NIHSS 0-1 or decrease ≥10 from baseline

The proportion of 36h (24-48h) NIHSS 0-1 or decrease  $\geq 10$  points from baseline will be analyzed using a binary logistic regression model with site as a random effect. The odds ratio with 95% CI will be reported.

#### 36h (24-48h) infarct volume change (by CT or MRI)

The change of 36h (24-48h) infarct volume change (by CT or MRI) will be analyzed using student t-test or Wilcoxon rank sum test as appropriate.

#### 36h (24-48h) target artery recanalization rate (by CTA or MRA)

The 36h (24-48h) target artery recanalization rate (by CTA or MRA) will be analyzed using a logistic regression model with site as a random effect. The odds ratio with 95% CI will be reported.

## **13.Safety Analyses**

All analyses of safety data will be carried out using the safety set (SS) population.

#### **Primary Safety Endpoints**

Rate of symptomatic intracranial hemorrhage within 48 hours from randomization (Heidelberg Bleeding Classification).

#### **Secondary Safety Endpoints**

All-cause mortality within 90 days.

Rate of any intracranial hemorrhage within 48 hours from randomization (Heidelberg Bleeding Classification).

Rate of decompressive hemicraniectomy during hospitalization.

For most bleeding events, the binary logistic model with site as a random effect will be used to compare the odds ratio between the two treatments, or Poisson regression or negative binomial regression which are more appropriate for the analysis of rare event. For all-cause mortality within 90 days, the Cox proportional hazards model with site as a random effect will be used to compare the hazard ratio between the two treatments.

#### **Adverse Events**

Adverse events (AEs) will be coded using the MedDRA coding dictionary (Version 6.0 or a later release) and grouped by system organ class (as detailed in the study protocol).

Separate data display listings and summaries will be presented for adverse events that start prior to first dose of study medication (pre-treatment), whilst on study medication (during treatment) and after the last dose of study medication (post-treatment).

Within each treatment group, the number and percentage of subjects experiencing an AE will be summarized by system organ class and preferred term and Fisher's Exact test will be used to compare the number of each grouped AE event between treatment groups. In addition, a separate summary will be provided for AEs experienced by more than 5% of subjects in either of the treatment groups.

#### **Serious Adverse Events**

Summary tables and data displays will be provided for serious adverse events (as detailed in the study protocol). In addition, all deaths and serious AE's will be documented in a case narrative format in the clinical study report.

The number of adverse events or serious adverse events occurring over the treatment period will be summarized and Fisher's Exact test will be used to compare between treatment groups.

## 14.References

- De Mets DL, Furberg CD, Friedman LM. Data monitoring in clinical trials. New York: Springer; 2006.
- Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials. New York: Chapman & Hall; 2000.
- Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372(11):1019-1030.

## Revisions to previous SAP version

SAP version 1.0	Changes in SAP version 2.0
5. Design	5. Design
The planned sample size is 488 cases, and	The planned sample size is 502 cases, and two
two analyses will be conducted when the 90-	analyses will be conducted when the 90-day
day follow-up of 1/2 (244 cases) and 3/4 (366	follow-up of 1/3 (168 cases) and 2/3 (336
cases) of the total sample size is completed.	cases) of the total sample size is completed.
6. Sample size estimates	6. Sample size estimates
The average treatment effect of EVT	The average treatment effect of EVT
improved the outcome with the common OR	improved the outcome with the common OR
value for improvement of mRS reached 1.74;	value for improvement of mRS reached 1.73;
(3) Two Interim analysis were considered.	(3) Two Interim analysis were considered.
Adjusted level $\alpha$ =0.05 and power 1- $\beta$ =0.90.	Adjusted level $\alpha$ =0.046 (two-sided) and
(4) The sample size was allocated to the	power 1- $\beta$ =0.90. (4) The sample size was
intervention group and the control group in a	allocated to the intervention group and the
1:1 ratio. Based on these parameters, the total	control group in a 1:1 ratio. Based on these
sample size was 438. Considering 10%	parameters, the total sample size was 452.
attrition rate, the final total sample size was	Considering 10% attrition rate, the final total
488 cases, 244 cases in each group.	sample size was 502 cases, 251 cases in each
Interim analysis will take place when 1/2	group.
(244 cases) and 3/4 (366 cases) have	Interim analysis will take place when 1/3
completed 3-month follow-up. O'Brien-	(18 cases) and 2/3 (336 cases) have
Fleming boundaries will be used at the	completed 3-month follow-up. O'Brien-
interim analysis as follows:	Fleming boundaries will be used at the
For an RCT comparing two treatment	interim analysis as follows:
groups with respect to a binary outcome and	For an RCT comparing two treatment
two interim analysis, corresponding	groups with respect to a binary outcome and
significance levels based on O'Brien &	two interim analysis, corresponding
Fleming boundary are two-sided 0.003 (stage	significance levels based on O'Brien &
1), 0.018 (stage 2) and 0.044 (stage 3, final	Fleming boundary are two-sided 0.0002
analysis).	(stage 1), 0.0123 (stage 2) and 0.046 (stage 3,

	final analysis).
<ul> <li>The predefined subgroups including:</li> <li>Age (&lt; 75 vs. ≥75)</li> <li>Last known well to randomization time (&lt; 6h vs. ≥ 6h)</li> <li>Stroke severity before randomization (NIHSS&lt;16 vs. NIHSS≥16)</li> <li>Intravenous thrombolysis or not</li> <li>Occlusion site (ICA vs. M1 segment)</li> <li>ASPECT score (&lt; 3 points vs. ≥3 points)</li> <li>Infarct core volume (&lt; 70ml vs. ≥70ml)</li> <li>Etiological stroke subtype (cardiac embolism vs. large artery atherosclerosis)</li> </ul>	<ul> <li>The predefined subgroups including:</li> <li>Age (&lt; 75 vs. ≥75)</li> <li>Weak-up stroke or not</li> <li>Last known well to randomization time (&lt; 6h vs. ≥ 6h)</li> <li>Stroke severity before randomization (NIHSS&lt;16 vs. NIHSS≥16)</li> <li>Intravenous thrombolysis or not</li> <li>Occlusion site (ICA vs. M1 segment)</li> <li>Ipsilateral carotid artery occlusion or not</li> <li>ASPECT score (&lt; 3 points vs. ≥3 points)</li> <li>Infarct core volume (&lt; 70ml vs. ≥70ml)</li> <li>Etiological stroke subtype (cardiac embolism vs. large artery atherosclerosis)</li> </ul>

# eClinicalMedicine Part of THE LANCET Discovery Science

## Author statements

Please insert the relevant text under the subheadings below. A completed form must be signed by all authors. Please note that we will accept hand-signed and electronic (typewritten) signatures. Please complete multiple forms if necessary, and upload the signed copy with your submission, scan and email to: eclinm@lancet.com.

Manuscript title: Endovascular therapy in acute ischemic stroke with large infarction with matched or mismatched clinic al-radiological severities: a post-hoc analysis of the ANGEL-ASPECT trial

Corresponding author: Prof. Liping Liu or Prof. Zhongrong Miao or Dr. Xinyi Leng

Article type: Original Research Article

I irrevocably authorise and grant my full consent to the corresponding author of the manuscript to: (1) enter into an exclusive publishing agreement with Elsevier on on my behalf (or, if the article is to be published under a CC BY license, a non-exclusive publishing agreement), in the relevant form set out at <a href="http://www.elsevier.com/copyright;">www.elsevier.com/copyright;</a> and (2) unless I am a US government employee, to transfer my copyright or grant an exclusive license of rights (or, for CC BY articles, a non-exclusive license of rights) to Elsevier as part of that publishing agreement, effective on acceptance of the article for publication. If the article is a work made for hire, I am authorized to confirm this on behalf of my employer. I agree that the copyright status selected by the corresponding author for the article if it is accepted for publication shall apply and that this agreement is subject to the governing law of the country in which the journal owner is located.

Does your manuscript have a reference number? No 🖸 Yes 🖬 If yes, enter number here: eclinm-D-24-00250

Does your manuscript have a handling editor? No 🗖 Yes 🖬 If yes, enter name here: Bianca Brandon

#### Authors' contributions

Please insert here the contribution each author made to the manuscript—eg, literature search, figures, study design, data collection, data analysis, data interpretation, writing etc. You may also find the CRediT taxonomy helpful. See <a href="http://credit.niso.org/">http://credit.niso.org/</a> for more information on 14 roles that can be attributed to authors: conceptualisation, data curation, formal analysis, funding acquisition, investigation, methodology, project administration, resources, software, supervision, validation, visualisation, writing – original draft, and writing – review & editing. If all authors contributed equally, please state this. The information provided here must match the contributors' statement in the manuscript. We require that more than one author has directly accessed and verified the underlying data reported in the manuscript. For research articles that are the result of an academic and commercial partnership, at least one of the authors named as having accessed and verified data must be from the academic team.

XL, ZM and LL had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: LZ, XN, YP, XL, LL. Acquisiti on, analysis, or interpretation of data: LZ, MW, XL, WD, ZZ, YW, JL, GM, XH. Drafting of the man uscript: LZ, XL. Critical revision of the manuscript for important intellectual content: TNN, MW, ZY, TWL, ZM, LL. Statistical analysis: LZ, MW, YP. Obtained funding: ZM, LL. Supervision: TWL, XL, ZM, LL. ZM and LL had access to the database and LL had final responsibility for the decision to s ubmit for publication. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

# eClinicalMedicine Part of THE LANCET Discovery Science

#### Role of the funding source

Please disclose any funding sources and their role, if any, in the writing of the manuscript or the decision to submit it for publication. Examples of involvement include: data collection, analysis, or interpretation; trial design; patient recruitment; or any aspect pertinent to the study. Please also comment whether you have been paid to write this article by a pharmaceutical company or other agency. The information provided here must match the role of the funding source statement in the manuscript. If you are the corresponding author, please state that authors were not precluded from accessing data in the study, and they accept responsibility to submit for publication.

The funder of the study had no role in study design, data collection, data analysis, data interpretati on, or writing of the report.

#### **Conflicts of interest**

Please complete the ICMJE conflict of interest form, which is available at <a href="https://www.thelancet.com/for-authors/forms?section=icmje-coi.">https://www.thelancet.com/for-authors/forms?section=icmje-coi.</a> Please ensure that a conflict of interest statement is included at the end of the manuscript, which matches what is declared on the ICMJE conflict of interest form.

Patient consent (if applicable) - completion of this section is mandatory for Case Reports, Clinical Pictures, and Adverse Drug Reactions. Please sign below to confirm that all necessary consents required by applicable law from any relevant patient, research participant, and/or other individual whose information is included in the article have been obtained in writing. <u>The signed consent form(s) should be</u> retained by the corresponding author and NOT sent to eClinicalMedicine.

I agree with: the plan to submit to eClinicalMedicine; the contents of the manuscript; the statements on data access; to being listed as an author; and to the conflicts of interest statement as summarised.

Title and name: Lina Zheng	Highest degree: PhD
Title and name: Ximing Nie	Highest degree: MD
Title and name: Mengxing Wang	Highest degree: MD
Title and name: Xin Liu	Highest degree: MD
Title and name: Wanying Duan	Highest degree:MD
Title and name: Zhe Zhang	Highest degree: MD
Title and name: Jingyi Liu	Highest degree: MD
Title and name: Yufei Wei	Highest degree: MD
Title and name: Miao Wen	Highest degree: MD
Title and name: Zhonghua Yang	Highest degree: MD

Signature: Lina 21- ENG Date: 11Mar 2024 Signature: .. Date: 11 Mar 2024 Signature: .. Date: 11Mar 2024 xin lin Signature: .. Date: 11Mar2024 Signature: ... Wan ling Date: 05Mar2024 Signature: Date: 05Mar2024 Date: 11Mar2024 Signature: Jufer We Date: 05Mar2024 Mino Signature: Date: 05Mar2024 Signature: . Date: 05Mar2024

#### Corresponding author declaration

# eClinicalMedicine Part of THE LANCET Discovery Science

#### Role of the funding source

Please disclose any funding sources and their role, if any, in the writing of the manuscript or the decision to submit it for publication. Examples of involvement include: data collection, analysis, or interpretation; trial design; patient recruitment; or any aspect pertinent to the study. Please also comment whether you have been paid to write this article by a pharmaceutical company or other agency. The information provided here must match the role of the funding source statement in the manuscript. If you are the corresponding author, please state that authors were not precluded from accessing data in the study, and they accept responsibility to submit for publication.

The funder of the study had no role in study design, data collection, data analysis, data interpretati on, or writing of the report.

#### Conflicts of interest

Please complete the ICMJE conflict of interest form, which is available at <a href="https://www.thelancet.com/for-authors/forms?section=icmje-coi">https://www.thelancet.com/for-authors/forms?section=icmje-coi</a>. Please ensure that a conflict of interest statement is included at the end of the manuscript, which matches what is declared on the ICMJE conflict of interest form.

Patient consent (if applicable) - completion of this section is mandatory for Case Reports, Clinical Pictures, and Adverse Drug Reactions. Please sign below to confirm that all necessary consents required by applicable law from any relevant patient, research participant, and/or other individual whose information is included in the article have been obtained in writing. <u>The signed consent form(s) should be</u> retained by the corresponding author and NOT sent to eClinicalMedicine.

I agree with: the plan to submit to eClinicalMedicine; the contents of the manuscript; the statements on data access; to being listed as an author; and to the conflicts of interest statement as summarised.

Title and name: Thomas W Leung	Highest degree: MD	Signature:	Date: 12Mar2024
Title and name: Gaoting Ma	Highest degree: MD	Signature:	Date: 11Mar2024
Title and name: Xiaochuan Huo	Highest degree: MD	Niaochnan Huo Signature:	Date: 13Mar2024
Title and name: Yuesong Pan	Highest degree:MD	Signature: Julesong Jan	Date: 11Mar2024
Title and name: Thanh N Nguyen	Highest degree:MD	Signature: Thank Nguyen	Date: 11Mar2024
Title and name: Xinyi Leng	Highest degree: PhD	Signature:	Date: 12Mar2024
Title and name: Zhongrong Miao	Highest degree: MD	Signature: Sally	Date: 13Mar2024
Title and name: Liping Liu	Highest degree: PhD	Signature: Lipig Lin	Date: 13Mar 2024
Title and name:	Highest degree:	Signature:	Date:
Title and name:	Highest degree:	Signature:	Date:

#### Corresponding author declaration

#### ICMJE DISCLOSURE FORM

Date:	Mar 22, 2024
Your Name:	: Lina Zheng
Manuscript	Title: <u>Endovascular therapy in acute ischemic stroke with large infarction with matched or</u>
-	mismatched clinical-radiological severities: a post-hoc analysis of the ANGEL-ASPECT trial
Manuscript	number (if known): <u>eclinm-D-24-00250</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to you or to your
		none (add rows as needed)	institution)
		Time frame: Since the initial plannir	ng of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 mon	ths
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

	Payment or honoraria for		
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
Ŭ	testimony		
	countory		
_			
7	Support for attending	None	
	meetings and/or travel		
	Deterring a large state of the	Neg	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		<u> </u>
	group, paid or unpaid		
10		Nega	
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
15	financial interests		

Please place an "X" next to the following statement to indicate your agreement:

<u>X</u> I certify that I have answered every question and have not altered the wording of any of the questions on this form.

#### ICMJE DISCLOSURE FORM

Date:	Nar 22, 2024
Your Name:	Ximing Nie
Manuscript	Title: Endovascular therapy in acute ischemic stroke with large infarction with matched or
	mismatched clinical-radiological severities: a post-hoc analysis of the ANGEL-ASPECT trial
Manuscript	number (if known): <u>eclinm-D-24-00250</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to you or to your
		none (add rows as needed)	institution)
		Time frame: Since the initial plannin	ng of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 mon	ths
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

	Payment or honoraria for		
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0			
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
5	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
		<sup>_</sup>	
12	Dessist of equipment	Nere	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Date: Mar 22, 2024
Your Name: Mengxing Wang
Manuscript Title: <u>Endovascular therapy in acute ischemic stroke with large infarction with matched or</u>
mismatched clinical-radiological severities: a post-hoc analysis of the ANGEL-ASPECT trial
Manuscript number (if known):eclinm-D-24-00250

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to you or to your
		none (add rows as needed)	institution)
		Time frame: Since the initial plannin	ng of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 mon	ths
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

	Payment or honoraria for		
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0			
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
5	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
		<sup>_</sup>	
12	Dessist of equipment	Nere	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Date: <u>Mar 22, 2024</u> Your Name: <u>Xin Liu</u> Manuscript Title: <u>Endovascular therapy in acute ischemic stroke with large infarction with matched or</u> <u>mismatched clinical-radiological severities: a post-hoc analysis of the ANGEL-ASPECT trial</u> Manuscript number (if known): <u>eclinm-D-24-00250</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
	T	Time frame: Since the initial plannin	ig of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 mon	ths
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

	Payment or honoraria for		
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0			
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
5	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
		<sup>_</sup>	
12	Dessist of equipment	Nere	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Date: <u>Mar 22, 2024</u>	
Your Name: Wanying Duan	
Manuscript Title: <u>Endovascular therapy in acute ischemic stroke with large infarction with matched or</u>	
mismatched clinical-radiological severities: a post-hoc analysis of the ANGEL-ASPECT trial	
Manuscript number (if known):eclinm-D-24-00250	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to you or to your
		none (add rows as needed)	institution)
		Time frame: Since the initial plannir	ng of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 mon	ths
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

	Payment or honoraria for		
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0			
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
5	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
		<sup>_</sup>	
12	Dessist of equipment	Nere	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Date: <u>Mar 22, 2024</u> Your Name: <u>Zhe Zhang</u> Manuscript Title: <u>Endovascular therapy in acute ischemic stroke with large infarction with matched or</u> <u>mismatched clinical-radiological severities: a post-hoc analysis of the ANGEL-ASPECT trial</u> Manuscript number (if known): <u>eclinm-D-24-00250</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to you or to your
		none (add rows as needed)	institution)
		Time frame: Since the initial plannir	ng of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 mon	ths
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

	Payment or honoraria for		
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0			
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
5	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
		<sup>_</sup>	
12	Dessist of equipment	Nere	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Date:	<u>Mar 22, 2024</u>
Your Nam	e: Jingyi Liu
Manuscrip	ot Title: <u>Endovascular therapy in acute ischemic stroke with large infarction with matched or</u>
	mismatched clinical-radiological severities: a post-hoc analysis of the ANGEL-ASPECT trial
Manuscrip	ot number (if known): <u>eclinm-D-24-00250</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to you or to your
		none (add rows as needed)	institution)
		Time frame: Since the initial plannin	ng of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 mon	ths
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

	Payment or honoraria for		
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0			
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
5	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
		<sup>_</sup>	
12	Dessist of equipment	Nere	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Date: <u>M</u>	lar 22, 2024
Your Name:	Yufei Wei
Manuscript 1	Title: <u>Endovascular therapy in acute ischemic stroke with large infarction with matched or</u>
-	mismatched clinical-radiological severities: a post-hoc analysis of the ANGEL-ASPECT trial
Manuscript r	number (if known): <u>eclinm-D-24-00250</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to you or to your
		none (add rows as needed)	institution)
		Time frame: Since the initial plannin	ng of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 mon	ths
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

	Payment or honoraria for		
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0			
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
5	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
		<sup>_</sup>	
12	Dessist of equipment	Nere	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Date:	Mar 22, 2024
Your Nan	ne: <u>Miao Wen</u>
Manuscri	ipt Title: <u>Endovascular therapy in acute ischemic stroke with large infarction with matched or</u>
	mismatched clinical-radiological severities: a post-hoc analysis of the ANGEL-ASPECT trial
Manuscri	ipt number (if known): <u>eclinm-D-24-00250</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to you or to your
		none (add rows as needed)	institution)
		Time frame: Since the initial plannin	ng of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 mon	ths
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

	Payment or honoraria for		
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0			
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
5	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
		<sup>_</sup>	
12	Dessist of equipment	Nere	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Date: <u>Mar 22, 2024</u>	
Your Name: Zhonghua Yang	
Manuscript Title: <u>Endovascular therapy in acute ischemic stroke with large infarction with matched or</u>	
mismatched clinical-radiological severities: a post-hoc analysis of the ANGEL-ASPECT trial	
Manuscript number (if known):eclinm-D-24-00250	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to you or to your
		none (add rows as needed)	institution)
		Time frame: Since the initial plannir	ng of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 mon	ths
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

	Payment or honoraria for		
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0			
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
5	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
		<sup>_</sup>	
12	Dessist of equipment	Nere	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Date: <u>Mar 22, 2024</u>	
Your Name: Thomas W Leung	
Manuscript Title: <u>Endovascular therapy in acute ischemic stroke with large infarction with matched or</u>	
mismatched clinical-radiological severities: a post-hoc analysis of the ANGEL-ASPECT trial	
Manuscript number (if known): <u>eclinm-D-24-00250</u>	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to you or to your
		none (add rows as needed)	institution)
		Time frame: Since the initial plannir	ng of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 mon	ths
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

	Payment or honoraria for		
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0			
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
5	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
		<sup>_</sup>	
12	Dessist of equipment	Nere	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Date: Mar 22, 2024
Your Name: Gaoting Ma
Manuscript Title: <u>Endovascular therapy in acute ischemic stroke with large infarction with matched or</u>
mismatched clinical-radiological severities: a post-hoc analysis of the ANGEL-ASPECT trial
Manuscript number (if known):eclinm-D-24-00250

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to you or to your
		none (add rows as needed)	institution)
		Time frame: Since the initial plannir	ng of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 mon	ths
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

	Payment or honoraria for		
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0			
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
5	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
		<sup>_</sup>	
12	Dessist of equipment	Nere	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Date:	<u>Mar 22, 2024</u>	
Your Nan	ne: <u>Xiaochuan Huo</u>	
Manuscr	ipt Title: <u>Endovascular therapy in acute ischemic stroke with large infar</u>	<u>ction with matched or</u>
	mismatched clinical-radiological severities: a post-hoc analysis	of the ANGEL-ASPECT trial
Manuscr	ipt number (if known): <u>eclinm-D-24-00250</u>	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to you or to your
		none (add rows as needed)	institution)
		Time frame: Since the initial plannin	ng of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 mon	ths
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

	Payment or honoraria for		
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0			
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
5	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
		<sup>_</sup>	
12	Dessist of equipment	Nere	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Date: <u>Mar 22, 2024</u>			
Your Name: Yuesong Pan			
Manuscript Title: <u>Endovascular therapy in acute ischemic stroke with large infarction with matched or</u>			
mismatched clinical-radiological severities: a post-hoc analysis of the ANGEL-ASPECT trial			
Manuscript number (if known): eclinm-D-24-00250			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to you or to your
		none (add rows as needed)	institution)
		Time frame: Since the initial plannin	ng of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 mon	ths
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

Date: <u>Mar 22, 2024</u> Your Name: <u>Thanh N Nguyen</u> Manuscript Title: <u>Endovascular therapy in acute ischemic stroke with large infarction with matched or</u> <u>mismatched clinical-radiological severities: a post-hoc analysis of the ANGEL-ASPECT trial</u> Manuscript number (if known): <u>eclinm-D-24-00250</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to you or to your
		none (add rows as needed)	institution)
		Time frame: Since the initial plannir	ng of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 mon	ths
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

Date:	Mar 22, 2024
Your Nar	ne: Xinyi Leng
Manuscr	ipt Title: <u>Endovascular therapy in acute ischemic stroke with large infarction with matched or</u>
	mismatched clinical-radiological severities: a post-hoc analysis of the ANGEL-ASPECT trial
Manuscr	ipt number (if known): <u>eclinm-D-24-00250</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to you or to your
		none (add rows as needed)	institution)
		Time frame: Since the initial plannin	ng of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 mon	ths
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

Date: <u>Mar 22, 2024</u> Your Name: <u>Zhongrong Miao</u> Manuscript Title: <u>Endovascular therapy in acute ischemic stroke with large infarction with matched or</u> <u>mismatched clinical-radiological severities: a post-hoc analysis of the ANGEL-ASPECT trial</u> Manuscript number (if known): <u>eclinm-D-24-00250</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
	T	Time frame: Since the initial plannin	ig of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 mon	ths
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

Date: _	Mar 22, 2024
Your N	ame: Liping Liu
Manus	cript Title: <u>Endovascular therapy in acute ischemic stroke with large infarction with matched or</u>
	mismatched clinical-radiological severities: a post-hoc analysis of the ANGEL-ASPECT trial
Manus	cript number (if known): <u>eclinm-D-24-00250</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to you or to your
		none (add rows as needed)	institution)
		Time frame: Since the initial plannin	ng of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 mon	ths
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	